CN116925077A

CN116925077A - Pyrido ring compound, and preparation method, intermediate, composition and application thereof

Info

Publication number: CN116925077A
Application number: CN202310918603.9A
Authority: CN
Inventors: 李志裕; 徐鹏飞; 沈沛; 卞金磊; 王举波; 邱志霞; 徐熙
Original assignee: Yiyou Biology Shanghai Co ltd
Current assignee: Yiyou Biology Shanghai Co ltd
Priority date: 2020-09-08
Filing date: 2021-01-06
Publication date: 2023-10-24
Also published as: CN114149428B; CN114149428A

Abstract

The application discloses a pyrido ring compound, a preparation method, an intermediate, a composition and application thereof. The pyrido ring compound has a structure shown in the following formula I, has JAK inhibitory activity, and can be used for treating diseases related to JAK, such as autoimmune diseases or cancers.

Description

Pyrido ring compound, and preparation method, intermediate, composition and application thereof

The application relates to a split application of a Chinese patent application with 2021, 01-06 and 2021100143537, and the application and the name of the pyrido ring compound, a preparation method, an intermediate, a composition and an application thereof.

Technical Field

The application relates to a pyrido ring compound, a preparation method, an intermediate, a composition and application thereof.

Background

Janus kinases (JAKs) belong to a family of tyrosine kinases involved in inflammation, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL 6.

JAK kinases are cytoplasmic tyrosine kinases that transduce cytokine signals from membrane receptors to STAT transcription factors. Four JAK kinase family members have been described in the art: JAK1, JAK2, JAK3 and TYK2. When cytokines bind to their receptors, JAK family members autophosphorylate and/or transphosphorylate each other, followed by stat phosphorylation and then migrate into the nucleus to regulate transcription. JAK-STAT intracellular signaling is applicable to interferons, most interleukins, and a variety of cytokines and endocrine factors, such as EPO, TPO, GH, OSM, LIF, CNTF, GM-CSF and PRL.

Combination studies of genetic models and small molecule JAK inhibitors reveal the therapeutic potential of several JAKs. JAK3 was confirmed to be an immunosuppressive target by mouse and human genetics. JAK3 inhibitors were successfully used in clinical development, initially for organ transplant rejection, but also later for other immunoinflammatory indications, such as Rheumatoid Arthritis (RA), psoriasis and crohn's disease. TYK2 is a potential target for immune inflammatory disease, which has been confirmed by human genetics and mouse knockout studies. JAK2 is an effective target for the treatment of myeloproliferative diseases, and two drugs have been marketed for the treatment of myelofibrosis. JAK1 is a novel target in the area of immunoinflammatory disorders, heterodimerizing JAK1 with other JAKs to transduce cytokine-driven pro-inflammatory signaling. Thus, inhibition of JAK1 and/or other JAKs is expected to be of therapeutic benefit for a range of inflammatory disorders and other diseases driven by JAK-mediated signal transduction.

Tofacitinib (Tofacitinib) was developed by the company pyroxene and was successfully marketed in the United states at 11/7 of 2012 for the treatment of rheumatoid arthritis under the trade name Xerljanz.

Ruxolitinib (Ruxolitinib) was developed by a combination of incyte and nowa, and was marketed in 2011 in the united states for the treatment of myelofibrosis under the trade name Jakafi.

Baratinib (Baricitinib) was developed by a combination of incyte and gift, marketed in 2018 in the united states for the treatment of rheumatoid arthritis under the trade name of ol.

Wu Pati Nib (Upadacitinib) is a selective JAK1 inhibitor developed by Abovine, and is marketed in 2019 for the treatment of rheumatoid arthritis, and the reported activity in the literature is JAK1 IC ₅₀ ＝43nM，JAK2 IC ₅₀ ＝200nM。

Fedratinib is a selective JAK2 inhibitor developed by Sainofil and marketed in 2019 for the treatment of myelofibrosis, the activity reported in the literature being JAK2 IC ₅₀ ＝3nM。

Disclosure of Invention

The invention aims to provide a pyrido ring compound with a novel structure, and a preparation method, an intermediate, a composition and application thereof.

In one aspect, the invention provides a compound of formula I:

or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing (referring to a compound, tautomer, stereoisomer, racemate, or isotopic derivative of the foregoing) or a crystalline form or solvate of any of the foregoing (referring to a compound, tautomer, stereoisomer, racemate, isotopic derivative, or pharmaceutically acceptable salt of the foregoing) as shown in formula I;

Wherein X is CH or N;

y is NH or N; when Y is N, then it is connected to YIs a double bond; when Y is NH, +.>Is a single bond;

R ¹ and R is ² Is defined as (i), (ii) or (iii):

(i)R ¹ is that(e.g.)>For example->)，R ² Is->(e.g.For example->) Or->(e.g.)>)；

Ring B is a benzene ring or a 5-6 membered heteroaromatic ring;

R ^1a is C _1–3 Alkyl (e.g., methyl);

each R ³ Independently halogen (e.g., fluorine), cyano, C _1–4 Alkyl (e.g. methyl), C _1–4 Haloalkyl (e.g. C _1–4 Fluoroalkyl groups, e.g. -CF ₃ )、–O–C _1–4 Alkyl (e.g. -O-CH ₃ ) or-O-C _1–4 Haloalkyl (e.g. -O-C _1–4 Fluoroalkyl groups, e.g. -OCF ₃ )；

Each R ⁴ Independently a halogen (e.g., fluorine), hydroxy, C _1–4 Alkyl (e.g. methyl), C _1–4 Haloalkyl (e.g. C _1–4 Fluoroalkyl groups, e.g. -CF ₃ )、–O–C _1–4 Alkyl (e.g. -O-CH ₃ )、–O–C _1–4 Haloalkyl (e.g. -O-C _1–4 Fluoroalkyl groups, e.g. -OCF ₃ ) Or C _1–4 Hydroxyalkyl (e.g. -CH ₂ OH)；

Alternatively, two R's on the same carbon atom or on different carbon atoms ⁴ Are connected with each other to form-CH ₂ -or- (CH) ₂ ) ₂ - (e.g. forming)For example->)；

R ⁵ is-S (O) ₂ R ^5a 、–C(O)R ^5b 、–C(O)NR ^5c R ^5d 、–C(O)OR ^5e 、–C(O)NHR ^5k or-L ¹ –R ^5f ；

R ^5a Is C _2–6 Alkyl (e.g. ethyl, n-propyl or n-butyl), C _2–6 Haloalkyl, -L ¹ –R ^5f Unsubstituted or substituted 6-10 membered aryl (said 6-10 membered aryl, e.g. phenyl or naphthyl) or unsubstituted or substituted 5-10 membered heteroaryl (said 5-10 membered heteroaryl, e.g. 5-6 membered heteroaryl), said substituted 6-10 membered aryl and substituted 5-10 membered heteroaryl referring to 1, 2, 3 or 4 hydrogen atoms in the 6-10 membered aryl and 5-10 membered heteroaryl being independently replaced by R ^5g Substitution;

R ^5b 、R ^5c 、R ^5d 、R ^5e and R is ^5k Each independently is C _1–6 Alkyl, C _1–6 Haloalkyl, -L ¹ –R ^5f Unsubstituted or substituted 6-10 membered aryl (said 6-10 membered aryl, e.g. phenyl or naphthyl) or unsubstituted or substituted 5-10 membered heteroaryl (said 5-10 membered heteroaryl, e.g. 5-6 membered heteroaryl), said substituted 6-10 membered aryl and substituted 5-10 membered heteroaryl referring to 1, 2, 3 or 4 hydrogen atoms in the 6-10 membered aryl and 5-10 membered heteroaryl being independently replaced by R ^5h Substitution;

each R ^5g And R is ^5h Each independently is halogen (e.g., fluorine), cyano, C _1–4 Alkyl (e.g. methyl), C _1–4 Haloalkyl (e.g. C _1–4 Fluoroalkyl groups, e.g. -CF ₃ )、–O–C _1–4 Alkyl (e.g. -O-CH ₃ )、–O–C _1–4 Haloalkyl (e.g. -O-C _1–4 Fluoroalkyl, -OCF ₃ ) Or phenyl;

each L ¹ Independently is- [ C (R) ^a R ^b )] _1-5 - (e.g. -CH) ₂ –、–(CH ₂ ) ₂ –、–(CH ₂ ) ₃ –、–(CH ₂ ) ₄ –、–(CH ₂ ) ₅ -or)、–[C(R ^a R ^b )] _1–2 –C(O)–[C(R ^a R ^b )] _1–2 –、–[C(R ^a R ^b )] _1–2 –C(O)NH–[C(R ^a R ^b )] _1–2 - (e.g. -C (R) ^a R ^b )–C(O)NH–C(R ^a R ^b )–R ^5f )、–[C(R ^a R ^b )] _1–2 –NHC(O)–[C(R ^a R ^b )] _1–2 –、–[C(R ^a R ^b )] _1–2 –S(O) ₂ –[C(R ^a R ^b )] _1–2 –、–[C(R ^a R ^b )] _1–2 –NHS(O) ₂ –[C(R ^a R ^b )] _1–2 -or- [ C (R) ^a R ^b )] _1–2 –S(O) ₂ NH–[C(R ^a R ^b )] _1–2 –；

Each R ^5f H, F, CHF independently ₂ 、CH ₂ F、CF ₃ Or CN;

each R ^a Independently H, halogen (e.g., fluorine), or C _1–3 Alkyl (e.g., methyl or ethyl);

each R ^b Independently H, halogen (e.g., fluorine), or C _1–3 Alkyl (e.g., methyl or ethyl);

alternatively, R ^a And R is ^b Form a cyclopropyl group together with the carbon atom to which they are attached;

m is 0, 1, 2, 3 or 4;

n is 0, 1, 2, 3 or 4;

(ii)R ¹ Is thatR ² Is->(e.g.)>) Or->(e.g., trans or cis);

ring C is a benzene ring or a 5-6 membered heteroaromatic ring (e.g. imidazole, thiazole, furan, thiophene or pyridine, e.g. )；

Each R ⁶ Independently a halogen (e.g., fluorine or chlorine, e.g., fluorine), hydroxy, amino, cyano, C _1–4 Alkyl (e.g. methyl), C _1–4 Haloalkyl (e.g. C _1–4 Fluoroalkyl groups, e.g. CF ₃ )、–O–C _1–4 Alkyl (e.g. -O-CH ₃ )、–O–C _1–4 Haloalkyl (e.g. -O-C _1–4 Fluoroalkyl groups, e.g. O-CF ₃ )、–S–C _1–4 Alkyl (e.g. -S-CH ₃ )、–S(O) ₂ –C _1–4 Alkyl (e.g. -S (O) ₂ –CH ₃ ) Or C _1–4 Hydroxyalkyl (e.g. -CH ₂ –OH)；

Each R ⁷ Independently R is ⁴ (i.e. R ⁷ And R in the compound shown as the formula I in any one of the embodiments ⁴ Is the same as defined in the definition of (a);

alternatively, two R's on the same carbon atom or on different carbon atoms ⁷ Are connected with each other to form-CH ₂ -or- (CH) ₂ ) ₂ –；

R ⁸ Is R ⁵ (i.e. R ⁸ And R in the compound shown as the formula I in any one of the embodiments ⁵ Is the same as defined in the specification), -S (O) ₂ R ^8a 、–C(O)R ^8b 、–C(O)NR ^8c R ^8d 、–C(O)OR ^8e or-C (O) NHR ^8k ；

R ^8a 、R ^8b 、R ^8c 、R ^8d 、R ^8e And R is ^8k Each independently is methyl, -CF ₃ 、C _2–6 Alkenyl (e.g. vinyl) or C _3–6 Cycloalkyl (e.g., cyclopropyl, cyclobutyl, or cyclopentyl);

each R ⁹ Independently R is ⁴ ；

Alternatively, two R's on the same carbon atom or on different carbon atoms ⁹ Are connected with each other to form-CH ₂ -or- (CH) ₂ ) ₂ –；

z is 0, 1, 2, 3 or 4;

y is 0, 1, 2, 3 or 4;

t is 0, 1, 2, 3 or 4;

(iii)R ¹ h, CF of a shape of H, CF ₃ Or (b)R ² Is->

Ring D is C _3–6 Cycloalkyl (e.g. cyclopropyl or cyclobutyl), benzene ring or 5-6 membered heteroaryl ring (e.g. furan or thiophene, e.g. )；

Ring E is a benzene ring or a 5-6 membered heteroaromatic ring (e.g. furan or thiophene, e.g)；

Each R ¹⁰ And R is ¹¹ Independently a halogen (e.g., fluorine or chlorine, e.g., fluorine), hydroxy, amino, cyano, C _1–4 Alkyl group(e.g. methyl), C _1–4 Haloalkyl (e.g. C _1–4 Fluoroalkyl groups, e.g. CF ₃ )、–O–C _1–4 Alkyl (e.g. -O-CH ₃ )、–O–C _1–4 Haloalkyl (e.g. -O-C _1–4 Fluoroalkyl groups, e.g. O-CF ₃ )、–S–C _1–4 Alkyl (e.g. -S-CH ₃ )、–S(O) ₂ –C _1–4 Alkyl (e.g. -S (O) ₂ –CH ₃ ) Or C _1–4 Hydroxyalkyl (e.g. -CH ₂ –OH)；

R ¹² Is cyano, -L ³ –R ^12f Or (b)

Each R ^14a Independently halogen (e.g., fluorine), cyano, C _1–4 Alkyl (e.g. methyl), cyano substituted C _1–4 Alkyl (e.g. -CH ₂ CN)、C _1–4 Haloalkyl (e.g. C _1–4 Fluoroalkyl groups, e.g. CF ₃ )、–O–C _1–4 Alkyl (e.g. -O-CH ₃ )、–O–C _1–4 Haloalkyl (e.g. -O-C _1–4 Fluoroalkyl groups, e.g. O-CF ₃ ) Or C _1–4 Hydroxyalkyl (e.g. -CH ₂ OH)；

R ^14b Is R ⁵ (i.e. R ^14b And R in the compound shown as the formula I in any one of the embodiments ⁵ The definitions of (a) being the same) or-S (O) ₂ –C _1–4 Alkyl (e.g. -S (O) ₂ –CH ₂ CH ₃ 、–S(O) ₂ –CH ₂ CH ₂ CH ₃ or-S (O) ₂ –CH ₂ CH ₂ CH ₂ CH ₃ )；

L ³ Is- [ C (R) ^e R ^f )] ₁ 5- (e.g. -CH) ₂ –、–(CH ₂ ) ₂ –、–(CH ₂ ) ₃ –、–(CH ₂ ) ₄ -or- (CH) ₂ ) ₅ –)、–C(O)–、–C(O)NH–、–NHC(O)–、–S(O) ₂ –、–NHS(O) ₂ –、–S(O) ₂ NH–、–[C(R ^e R ^f )] _1–2 –C(O)–[C(R ^e R ^f )] _1–2 –、–[C(R ^e R ^f )] _1–2 –C(O)NH–[C(R ^e R ^f )] _1–2 –、–[C(R ^e R ^f )] _1–2 –NHC(O)–[C(R ^e R ^f )] _1–2 –、–[C(R ^e R ^f )] _1–2 –S(O) ₂ –[C(R ^e R ^f )] _1–2 –、–[C(R ^e R ^f )] _1–2 –NHS(O) ₂ –[C(R ^e R ^f )] _1–2 -or- [ C (R) ^e R ^f )] _1–2 –S(O) ₂ NH–[C(R ^e R ^f )] _1–2 –；

R ^12f H, F, CHF of a shape of H, F, CHF ₂ 、CH ₂ F、CF ₃ Or CN;

each R ^e And R is ^f Independently H, halogen (e.g., fluorine), C _1–3 Alkyl (e.g. methyl or ethyl) or C _3–6 Cycloalkyl (e.g., cyclopropyl, cyclobutyl, or cyclopentyl);

alternatively, R ^e And R is ^f Form a cyclopropyl group together with the carbon atom to which they are attached;

p is 0, 1, 2, 3 or 4;

q is 0, 1, 2, 3 or 4;

v is 0, 1, 2 or 3;

u is 0, 1 or 2;

the hetero atoms in the heteroaryl are N, O or S independently, and the number of the hetero atoms is 1, 2, 3 or 4 independently.

In some embodiments, the compound of formula I has the structure of formula I-1:

wherein R is ^1a 、R ⁴ 、R ⁵ X and n are as defined in the inventionThe compounds of formula I as defined in any of the schemes.

In some embodiments, the compound of formula I or I-1 has a structure of formula I-1C, I-1D, I-1E, or I-1F as follows:

wherein R is ^1a 、R ⁴ 、R ⁵ The definitions of X and n are as described in the compounds of formula I as defined in any one of the schemes of the present invention.

In some embodiments, the compound of formula I or I-1 has a structure as shown in formula I-1a, I-1b, I-1c or I-1d below, preferably having a structure as shown in I-1 d:

wherein R is ^1a 、R ⁴ 、R ^5g 、X、n、L ¹ And R is ^5f Is described in the definition of the compounds of formula I as defined in any one of the aspects of the invention;

Each f is independently 0, 1, 2, 3 or 4, for example 0 or 1.

In some embodiments, the compound of formula I has a structure as shown in formula I-2, I-2A or I-2B:

wherein R is ^1a 、R ³ The definitions of X and m are as described in the compounds of formula I as defined in any one of the schemes of the invention.

In some embodiments, X is CH in a compound represented by formula I, I-1C, I-1D, I-1E, I-1F, I-1a, I-1B, I-1C, I-1D, I-2A, or I-2B.

In some embodiments, X is N in a compound represented by formula I, I-1C, I-1D, I-1E, I-1F, I-1a, I-1B, I-1C, I-1D, I-2A, or I-2B.

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, I-1F, I-1a, I-1B, I-1C, I-1D, I-2A, or I-2B ^1a Is methyl.

In some embodiments, among the compounds represented by formula I, I-1a, I-1b, I-1c, I-1d, or I-2,is->Preferably->

In some embodiments, m is 1 in a compound as shown in formula I, I-2A or I-2B.

In some embodiments, of the compounds represented by formula I, I-1a, I-1b, I-1c or I-1d,is-> In some embodiments, the- >Is->In some embodiments, the->Is->

In some embodiments, each R in a compound represented by formula I, I-1C, I-1D, I-1E, I-1F, I-1a, I-1b, I-1C, or I-1D ⁴ Independently halogen (e.g. fluorine) or C _1–4 Hydroxyalkyl (e.g. -CH ₂ OH), or two R on the same carbon atom or on different carbon atoms ⁴ Are connected with each other to form-CH ₂ -or- (CH) ₂ ) ₂ –。

In some embodiments, n is 0, 1 or 2 in a compound represented by formula I, I-1C, I-1D, I-1E, I-1F, I-1a, I-1B, I-1C, I-1D, I-2A or I-2B.

In some embodiments, of the compounds represented by formula I, I-1C, I-1D, I-1E, I-1F, I-1a, I-1b, I-1C, or I-1D,is->Is->(e.g.)>)、(e.g.)>) Or->(e.g.)>)。

In some embodiments, of the compounds represented by formula I, I-1C, I-1D, I-1E, I-1F, I-1a, I-1b, I-1C, or I-1D,is->Is->

In some embodiments, ring B is a benzene ring in a compound of formula I.

In some embodiments, in a compound as shown in formula I, m is 1.

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^5a Is C _2–6 Alkyl (e.g., ethyl, n-propyl, or n-butyl), unsubstituted or substituted 6-10 membered aryl (e.g., phenyl or naphthyl), or unsubstituted or substituted 5-10 membered heteroaryl (e.g., 5-10 membered heteroaryl).

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^5a The "unsubstituted or substituted 6-10 membered aryl" in the definition may be unsubstituted or substituted phenyl, or unsubstituted or substituted naphthyl. Wherein the unsubstituted or substituted phenyl may be, for example, unsubstituted phenyl, or substituted with 1, 2, 3 and 4 (e.g., 1) groups independently selected from halogen (e.g., fluorine), C _1–4 Alkyl (e.g. methyl), -O-C _1–4 Haloalkyl (e.g. -OCF) ₃ ) And phenyl substituted phenyl groups, e.g Wherein said unsubstituted or substituted naphthyl may be, for example, unsubstituted naphthyl, for example +.>In some embodiments, R ^5a The "unsubstituted or substituted 6-to 10-membered aryl" in (a) is preferably-OCF ₃ Substituted phenyl (e.g.)>)。

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^5a "unsubstituted or substituted 5-10 membered heteroaryl" in the definition may be "unsubstituted or substituted 5-or 6 membered heteroaryl", for example unsubstituted or substituted thienyl, preferably

In some embodiments, each R in a compound represented by formula I, I-1C, I-1D, I-1E, I-1F, I-1a, I-1b, or I-1C ^5g Independently halogen (e.g. fluorine), C _1–4 Alkyl (e.g. methyl), -O-C _1–4 Haloalkyl (e.g. -OCF) ₃ ) Or phenyl, preferably-OCF ₃ 。

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ⁵ In the definition-S (O) ₂ R ^5a is-S (O) ₂ (CH ₂ ) ₂ –CF ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CH ₃ 、–S(O) ₂ CH ₂ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₃ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、preferably-S (O) ₂ (CH ₂ ) ₂ –CF ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CH ₃ 、–S(O) ₂ CH ₂ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₃ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^5b is-L ¹ –R ^5f Or unsubstituted or substituted phenyl.

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^5b -L in the definition ¹ –R ^5f is-C (R) ^a R ^b )–R ^5f For example

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^5b "unsubstituted or substituted 6-10 membered aryl" in the definition may be unsubstituted or substituted phenyl, or unsubstituted or substituted naphthyl; wherein unsubstituted or substituted phenyl may be, for example, unsubstituted phenyl, or phenyl substituted with 1, 2, 3 and 4 (e.g., 1) groups independently selected from halogen (e.g., fluorine) and cyano, e.g.

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ⁵ In the definition-C (O) R ^5b Is that

In some embodiments, the compounds of formula I, I-1C, I1D, I-1E or I-1F, R ^5e Is C _1–6 Alkyl groups such as t-butyl.

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ⁵ In the definition-C (O) OR ^5e is-C (O) OC (CH) ₃ ) ₂ –CH ₃ 。

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^5c 、R ^5d And R is ^5k Each independently is-L ¹ –R ^5f 。

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^5c 、R ^5d And R is ^5k -L in the definition ¹ –R ^5f is-C (R) ^a R ^b )–R ^5f For example-CH ₂ –R ^5f For example-CH ₂ –CF ₃ 。

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ⁵ -C (O) NHR in the definition ^5k is-C (O) NHC (R) ^a R ^b )–R ^5f For example-C (O) NHCH ₂ –R ^5f For example-C (O) NHCH ₂ –CF ₃ 。

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ⁵ -L in the definition ¹ –R ^5f Is- [ C (R) ^a R ^b )] _1-5 –R ^5f Or- [ C (R) ^a R ^b )] _1–2 –C(O)NH–[C(R ^a R ^b )] _1–2 -, preferably-C (R) ^a R ^b )–R ^5f 、–[C(R ^a R ^b )] ₂ –R ^5f 、–[C(R ^a R ^b )] ₃ –R ^5f 、–[C(R ^a R ^b )] ₄ –R ^5f Or- [ C (R) ^a R ^b )] ₅ –R ^5f Further preferred is- [ C (R ^a R ^b )] ₂ –R ^5f Or- [ C (R) ^a R ^b )] ₃ –R ^5f 。

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ⁵ -L in the definition ¹ –R ^5f is-C (R) ^a R ^b )–R ^5f 、–[C(R ^a R ^b )] ₂ –R ^5f 、–[C(R ^a R ^b )] ₃ –R ^5f 、–[C(R ^a R ^b )] ₄ –R ^5f 、–[C(R ^a R ^b )] ₅ –R ^5f or-C (R) ^a R ^b )–C(O)NH–C(R ^a R ^b )–R ^5f Preferably- [ C (R) ^a R ^b )] ₂ –R ^5f Or- [ C (R) ^a R ^b )] ₃ –R ^5f 。

In some embodiments, each R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^5f F, CF independently ₃ Or CN. In some embodiments, each R ^5f Independently F. In some embodiments, each R ^5f Independently CF ₃ . In some embodiments, each R ^5f Independently CN.

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ⁵ -L in the definition ¹ –R ^5f is-C (R) ^a R ^b )–CN、–[C(R ^a R ^b )] ₂ –CN、–[C(R ^a R ^b )] ₃ –CN、–[C(R ^a R ^b )] ₄ –CN、–[C(R ^a R ^b )]–CF ₃ 、–[C(R ^a R ^b )] ₂ –CF ₃ 、–[C(R ^a R ^b )] ₃ –CF ₃ 、–C(R ^a R ^b )C(O)NH–C(R ^a R ^b )CF ₃ Or- [ C (R) ^a R ^b )] ₅ -F, preferably-C (R ^a R ^b )–CN、–[C(R ^a R ^b )] ₂ –CN、–[C(R ^a R ^b )] ₃ –CN、–[C(R ^a R ^b )] ₄ –CN、–[C(R ^a R ^b )]–CF ₃ 、–[C(R ^a R ^b )] ₂ –CF ₃ 、–[C(R ^a R ^b )] ₃ –CF ₃ Or- [ C (R) ^a R ^b )] ₅ –F。

In some embodiments, each R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^a Independently H, fluoro, methyl or ethyl; each R ^b Independently H, fluoro, methyl or ethyl; alternatively, R ^a And R is ^b Together with the carbon atoms to which they are attached form a cyclopropyl group.

In some embodiments, each R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^a Independently H, fluoro, methyl or ethyl.

In some embodiments, each R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^a Independently H or fluorine.

In some embodiments, each R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^b Independently H, fluoro, methyl or ethyl.

In some embodiments, each R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ^b Independently H or fluoro, methyl or ethyl.

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ⁵ -L in the definition ¹ –R ^5f is-CH ₂ –CN、–(CH ₂ ) ₂ –CN、–(CH ₂ ) ₃ –CN、–(CH ₂ ) ₄ –CN、–(CH ₂ ) ₂ –CF ₃ 、–CH ₂ (CF ₂ ) ₂ –CF ₃ 、–(CF ₂ ) ₃ –CF ₃ 、–(CH ₂ ) ₂ CF ₂ –CF ₃ 、–(CH ₂ ) ₃ –CF ₃ 、–CH(CH ₂ CH ₃ )C(O)NH–CH ₂ CF ₃ 、–CH ₂ C(O)NHCH ₂ –CF ₃ 、–CH(CH ₃ )C(O)NHCH ₂ –CF ₃ Or- (CH) ₂ ) ₅ F, preferably- (CH) ₂ ) ₂ –CN、–(CH ₂ ) ₃ –CN、–(CH ₂ ) ₂ –CF ₃ 、–CH ₂ (CF ₂ ) ₂ –CF ₃ 、–(CF ₂ ) ₃ –CF ₃ 、–(CH ₂ ) ₂ CF ₂ –CF ₃ Or- (CH) ₂ ) ₃ –CF ₃ 。

In some embodiments, R in a compound represented by formula I, I-1C, I-1D, I-1E, or I-1F ⁵ is-CH ₂ –CN、–(CH ₂ ) ₂ –CN、–(CH ₂ ) ₃ –CN、–(CH ₂ ) ₄ –CN、–(CH ₂ ) ₂ –CF ₃ 、–CH ₂ (CF ₂ ) ₂ –CF ₃ 、–(CF ₂ ) ₃ –CF ₃ 、–(CH ₂ ) ₂ CF ₂ –CF ₃ 、–(CH ₂ ) ₃ –CF ₃ 、–CH(CH ₂ CH ₃ )C(O)NH–CH ₂ CF ₃ 、–CH ₂ C(O)NHCH ₂ –CF ₃ 、–CH(CH ₃ )C(O)NHCH ₂ –CF ₃ 、–(CH ₂ ) ₅ –F、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、–C(O)NHCH ₂ –CF ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CH ₃ 、–S(O) ₂ CH ₂ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₃ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、 –C(O)OC(CH ₃ ) ₂ –CH ₃ 、preferably-CH ₂ –CN、–(CH ₂ ) ₂ –CN、–(CH ₂ ) ₃ –CN、–(CH ₂ ) ₄ –CN、–(CH ₂ ) ₂ –CF ₃ 、–CH ₂ (CF ₂ ) ₂ –CF ₃ 、–(CF ₂ ) ₃ –CF ₃ 、–(CH ₂ ) ₂ CF ₂ –CF ₃ 、–(CH ₂ ) ₃ –CF ₃ 、–CH(CH ₂ CH ₃ )C(O)NH–CH ₂ CF ₃ 、–CH ₂ C(O)NHCH ₂ –CF ₃ 、–CH(CH ₃ )C(O)NHCH ₂ –CF ₃ 、–(CH ₂ ) ₅ –F、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、–S(O) ₂ CH ₂ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₃ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、

In some embodiments, the compound of formula I has a structure as shown in formula I-3, I-3A or I-3B:

wherein X, Y is,Ring C, R ⁶ 、R ⁷ 、R ⁸ The definition of z and y is as in any one of the inventionThe compounds shown in the formula I are described in scheme definition.

In some embodiments, the compound of formula I has the structure of formula I-4 as follows:

wherein X, Y is,Ring C, R ⁶ 、R ⁹ The definitions of z and t are as described in the compounds of formula I as defined in any one of the schemes of the invention.

In some embodiments, of the compounds represented by formula I, I-3A, I-3B or I-4, Is a double bond and Y is N.

In some embodiments, of the compounds represented by formula I, I-3A, I-3B or I-4,and Y is NH.

In some embodiments, in compounds of formula I, I-3A, I-3B or I-4, the 5-6 membered heteroaromatic ring in the definition of ring C is an imidazole (e.g) Thiazole (e.g.)>) Furan (e.g.)>) Thiophene (e.g.)>) Or pyridine (e.g.)>)。

In some embodiments, R in a compound represented by formula I, I-3A, I-3B, I-4A, I-4B, I-4C, or I-4D ² Is thatWhen ring C is a benzene ring, imidazole (e.g.)>) Furan (e.g.)>) Or pyridine (e.g)。/>

In some embodiments, R in a compound represented by formula I, I-3A, I-3B, I-4A, I-4B, I-4C, or I-4D ² Is thatWhen ring C is a benzene ring, thiazole (e.g.)>) Furan (e.g.)>) Or thiophenes (e.g)。

In some embodiments, of the compounds represented by formula I, I-3A, I-3B, I-4A, I-4B, I-4C or I-4D,is->

In some embodiments, the compound of formula I has a structure as shown in formula I-3C, I-3D, I-3E, I-3F, or I-3G:

therein, X, R ⁶ 、R ⁷ 、R ⁸ Definition of z and y are described in any of the embodiments of the invention.

In some embodiments, of the compounds represented by formula I, I-3C, I-3D, I-3E, I-3F, or I-3G,is->In some embodiments, the->Is->In some embodiments, the->Is->

In some embodiments, R in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, or I-3G ⁷ Is R ⁴ I.e. R ⁷ R as defined in any one of the embodiments of the present invention in the compound of formula I ⁴ The same applies.

In some embodiments, a compound of formulaI. R in the compounds shown as I-3, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F or I-3G ⁸ Is R ⁵ I.e. R ⁸ R as defined in any one of the embodiments of the present invention in the compound of formula I ⁵ The same applies.

In some embodiments, y is 0 in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, or I-3G.

In some embodiments, R in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, or I-3G ⁸ Is R ⁵ 、–S(O) ₂ R ^8a or-C (O) R ^8b Wherein R is ⁵ R as defined in any one of the embodiments of the present invention in the compound of formula I ⁵ The same applies.

In some embodiments, R in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, or I-3G ⁸ is-S (O) ₂ C(R ^a R ^b )–C _1–6 Alkyl, -S (O) ₂ –CF ₃ 、–S(O) ₂ C(R ^a R ^b )–R ^5f 、–S(O) ₂ [C(R ^a R ^b ) ₂ ]–R ^5f 、–S(O) ₂ [C(R ^a R ^b ) ₃ ]–R ^5f 、–C(R ^a R ^b )–R ^5f 、–[C(R ^a R ^b ) ₂ ]–R ^5f 、–[C(R ^a R ^b ) ₃ ]–R ^5f 、–C(O)CH＝CH ₂ or-C (O) NHC (R) ^a R ^b )–R ^5f The method comprises the steps of carrying out a first treatment on the surface of the Wherein R is ^5f R as defined in any one of the embodiments of the present invention in the compound of formula I ^5f Identical, e.g. R ^5f Is CF (CF) ₃ Or CN.

In some embodiments, R in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, or I-3G ⁸ is-S (O) ₂ C(R ^a R ^b )–CH ₃ 、–S(O) ₂ –CF ₃ 、–C(O)NHC(R ^a R ^b )–CF ₃ 、–C(O)CH＝CH ₂ 、–C(R ^a R ^b )–CN、–[C(R ^a R ^b ) ₂ ]-CN or- [ C (R) ^a R ^b ) ₃ ]–CF ₃ preferably-S (O) ₂ C(R ^a R ^b )–CH ₃ 、–S(O) ₂ –CF ₃ 、 –[C(R ^a R ^b ) ₂ ]-CN or- [ C (R) ^a R ^b ) ₃ ]–CF ₃ 。

In some embodiments, R in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, or I-3G ⁸ is-S (O) ₂ (CH ₂ ) ₂ –CH ₃ 、–S(O) ₂ –CF ₃ 、–C(O)NHCH ₂ –CF ₃ 、–C(O)CH＝CH ₂ 、–CH ₂ –CN、–(CH ₂ ) ₂ -CN or- (CH) ₂ ) ₃ –CF ₃ preferably-S (O) ₂ (CH ₂ ) ₂ –CH ₃ 、–S(O) ₂ –CF ₃ 、–(CH ₂ ) ₂ -CN or- (CH) ₂ ) ₃ –CF ₃ 。

In some embodiments, the compound of formula I has a structure as shown in formulas I-4E, I-4F, I-4J, I-4L, or I-4M below:

therein, X, R ⁶ 、R ⁹ The definitions of z and t are as described in the compounds of formula I as defined in any one of the schemes of the invention.

In some embodiments, of the compounds represented by formula I, I-4E, I-4F, I-4J, I-4L, or I-4M,in cis or trans configuration, e.g., trans.

In some embodiments, t is 0 in a compound represented by formula I, I-4E, I-4F, I-4J, I-4L, or I-4M.

In some embodiments, X is CH in a compound as shown in formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, I-3G, I-4E, I-4F, I-4J, I-4L, or I-4M.

In some embodiments, X is N in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, I-3G, I-4E, I-4F, I-4J, I-4L, or I-4M.

In some embodiments, z is 0, 1 or 2 in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, I-3G, I-4E, I-4F, I-4J, I-4L or I-4M.

In some embodiments, each R in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, I-3G, I-4E, I-4F, I-4J, I-4L, or I-4M ⁶ Independently halogen (e.g., fluorine), hydroxy, amino, cyano, C _1–4 Alkyl (e.g. methyl), C _1–4 Haloalkyl (e.g. C _1–4 Fluoroalkyl groups, e.g. CF ₃ )、–O–C _1–4 Alkyl (e.g. -O-CH ₃ )、–S–C _1–4 Alkyl (e.g. -S-CH ₃ )、–S(O) ₂ –C _1–4 Alkyl (e.g. -S (O) ₂ –CH ₃ ) Or C _1–4 Hydroxyalkyl (e.g. -CH ₂ –OH)。

In some embodiments, each R in a compound represented by formula I, I-3A, I-3B, I-3C, I-3D, I-3E, I-3F, I-3G, I-4E, I-4F, I-4J, I-4L, or I-4M ⁶ Independently fluorine, hydroxy, amino, cyano, methyl, CF ₃ 、–O–CH ₃ 、–S–CH ₃ 、–S(O) ₂ –CH ₃ or-CH ₂ –OH。

In some embodiments, in the compounds of formulas I-3C, z is 0.

In some embodiments, of the compounds of formula I-3D or I-4F, Independently is->Wherein R is ⁶ Is as defined in any of the schemes of the present invention for compounds of formula I, e.g. C _1–4 Alkyl (e.g. methyl) or C _1–4 Hydroxyalkyl (e.g. -CH ₂ -OH). For example, in some embodiments, +.>Can be +.>For example, in some embodiments, +.>Can be +.>

In some embodiments, of the compounds represented by formulas I-3E, I-3G, I-4L, or I-4M,independently is->(e.g.)>)、(e.g.)>)、(e.g. )、(e.g.)>)、(e.g.)>) The method comprises the steps of carrying out a first treatment on the surface of the Wherein each R is ⁶ Is independently as defined in any of the schemes of the present invention for compounds of formula I, e.g. halogen (e.g. fluorine), hydroxy, C _1–4 Haloalkyl (e.g. C _1–4 Fluoroalkyl groups, e.g. CF ₃ )、–O–C _1–4 Alkyl (e.g. -O-CH ₃ )、–S–C _1–4 Alkyl (e.g. -S-CH ₃ ) or-S (O) ₂ –C _1–4 Alkyl (e.g. -S (O) ₂ –CH ₃ )。

In some embodiments, as shown in formulas I-3FOf the compounds of (a) are those,is->Wherein R is ⁶ Such as amino, as described in the compounds of formula I defined in any of the schemes of the present invention. />

In some embodiments, of the compounds of formulas I-4E,is->Wherein R is ⁶ Is described in the compounds of the formula I as defined in any of the aspects of the invention, e.g. amino or C _1–4 Alkyl (e.g., methyl). For example, in some embodiments, +. >Can be +.>For example, in some embodiments, +.>Can be +.>

In some embodiments, of the compounds of formulas I-4J,is->Wherein R is ⁶ Is as defined in any of the schemes of the present invention for compounds of formula I, e.g. C _1–4 Alkyl (e.g., methyl). For example, in some embodiments, +.>Can be +.>

In some embodiments, the compound of formula I has the structure of formula I-5 as follows:

therein, X, R ¹¹ 、R ¹² And q is as defined in the compounds of formula I defined in any one of the schemes of the present invention.

In some embodiments, the compound of formula I has the structure of formula I-6 as follows:

In some embodiments, R in a compound of formula I-5 or I-6 ¹² independently-C (R) ^e R ^f )–CN、–[C(R ^e R ^f ) ₂ ]-CN or- [ C (R) ^e R ^f ) ₃ ]-CN, e.g. -CH ₂ –CN、–(CH ₂ ) ₂ –CN、–(CH ₂ ) ₃ -CN or

In some embodiments, R in a compound of formula I-5 ¹² Preferably- [ C (R) ^e R ^f ) ₃ ]CN, e.g., - (CH) ₂ ) ₃ –CN。

In some embodiments, R in a compound of formula I-6 ¹² preferably-CH ₂ -CN or

In some embodiments, the compound of formula I has the structure of formula I-7 as follows:

Wherein X, Y is,Ring D, ring E, R ¹⁰ 、R ¹¹ 、R ¹² The definitions of p and q are as described in the compounds of formula I as defined in any one of the schemes of the present invention.

In some embodiments, in the compounds of formula I or I-7,is a double bond and Y is N.

In some embodiments, in the compounds of formula I or I-7,and Y is NH.

In some embodiments, the 5-6 membered heteroaromatic ring in the definition of ring D in the compound of formula I or I-7 is furan (e.g) Or thiophenes (e.g.)>)；

In some embodiments, ring D is cyclopropyl, cyclobutyl, a benzene ring, a compound of formula I or I-7,

In some embodiments, in the compounds of formula I or I-7,independently is

In some embodiments, the compound of formula I has a structure as shown in formulas I-7A, I-7B, I-7C, I-7D, I-7E, or I-7F:

therein, X, R ¹⁰ 、R ¹¹ 、R ¹² The definitions of p and q are as described in any of the schemes of the invention.

In some embodiments, R in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, or I-7F ¹² Is cyano, -C (R) ^e R ^f )–R ^12f 、–[C(R ^e R ^f ) ₂ ]–R ^12f 、–[C(R ^e R ^f ) ₃ ]–R ^12f Or (b)

In some embodiments, v is 0 in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, or I-7F.

In some embodiments, the compounds of formula I, I-5, I-6, I-7A,Of the compounds shown as I-7B, I-7C, I-7D, I-7E or I-7F,is->For example->

In some embodiments, R in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, or I-7F ^14a C substituted by cyano _1–4 Alkyl radicals, e.g. -CH ₂ CN。

In some embodiments, R in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, or I-7F ¹² is-CN, -C (R) ^e R ^f )–CN、–[C(R ^e R ^f ) ₂ ]–CN、–[C(R ^e R ^f ) ₃ ]-CN or

In some embodiments, each R in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, or I-7F ^e Independently H or C _1–3 An alkyl group.

In some embodiments, each R in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, or I-7F ^f Independently H or C _1–3 An alkyl group.

In some embodiments, R in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, or I-7F ¹² is-CN, -CH ₂ –CN、–(CH ₂ ) ₂ –CN、–(CH ₂ ) ₃ –CN、 preferably-CH ₂ –CN、–(CH ₂ ) ₂ –CN、–(CH ₂ ) ₃ -CN, further preferably- (CH) ₂ ) ₂ –CN。

In some embodiments, R in a compound represented by formula I-7A, I-7B or I-7C ¹² Is cyano.

In some embodiments, R in a compound represented by formula I-7E or I-7F ¹² is-C (R) ^e R ^f )–R ^12f 、–[C(R ^e R ^f ) ₂ ]–R ^12f 、–[C(R ^e R ^f ) ₃ ]–R ^12f Or (b)preferably-C (R) ^e R ^f )–R ^12f 、–[C(R ^e R ^f ) ₂ ]–R ^12f Or- [ C (R) ^e R ^f ) ₃ ]–R ^12f Further preferred is- [ C (R ^e R ^f ) ₂ ]–R ^12f 。

In some embodiments, the compounds of formula I, I-7E or I-7F have the structure shown below as formulas I-7G or I-7H:

therein, X, R ¹⁰ 、R ¹¹ 、R ^14b The definitions of p and q are as described in any of the schemes of the invention.

In some embodiments, R in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, I-7F, I-7G, or I-7H ^14b Is R ⁵ I.e. R ^14b R as defined in any one of the embodiments of the present invention in the compound of formula I ⁵ The same applies.

In some embodiments, the compounds of formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D,In the compounds shown as I-7E, I-7F, I-7G or I-7H, R ^14b is-S (O) ₂ –C _1–4 Alkyl radicals, e.g. -S (O) ₂ –CH ₂ CH ₃ 、–S(O) ₂ –CH ₂ CH ₂ CH ₃ or-S (O) ₂ –CH ₂ CH ₂ CH ₂ CH ₃ 。

In some embodiments, X is N in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, I-7F, I-7G, or I-7H.

In some embodiments, X is CH in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, I-7F, I-7G, or I-7H.

In some embodiments, q is 0 in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, I-7F, I-7G, or I-7H.

In some embodiments, p is 0, 1 or 2 in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, I-7F, I-7G or I-7H.

In some embodiments, each R in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, I-7F, I-7G, or I-7H ¹⁰ Independently halogen (e.g., fluorine or chlorine), hydroxy, amino, cyano, C _1–4 Alkyl (e.g. methyl), C _1–4 Haloalkyl (e.g. C _1–4 Fluoroalkyl groups, e.g. CF ₃ )、–O–C _1–4 Alkyl (e.g. -O-CH ₃ )、–S(O) ₂ –C _1–4 Alkyl (e.g. -S (O) ₂ –CH ₃ ) Or C _1–4 Hydroxyalkyl (e.g. -CH ₂ –OH)。

In some embodiments, each R in a compound represented by formula I, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, I-7F, I-7G, or I-7H ¹⁰ Independently fluorine, chlorine, hydroxy, methyl, -S (O) ₂ –CH ₃ or-CH ₂ –OH。

In some embodiments, of the compounds represented by formulas I-7A, I-7F or I-7H,independently isWherein each R is ¹⁰ Is defined as in any one of the embodiments of the invention, e.g. C _1–4 Alkyl (e.g. methyl) or C _1–4 Hydroxyalkyl (e.g. -CH ₂ OH). For example, in some embodiments, +.>Can be +.>For example, in some embodiments, +.>Can be +.>

In some embodiments, of the compounds of formula I-7E or I-7G, Independently isWherein each R is ¹⁰ Is defined as in any one of the embodiments of the invention, e.g. C _1–4 Alkyl (e.g., methyl).

In some embodiments, of the compounds represented by formulas I-7B, I-7C or I-7D,is->(e.g.)> )、(e.g.)>) Or->(e.g.)>) Wherein each R is ¹⁰ Is defined as in any one of the embodiments of the invention, e.g. hydroxy, halogen (e.g. fluorine or chlorine) or-S (O) ₂ –C _1–4 Alkyl (e.g. -S (O) ₂ –CH ₃ )。

In some embodiments, the compound of formula I has the structure:

in another aspect, the present invention also provides a method for preparing a compound of formula I, comprising the steps of: reacting a compound shown in a formula II with a base (such as sodium hydroxide) in an organic solvent (such as a mixed solvent of tetrahydrofuran and methanol) to obtain the compound shown in the formula I;

wherein X, Y is,R ¹ And R is ² Is defined as in any one of the embodiments of the invention.

In another aspect, the present invention also provides a compound of formula II:

In another aspect, the present invention also provides a pharmaceutical composition comprising

(i) The compound shown in the formula I, or a tautomer, a stereoisomer, a racemate or an isotopic derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a crystal form or solvate of any one of the foregoing; and

(ii) A pharmaceutically acceptable carrier.

In another aspect, the present invention also provides the use of a compound of formula I, or a tautomer, stereoisomer, racemate or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, or a pharmaceutical composition as a medicament.

In another aspect, the invention also provides the use of a compound of formula I, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, or the pharmaceutical composition as a Janus kinase (e.g., JAK1 and/or JAK 2) inhibitor.

In another aspect, the invention provides a method of inhibiting a Janus kinase (e.g., JAK1 and/or JAK 2) in vivo, in vitro, or ex vivo comprising contacting a compound of formula I, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, or a pharmaceutical composition of the invention, with the Janus kinase.

In another aspect, the invention also provides the use of a compound of formula I, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, or a pharmaceutical composition for the manufacture of a medicament for the treatment of a disease associated with Janus kinase (e.g., JAK1 and/or JAK 2).

In another aspect, the invention also provides an application of the compound shown in the formula I, or a tautomer, stereoisomer, racemate or isotopic derivative thereof, or a pharmaceutically acceptable salt of any one of the above, or a crystal form or solvate of any one of the above, or a pharmaceutical composition in preparing a medicament for treating autoimmune diseases or cancers.

In another aspect, the invention provides a method of treating a disease associated with Janus kinases (e.g., JAK1 and/or JAK 2) comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, or a pharmaceutical composition.

In another aspect, the invention provides a method of treating an autoimmune disease or cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of the compound of formula I, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, or a pharmaceutical composition.

The disease associated with Janus kinase (e.g., JAK1 and/or JAK 2) of the present invention may be an autoimmune disease or cancer.

The autoimmune disease or autoimmune disease associated with Janus kinase according to the present invention may be, for example, psoriasis, rheumatoid arthritis, inflammatory bowel disease, sjogren's syndrome, behcet's disease, multiple sclerosis or systemic lupus erythematosus.

The cancer or cancer associated with Janus kinase according to the present invention may be, for example, kaposi's sarcoma, giant lymph node hyperplasia, lymphoma, leukemia multiple myeloma or myeloproliferative disease. The myeloproliferative disorder can be, for example, polycythemia Vera (PV), essential Thrombocythemia (ET), essential myelofibrosis (PMF), chronic Myelogenous Leukemia (CML), chronic monocytic leukemia (CMML), eosinophilic syndrome (HES), idiopathic Myelofibrosis (IMF), or Systemic Mastocytosis (SMCD).

Unless otherwise defined, terms used herein have the following definitions, and terms not referred to hereinafter are defined as commonly understood by those skilled in the art to which the present invention pertains.

The term "tautomer" refers to a functional group isomer that results from the rapid movement of an atom in a molecule at two positions. For example, acetone and 1-propen-2-ol can be converted to each other by rapid movement of a hydrogen atom on oxygen and on the alpha-carbon.

The term "stereoisomer" refers to an isomer, such as cis-trans isomer (e.g., Z-isomer, E-isomer), optical isomer (e.g., enantiomer, diastereomer), atropisomer, etc., which is caused by the same order of atoms or groups of atoms in a molecule connected to each other, but different spatial arrangement. These stereoisomers may be isolated, purified and enriched by asymmetric synthesis methods or chiral separation methods (including but not limited to thin layer chromatography, rotary chromatography, column chromatography, gas chromatography, high pressure liquid chromatography, etc.), and may be obtained by chiral resolution by bonding (chemical bonding, etc.) or salifying (physical bonding, etc.) other chiral compounds. Optical isomers include enantiomers and diastereomers. All such isomers and mixtures thereof are included within the scope of the present invention.

The term "isotopic derivative" means that one or more atoms in a compound are replaced by one or more atoms having a particular atomic mass or mass number. Examples of isotopes that can be incorporated into compounds include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (e.g. ² H、 ³ H、 ¹³ C、 ¹⁴ C、 ¹⁵ N、 ¹⁸ O、 ¹⁷ O、 ¹⁸ F、 ³⁵ S and ³⁶ cl). Isotopic compounds can generally be prepared according to the methods described herein by substituting a non-isotopically labeled reagent with an isotopically labeled reagent. Typical examples of isotopic derivatives include deuterated compounds.

The term "pharmaceutically acceptable salt" refers to salts of a compound prepared with relatively non-toxic, pharmaceutically acceptable acids or bases. When compounds contain relatively acidic functional groups, base addition salts may be obtained by contacting neutral forms of such compounds with a sufficient amount of a pharmaceutically acceptable base in pure solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include, but are not limited to: lithium salt, sodium salt, potassium salt, calcium salt, aluminum salt, magnesium salt, zinc salt, bismuth salt, ammonium salt, diethanolamine salt. When the compounds of the present invention contain relatively basic functional groups, the acid addition salts may be obtained by contacting the neutral form of such compounds with a sufficient amount of a pharmaceutically acceptable acid in pure solution or in a suitable inert solvent. The pharmaceutically acceptable acids include inorganic acids including, but not limited to: hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, phosphoric acid, phosphorous acid, sulfuric acid, and the like. The pharmaceutically acceptable acid includes organic acids including, but not limited to: acetic acid, propionic acid, oxalic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, salicylic acid, tartaric acid, methanesulfonic acid, isonicotinic acid, acidic citric acid, oleic acid, tannic acid, pantothenic acid, hydrogen tartrate, ascorbic acid, gentisic acid, fumaric acid, gluconic acid, sugar acid, formic acid, ethanesulfonic acid, pamoic acid (i.e., 4' -methylene-bis (3-hydroxy-2-naphthoic acid)), amino acids (e.g., glutamic acid, arginine), and the like. When the compound contains relatively acidic and relatively basic functional groups, it can be converted into a base addition salt or an acid addition salt. See, for example, berge et al, "Pharmaceutical Salts", journal of Pharmaceutical Science 66:1-19 (1977), or Handbook of Pharmaceutical Salts: properties, selection, and Use (P.Heinrich Stahl and Camille G.Wermuth, ed., wiley-VCH, 2002).

In some embodiments, the pharmaceutically acceptable salts of the compounds of formula (I) described herein may be acid addition salts of the compounds of formula (I) with pharmaceutically acceptable acids, including, but not limited to: hydrogen chloride, hydrogen bromide, sulfuric acid, carbonic acid, oxalic acid, citric acid, succinic acid, tartaric acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, maleic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, ferulic acid. The pharmaceutically acceptable salts of the compounds of formula (I) may be prepared by reaction with an equivalent or excess of an acid (inorganic or organic) in a suitable solvent or solvent mixture. The acids include, but are not limited to, hydrogen chloride, hydrogen bromide, sulfuric acid, carbonic acid, oxalic acid, citric acid, succinic acid, tartaric acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, maleic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, or ferulic acid. The solvent includes, but is not limited to, methanol, ethanol, methylene chloride, acetone, ethyl acetate, toluene or tetrahydrofuran, or any of several mixed solvents.

The term "crystalline form" refers to a form in which ions or molecules are strictly and periodically arranged in three dimensions in a defined manner and have a periodic recurrence pattern at certain intervals; due to the above-mentioned periodic arrangement, there may be various crystal forms, i.e., polymorphism.

The term "solvate" refers to a substance formed by the binding of a molecule with a stoichiometric or non-stoichiometric amount of a solvent. The solvent molecules in the solvate may be present in an ordered or unordered arrangement. Such solvents include, but are not limited to: water, methanol, ethanol, and the like.

The term "halogen" means fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.

The term "amino" means-NH ₂ A group.

The term "hydroxy" denotes an-OH group.

The term "cyano" denotes a-CN group.

The term "alkyl" refers to a saturated straight or branched monovalent hydrocarbon radical having a number of carbon atoms. C (C) _1–4 Alkyl means an alkyl group having 1 to 4 carbon atoms, including C ₁ Alkyl, C ₂ Alkyl, C ₃ Alkyl, C ₄ Alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and pentyl.

The term "haloalkyl" refers to an alkyl group substituted with one or more (e.g., 1, 2, 3, or 4) halogens (e.g., fluorine, chlorine, bromine, or iodine, preferably fluorine), including, but not limited to, -CHF ₂ 、–CH ₂ F、–CF ₃ 、–CHF–CH ₂ Cl。

The term "hydroxyalkyl" refers to an alkyl group substituted with one or more (e.g., 1, 2, 3, or 4) hydroxy groups, including but not limited to-CH ₂ OH、–CHOH–CH ₂ OH。C _1–4 Hydroxyalkyl groups include, but are not limited to, -CH ₂ OH、–CHOH–CH ₂ OH、–CH(CH ₂ OH)–CH ₂ OH。

The term "alkenyl" refers to a straight or branched chain monovalent hydrocarbon radical having a number of carbon atoms and at least one carbon-carbon double bond, wherein carbon-carbonThe double bond may be located anywhere within the alkenyl group (e.g)。C ₂ –C ₆ Alkenyl refers to alkenyl groups having 2 to 6 carbon atoms, including C ₂ Alkenyl, C ₃ Alkenyl, C ₄ Alkenyl, C ₅ Alkenyl, C ₆ Alkenyl groups. Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pent-dienyl, hexenyl.

The term "alkoxy" refers to-O-R ^X Wherein R is ^X Are alkyl groups as defined above. In some embodiments, C _1–4 The alkoxy group may be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.

The term "cycloalkyl" refers to a saturated monocyclic or polycyclic (e.g., fused, spiro, or bridged) hydrocarbon group formed from carbon atoms. In some embodiments, cycloalkyl is a monocyclic group. In some embodiments, C _3–6 Cycloalkyl may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, C _3–8 Cycloalkyl groups may be C _3–6 Cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

The term "heteroaryl" or "heteroaromatic ring" refers to an aromatic cyclic group formed by a carbon atom and at least one heteroatom, where the heteroatoms may be N, O and S. A 5 membered heteroaryl or heteroaromatic ring such as furan, thiophene, pyrrole, pyrazole, oxazole, thiazole, imidazole or triazole. A 6 membered heteroaryl or heteroaromatic ring or for example pyrazine, pyridazine, pyridine or pyrimidine.

As used herein, the term "x-y member" in a cyclic group means that the number of atoms on the ring is x-y. For example, cyclopropyl is 3 membered, tetrahydropyrrolyl is 5 membered, and piperidinyl is 6 membered.

The term "substituted" or "substituent" means that one or more hydrogen atoms are replaced by the indicated group. When no substitution positions are indicated, substitution may be at any position, but only formation of a stable or chemically feasible chemical is allowed.

When any variable (e.g., R) occurs more than once in the composition or structure of a compound, its definition in each case is independent. Thus, for example, if a group is substituted with 0 to 2R, the group may optionally be substituted with up to two R's, and R's in each case have independent options. Furthermore, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. For example, the number of the cells to be processed, Wherein w is 0, 1 or 2, each R is independently methyl or fluoro, then +.>Comprises->Etc.

The term "treatment" refers to therapeutic therapy. When specific conditions are involved, treatment refers to: (1) alleviating a disease or one or more biological manifestations of a disorder, (2) interfering with (a) one or more points in a biological cascade that results in or causes a disorder or (b) one or more biological manifestations of a disorder, (3) ameliorating one or more symptoms, effects, or side effects associated with a disorder, or one or more symptoms, effects, or side effects associated with a disorder or treatment thereof, or (4) slowing the progression of a disorder or one or more biological manifestations of a disorder.

The term "therapeutically effective amount" refers to an amount of a compound that is sufficient to be effective to treat or prevent a disease or disorder described herein when administered to a patient. The "therapeutically effective amount" will vary depending on the compound, the condition and severity thereof, and the age of the patient to be treated, but can be adjusted as desired by one of ordinary skill in the art. Generally, the compounds of the invention are used in therapy in a human dosage range of 1-1000 mg/day. Dosages outside this range may also be used depending on the dosage form and the severity of the disease.

The pharmaceutical composition may be formulated into various types of administration unit dosage forms such as tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, and injections (solutions or suspensions) and the like, preferably tablets, capsules, liquids, suspensions, and injections (solutions or suspensions), depending on the therapeutic purpose.

The compound of the invention can be clinically administrated by oral administration, injection and the like.

The term "subject" refers to any animal, preferably a mammal, most preferably a human, that is about to or has received administration of a compound or composition. The term "mammal" includes any mammal. Examples of mammals include, but are not limited to, cattle, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., with humans being preferred.

All patents and publications referred to herein are incorporated by reference in their entirety.

The above preferred conditions can be arbitrarily combined on the basis of not deviating from the common knowledge in the art, and thus, each preferred embodiment of the present invention can be obtained.

The reagents and materials used in the present invention are commercially available.

The invention has the positive progress effects that: the invention provides a novel-structure pyrido ring compound which has good JAK inhibition activity.

Detailed Description

For the purpose of further illustrating the invention, the following examples are given by way of illustration only and are not to be construed as limiting the invention.

Synthesis of key intermediate 1:

step 1: 4-chloro-7-azaindole (25.0 g,163.8 mmol) was dissolved in 250mL of dichloromethane and DMAP (2.0 g,16.5 mmol), triethylamine was added(34.0 mL,245.8 mmol) was followed by stirring at room temperature for 30 minutes. Benzenesulfonyl chloride (23.3 mL,180.3 mmol) was dissolved in 50mL of dichloromethane and then slowly added dropwise to the reaction solution, stirred at room temperature for about 4 hours, then filtered, and the filtrate was collected and concentrated in vacuo to give a brown solid. Pulping with appropriate amount of methanol to obtain 4-chloro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b ]]Pyridine was an off-white solid (43.0 g, 90%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₃ H ₁₀ ClN ₂ O ₂ S calculated 293.0146, found 293.0139.

Step 2: 4-chloro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (30.0 g,102.7 mmol) was dissolved in 300mL of dichloromethane and tetramethyl ammonium nitrate (28.0 g,205.5 mmol) was added to the solution at 25℃and stirred. Trifluoroacetic anhydride (57.3 ml,410.8 mmol) was slowly added dropwise while keeping the temperature of the reaction solution below 30 ℃. After the addition, the mixture was stirred at room temperature for 5 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give a yellow solid. Pulping with appropriate amount of methanol to obtain 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b ] ]Pyridine was a pale yellow solid (25.9 g, 75%). The product was used directly in the next step without further purification. ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝9.09(s,1H),8.29(d,J＝3.0Hz,1H),8.17(t,J＝4.5Hz,2H),7.79(t,J＝7.5Hz,1H),7.68(t,J＝7.5Hz,2H),7.11(d,J＝3.0Hz,1H)ppm；HRMS(ESI):m/z[M+Na] ⁺ .C ₁₃ H ₈ ClN ₃ NaO ₄ S calculated 359.9816, found 359.9801.

Step 3: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (10.0 g,29.7 mmol) was dissolved in 100mL of tetrahydrofuran, DIPEA (7.7 g,59.3 mmol) and 1-Boc-3-aminopyrrolidine (8.3 g,44.5 mmol) were added and the mixture was warmed to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Beating and solidifying the mixture by using a proper amount of methanol to obtain 3- (((5-nitro-1- (phenylsulfonyl)) room temperature-curing)1H-pyrrolo [2,3-b]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester was a yellow solid (10.1 g, 70%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₆ N ₅ O ₆ S calculated 488.1598, found 488.1607.

Step 4: 3- (((5-nitro-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridine-4-yl) amino-pyrrolidine-1-carboxylic acid tert-butyl ester (10.0 g,20.5 mmol) was dissolved in 100mL of methanol, palladium on carbon (1 g, 10%) was added, and after three more times the air in the reaction flask was replaced with hydrogen, the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. The filtrate is collected after suction filtration and concentrated in vacuo to give 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester was a pale pink foamy solid (9.2 g, 98%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₈ N ₅ O ₄ S calculated 458.1857, found 458.1862.

Step 5: triethyloxonium tetrafluoroboric acid (11.2 g,59.1 mmol) and (R) -lactamide (5.3 g,59.1 mmol) were dissolved in 100mL tetrahydrofuran, stirred at room temperature for 3 hours and concentrated in vacuo to give an oil of the mixture, which was then dissolved in 100mL ethanol and 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)) was added]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (9.0 g,19.7 mmol) was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give 3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester was a pale green oil (6.0 g, 60%). HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₅ H ₃₀ N ₅ O ₅ S calculated 512.1962, found 512.1983.

Step 6: 3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester (6.0 g,11.7 mmol) was dissolved in 60mL dichloromethane and trifluoroacetic acid (13.4 g,117.4 mmol) was slowly added and stirred at room temperature for 12 hours and concentrated in vacuo to give intermediate-1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a light brown oil (4.8 g, 100%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₀ H ₂₂ N ₅ O ₃ S calculated 412.1438, found 412.1448.

Synthesis of key intermediate 2:

step 1: a solution of 2-diethoxyphosphorylacetonitrile (5.7 g,32.1 mmol) in THF (50 mL) was added to a solution of NaH (1.2 g,30.7 mmol) in THF (50 mL) at 0deg.C. The mixture was stirred at room temperature for 1 hour, then cooled again to 0℃and a solution of tert-butyl 3-oxaazetidine-1-carboxylate (5.0 g,29.2 mmol) in THF (50 mL) was added over 1 hour. The reaction solution was then stirred at room temperature for 16 hours. After the reaction, a proper amount of water was added, and the aqueous phase was extracted twice with EA. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated in vacuo to give tert-butyl 3- (cyanomethylene) azetidine-1-carboxylate as a yellow solid (5.2 g, 78%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₁₀ H ₁₅ N ₂ O ₂ Calculated 195.1128, found 195.1121.

Step 2: DBU (11.8 g,77.4 mmol) was added to a solution of tert-butyl 3- (cyanomethylene) azetidine-1-carboxylate (5.0 g,25.8 mmol) and 4-nitropyrazole (3.2 g,28.7 mmol) in acetonitrile (30 mL). The mixture was then stirred at room temperature for 16 hours. After the reaction, a proper amount of water was added, and the aqueous phase was extracted twice with EA. The organic layers were combined and washed with brine, dried over sodium sulfateThe residue was purified by silica gel chromatography (petroleum ether: ethyl acetate=4:1) to give 3- (cyanomethyl) -3- (4-nitro-1H-pyrazol-1-yl) azetidine-1-carboxylic acid tert-butyl ester as a white oil (4.0 g, 50%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₃ H ₁₈ N ₅ O ₄ Calculated 308.1353, found 308.1346.

Step 3: tert-butyl 3- (cyanomethyl) -3- (4-nitro-1H-pyrazol-1-yl) azetidine-1-carboxylate (4.0 g,13.0 mmol) was dissolved in 50mL of methanol, palladium on carbon (0.4 g, 10%) was added thereto, the air in the reaction flask was replaced with hydrogen three or more times, and the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and the reaction was completed by TLC. The filtrate was collected after suction filtration and concentrated in vacuo to give 3- (4-amino-1H-pyrazol-1-yl) -3- (cyanomethyl) azetidine-1-carboxylic acid tert-butyl ester as a light brown foamy solid (3.5 g, 98%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₁₃ H ₂₀ N ₅ O ₂ Calculated 278.1612, found 278.1610.

Step 4: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (3.5 g,10.5 mmol) was dissolved in 100mL of tetrahydrofuran, DIPEA (4.1 g,31.5 mmol) and tert-butyl 3- (4-amino-1H-pyrazol-1-yl) -3- (cyanomethyl) azetidine-1-carboxylate (3.5 g,12.6 mmol) were added and then heated to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Beating solidification using an appropriate amount of methanol gives tert-butyl 3- (cyanomethyl) -3- (4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl-azetidine-1-carboxylic acid ester was a yellow solid (4.3 g, 70%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₇ N ₈ O ₆ S calculated 579.1769, found 579.1782.

Step 5: tert-butyl 3- (cyanomethyl) -3- (4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl azetidine-1-carboxylic acid ester (4.3 g,7.4 mmol) was dissolved in 50mL of methanol, and addedAfter palladium on carbon (0.4 g, 10%) was added, the reaction was maintained in a hydrogen atmosphere by replacing the air in the reaction flask with hydrogen three or more times, and stirred at room temperature for 12 hours, and the reaction was completed by TLC. The filtrate is collected after suction filtration and concentrated in vacuo to obtain tert-butyl 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) -1H-pyrazol-1-yl) -3- (cyanomethyl) azetidine-1-carboxylic acid ester was a light brown foamy solid (4.0 g, 98%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ Calculated value C ₂₆ H ₂₉ N ₈ O ₄ S549.2027, found 549.2043.

Step 6: tert-butyl 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl) -3- (cyanomethyl) azetidine-1-carboxylic acid ester (4.0 g,7.3 mmol) was dissolved in 50mL of DMF and Na was added ₂ S ₂ O ₅ (6.9 g,36.5 mmol) and 5-hydroxymethylfurfural (1.8 g,14.6 mmol) were then heated to 90℃and reacted with stirring for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give 3- (cyanomethyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (phenylsulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidine-1-carboxylic acid ester was a yellow solid (3.3 g, 69%). HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₃₂ H ₃₁ N ₈ O ₆ S calculated 655.2082, found 655.2063.

Step 7: 3- (cyanomethyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidine-1-carboxylic acid ester (3.0 g,4.6 mmol) was dissolved in 60mL of dichloromethane, trifluoroacetic acid (5.2 g,46.0 mmol) was slowly added, stirred at room temperature for 12 hours, and concentrated in vacuo to afford intermediate-2: 2- (3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl)1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile was a pale yellow oil (2.3 g, 91%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₃ N ₈ O ₄ S calculated 555.1557, found 555.1555.

Synthesis of key intermediate 3 and intermediate 4:

step 1: 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (3.0 g,6.6 mmol) was dissolved in 50mL of DMF and Na was added ₂ S ₂ O ₅ (6.2 g,32.8 mmol) and 5-hydroxymethylfurfural (1.7 g,13.2 mmol) were then warmed to 90℃and stirred for reaction for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give tert-butyl 3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4,5-d ]Pyrrolo [2,3-b]Pyridine-1 (6H) -ylpyrrolidine-1-carboxylate as a yellow solid (2.4 g, 65%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₃₀ N ₅ O ₆ S calculated 564.1911, found 564.1921.

Step 2: tert-butyl 3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -ylpyrrolidine-1-carboxylate (2.0 g,3.6 mmol) was dissolved in 50mL dichloromethane, trifluoroacetic acid (4.1 g,36.0 mmol) was slowly added and stirred at room temperature for 12 hours, and concentrated in vacuo to afford intermediate-3: (5- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-methanol was a pale yellow oil (1.5 g, 91%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₂ N ₅ O ₄ S calculated 464.1387, found 464.1385.

Step 3: 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (3.0 g,6.6 mmol) was dissolved in 50mL of DMF and Na was added ₂ S ₂ O ₅ (6.2 g,32.8 mmol) and 2-imidazolecarboxaldehyde (1.3 g,13.2 mmol) were then warmed to 90℃and reacted with stirring for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give tert-butyl 3- (2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) imidazo [4,5-d ]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid ester was a yellow solid (2.2 g, 63%). HRMS (ESI) M/z [ M+H ]] ⁺ Calculated value C ₂₆ H ₂₈ N ₇ O ₄ S534.1918, found 534.1910.

Step 4: tert-butyl 3- (2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid ester (2.0 g,3.8 mmol) was dissolved in 50mL dichloromethane and trifluoroacetic acid (4.3 g,38.0 mmol) was slowly added and stirred at room temperature for 12 hours and concentrated in vacuo to afford intermediate-4: 2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine was a pale yellow oil (1.2 g, 74%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₁ H ₂₀ N ₇ O ₂ S434.1394, found 434.1390.

Synthesis of key intermediate 5, intermediate 6, intermediate 7 and intermediate 8:

step 1: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (5.0 g,14.8 mmol) was dissolved in 50mL of tetrahydrochyseneDIPEA (3.8 g,29.7 mmol) and (R) - (+) -1-Boc-3-aminopyrrolidine (4.1 g,22.3 mmol) were added to furan and then heated to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Beating with an appropriate amount of methanol to obtain 3- ((5-nitro-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid (R) -tert-butyl ester was a yellow solid (4.8 g, 66%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₆ N ₅ O ₆ S calculated 488.1598, found 488.1605.

Step 2: 3- ((5-nitro-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridine-4-yl) amino) pyrrolidine-1-carboxylic acid (R) -tert-butyl ester (4.8 g,9.9 mmol) was dissolved in 50mL of methanol, palladium on carbon (0.5 g, 10%) was added, and after three more times the air in the reaction flask was replaced with hydrogen, the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. Vacuum filtering, collecting filtrate, and vacuum concentrating to obtain (R) 3- (((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester was a pale pink foamy solid (4.2 g, 93%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₈ N ₅ O ₄ S calculated 458.1857, found 458.1850.

Step 3: triethyloxonium tetrafluoroboric acid (5.0 g,26.3 mmol) and (R) -lactamide (2.3 g,26.3 mmol) were dissolved in 80mL tetrahydrofuran, stirred at room temperature for 3 hours and concentrated in vacuo to give an oil of the mixture, which was then dissolved in 80mL ethanol and (R) 3- (((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)) was added ]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (4.0 g,8.8 mmol) was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give (R) -tert-butyl 3- (2- ((R) -1-hydroxyethyl)-6- (benzenesulfonyl) imidazo [4,5-d ]]Pyrrolo [2,3-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester was a pale green oil (3.2 g, 72%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₃₀ N ₅ O ₅ S calculated 512.1962, found 512.1974.

Step 4: (R) -tert-butyl 3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester (3.0 g,5.9 mmol) was dissolved in 50mL dichloromethane and trifluoroacetic acid (6.7 g,58.6 mmol) was slowly added and stirred at room temperature for 12 hours, concentrated in vacuo to afford intermediate-5: (R) -1- (6- (benzenesulfonyl) -1- ((R-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a light brown oil (2.2 g, 91%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₀ H ₂₂ N ₅ O ₃ S calculated 412.1438, found 412.1433.

Step 5: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (8.0 g,23.7 mmol) was dissolved in 80mL of tetrahydrofuran, DIPEA (6.1 g,47.5 mmol) and (S) - (-) -1-Boc-3-aminopyrrolidine (6.6 g,35.6 mmol) were added and the mixture was warmed to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Beating with an appropriate amount of methanol to obtain 3- ((5-nitro-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid (S) -tert-butyl ester was a yellow solid (8.1 g, 70%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₆ N ₅ O ₆ S calculated 488.1598, found 488.1603.

Step 6: 3- ((5-nitro-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridine-4-yl) amino) pyrrolidine-1-carboxylic acid (S) -tert-butyl ester (8.0 g,16.4 mmol) was dissolved in 80mL of methanol, palladium on carbon (0.8 g, 10%) was added, and after three more times the air in the reaction flask was replaced with hydrogen, the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC monitored the reaction was complete. Vacuum concentrating the filtrate to obtain (S) 3- (((5-amino-1- (benzenesulfonyl) -1H-picolide) Pyrrolo [2,3-b]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester was a pale pink foamy solid (7.4 g, 99%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₈ N ₅ O ₄ S calculated 458.1857, found 458.1850.

Step 7: triethyloxonium tetrafluoroboric acid (8.7 g,46.0 mmol) and (R) -lactamide (4.1 g,46.0 mmol) were dissolved in 100mL tetrahydrofuran, stirred at room temperature for 3 hours and then concentrated in vacuo to give an oil of the mixture, which was then dissolved in 100mL ethanol and added with (S) 3- (((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b))]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (7.0 g,15.3 mmol) was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give (S) -tert-butyl 3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester was a pale green oil (5.3 g, 68%). HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₅ H ₃₀ N ₅ O ₅ S calculated 512.1962, found 512.1969.

Step 8: (S) -tert-butyl 3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester (5.0 g,9.8 mmol) was dissolved in 50mL dichloromethane and trifluoroacetic acid (11.2 g,97.8 mmol) was slowly added and stirred at room temperature for 12 hours, concentrated in vacuo to afford intermediate-6: (R) -1- (6- (benzenesulfonyl) -1- ((S-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a light brown oil (3.8 g, 94%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₀ H ₂₂ N ₅ O ₃ S calculated 412.1438, found 412.1433.

Step 9: (R) 3- (((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [ e ])2,3-b]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (3.0 g,6.6 mmol) was dissolved in 50mL of DMF and Na was added ₂ S ₂ O ₅ (6.2 g,32.8 mmol) and 5-hydroxymethylfurfural (1.7 g,13.2 mmol) were then warmed to 90℃and stirred for reaction for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give (R) -tert-butyl 3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4,5-d ]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid ester was a yellow solid (2.0 g, 54%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₃₀ N ₅ O ₆ S calculated 564.1911, found 564.1922.

Step 10: (R) -tert-butyl 3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid ester (2.0 g,3.6 mmol) was dissolved in 30mL dichloromethane and trifluoroacetic acid (4.1 g,36.0 mmol) was slowly added and stirred at room temperature for 12 hours and concentrated in vacuo to afford intermediate-7: (R) - (5- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-yl methanol was a pale yellow oil (1.6 g, 97%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₂ N ₅ O ₄ S calculated 464.1387, found 464.1380.

Step 11: (R) 3- (((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (3.0 g,6.6 mmol) was dissolved in 50mL of DMF and Na was added ₂ S ₂ O ₅ (6.2 g,32.8 mmol) and 2-imidazolecarboxaldehyde (1.3 g,13.2 mmol) were then warmed to 90℃and reacted with stirring for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and then vacuum Concentration and purification of the residue using a silica gel column (petroleum ether: ethyl acetate=1:1) gave (R) -tert-butyl 3- (2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester was a yellow solid (2.5 g, 71%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₈ N ₇ O ₄ S calculated 534.1918, found 534.1910.

Step 12: (R) -tert-butyl 3- (2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester (2.5 g,4.7 mmol) was dissolved in 30mL dichloromethane and trifluoroacetic acid (5.3 g,46.9 mmol) was slowly added and stirred at room temperature for 12 hours, concentrated in vacuo to afford intermediate-8: (R) -2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine was a pale yellow oil (1.7 g, 84%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₁ H ₂₀ N ₇ O ₂ S calculated 434.1394, found 434.1390.

Synthesis of key intermediate 9:

step 1: 4- ((tert-Butoxycarbonyl) amino) cyclohexanecarboxylic acid (10.0 g,41.1 mmol) was dissolved in 100mL of tetrahydrofuran and cooled to-15℃and isobutyl chloroformate (11.3 g,82.2 mmol) was added at low temperature followed by stirring at low temperature for 1 hour, followed by slow addition of 100mL of aqueous ammonia and stirring at room temperature for 4 hours, after the reaction was completed, suction filtration to give tert-butyl (4-carbamoyl cyclohexyl) carbamate as a white solid (8.0 g, 80%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₁₂ H ₂₃ N ₂ O ₃ Calculated 243.1703, found 243.1698.

Step 2: tert-butyl (4-carbamoyl-cyclohexyl) carbamate (8.0 g,33.1 mmol) was dissolved in 50mL of pyridine and cooled to-15℃and slowed down at low temperaturePhosphorus oxychloride (10 g,66.2 mmol) was slowly added dropwise, the mixture was stirred at low temperature for 3 hours after the completion of the reaction, the reaction solution was slowly poured into 200mL of ice water mixture, and the aqueous phase was extracted three times with EA. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give tert-butyl (4-cyanocyclohexyl) carbamate as a milky solid (5.5 g, 74%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₂ H ₂₁ N ₂ O ₂ Calculated 225.1598, found 225.1603.

Step 3: step 12: tert-butyl (4-cyanocyclohexyl) carbamate (5.5 g,24.6 mmol) was dissolved in 50mL of dichloromethane, trifluoroacetic acid (28.0 g,245.5 mmol) was slowly added and stirred at room temperature for 12 hours, and concentrated in vacuo to give trans-4-aminocyclohexane carbonitrile as an off-white solid (2.5 g, 82%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₇ H ₁₃ N ₂ Calculated 125.1073, found 125.1082.

Step 4: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (4.5 g,13.4 mmol) was dissolved in 50mL of tetrahydrofuran, DIPEA (3.5 g,26.9 mmol) and trans-4-aminocyclohexane carbonitrile (2.5 g,20.2 mmol) were added, and the mixture was heated to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Beating with an appropriate amount of methanol to obtain trans-4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) cyclohexanecarbonitrile was a yellow solid (4.2 g, 74%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₀ H ₂₀ N ₅ O ₄ S calculated 426.1231, found 426.1237.

Step 5: trans-4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (4.2 g,9.9 mmol) was dissolved in 50mL of methanol, palladium on carbon (0.4 g, 10%) was added, and after three more times the air in the reaction flask was replaced with hydrogen, the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. The filtrate is collected after suction filtration and concentrated in vacuum to obtain an intermediate-9: trans-4- ((5-amino-1)- (phenylsulfonyl) -1H-pyrrolo [2,3-b]Pyridin-4-yl) amino) cyclohexanecarbonitrile was a light brown foamy solid (3.5 g, 90%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₀ H ₂₂ N ₅ O ₂ S calculated 396.1489, found 396.1492.

Synthesis of key intermediate 10 and intermediate 11:

step 1: 4-nitropyrazole (5 g,44.2 mmol) was dissolved in 50mL of DMF, and potassium carbonate (12.2 g,88.4 mmol) and 3-bromopropionitrile (8.9 g,66.3 mmol) were added and stirred at room temperature for 12 hours, followed by TLC monitoring the reaction completion. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted three times with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (4-nitro-1H-pyrazol-1-yl) propionitrile as a pale yellow solid (4.8 g, 65%) which was used in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₆ H ₇ N ₄ O ₂ Calculated 167.0564, found 167.0569.

Step 2: 3- (4-Nitro-1H-pyrazol-1-yl) propionitrile (4.8 g,28.9 mmol) was dissolved in 50mL of methanol, palladium on carbon (0.5 g, 10%) was added, the air in the reaction flask was replaced with hydrogen three or more times, and the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. The filtrate was collected after suction filtration and concentrated in vacuo to give 3- (4-amino-1H-pyrazol-1-yl) propionitrile as a light brown foamy solid (3.5 g, 89%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₆ H ₉ N ₄ Calculated 137.0822, found 137.0833.

Step 3: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (5.8 g,17.2 mmol) was dissolved in 60mL of tetrahydrofuran and DIPEA (4.4 g,34.4 mmol) and 3- (4-amino-1H-pyrazol-1-yl) propionitrile (3) were added5g,25.7 mmol) and then heated to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Curing with a suitable amount of methanol to give 3- (4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl) propionitrile as a yellow solid (5.1 g, 68%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₁₉ H ₁₆ N ₇ O ₄ S calculated 438.0979, found 438.0985.

Step 4: 3- (4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (5.0 g,11.4 mmol) was dissolved in 50mL of methanol, palladium on carbon (0.5 g, 10%) was added, the air in the reaction flask was replaced three times with hydrogen, and the reaction was kept under a hydrogen atmosphere, stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. The filtrate is collected after suction filtration and concentrated in vacuum to obtain an intermediate-10: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl-propionitrile was a pale yellow foamy solid (4.5 g, 97%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₉ H ₁₈ N ₇ O ₂ S calculated 408.1237, found 408.1241.

Step 5: 4-nitropyrazole (2.5 g,22.1 mmol) was dissolved in 50mL of DMF, and after addition of potassium carbonate (6.1 g,44.2 mmol) and 2-bromoacetonitrile (4.0 g,33.2 mmol) the reaction was stirred at room temperature for 12 hours and monitored by TLC to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted three times with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (4-nitro-1H-pyrazol-1-yl) acetonitrile as a pale yellow solid (2.2 g, 65%) which was used in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₅ H ₅ N ₄ O ₂ Calculated 153.0407, found 153.0411.

Step 6: 3- (4-Nitro-1H-pyrazol-1-yl) acetonitrile (2.2 g,14.5 mmol) was dissolved in 30mL of methanol, and palladium on carbon (0.3 g, 10%) was added thereto and then the reaction was replaced with hydrogen gasAfter the reaction was carried out in a hydrogen atmosphere with air in the flask three or more times, the reaction was stirred at room temperature for 12 hours and monitored by TLC to be complete. The filtrate was collected after suction filtration and concentrated in vacuo to give 3- (4-amino-1H-pyrazol-1-yl) acetonitrile as a light brown foamy solid (1.6 g, 91%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₅ H ₇ N ₄ Calculated 123.0665, found 123.0671.

Step 7: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (2.8 g,8.2 mmol) was dissolved in 60mL of tetrahydrofuran, DIPEA (2.1 g,16.4 mmol) and 3- (4-amino-1H-pyrazol-1-yl) acetonitrile (1.5 g,12.3 mmol) were added, and the mixture was heated to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Curing with a suitable amount of methanol to give 3- (4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl) acetonitrile was a yellow solid (2.5 g, 72%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₁₈ H ₁₄ N ₇ O ₄ S calculated 424.0822, found 424.0833.

Step 8: 3- (4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl acetonitrile (2.5 g,5.9 mmol) was dissolved in 30mL of methanol, palladium on carbon (0.3 g, 10%) was added, the air in the reaction flask was replaced with hydrogen three or more times, and the reaction was kept under a hydrogen atmosphere, stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. The filtrate is collected after suction filtration and concentrated in vacuum to obtain an intermediate-11: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl) acetonitrile was a pale yellow, foamy solid (2.0 g, 86%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₈ H ₁₆ N ₇ O ₂ S calculated 394.1081, found 394.1084.

Synthesis of key intermediate 12:

step 1: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (2.0 g,5.9 mmol) was dissolved in 50mL of toluene, tris (dibenzylideneacetone) dipalladium (0.2 g, 10%), 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene (0.2 g, 10%) and p-cyanoaniline (1.4 g,11.9 mmol) were added under nitrogen and heated to reflux and stirred for 5 hours under nitrogen and TLC monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted three times with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=2:1) to give 4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) benzonitrile as a yellow solid (1.2 g, 48%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₀ H ₁₄ N ₅ O ₄ S calculated 420.0761, found 420.0771.

Step 2:4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino benzonitrile (1.2 g,2.9 mmol) was dissolved in 30mL of methanol, palladium on carbon (0.2 g, 10%) was added, and after three more times the air in the flask was replaced with hydrogen, the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC monitored the reaction was complete. The filtrate is collected after suction filtration and concentrated in vacuum to obtain an intermediate-12: 4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) benzonitrile as a yellow foamy solid (1.1 g, 99%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₀ H ₁₆ N ₅ O ₂ S calculated 390.1019, found 390.1023.

Synthesis of key intermediate 13:

step 1: 4-chloro-1H-pyrazolo [3,4-b]Pyridine (10.0 g,65.4 mmol) was dissolved in 100mL of dichloromethane, DMAP (0.8 g,6.5 mmol) was added,triethylamine (18.0 mL,130.7 mmol) was stirred at room temperature for 30 min. Benzenesulfonyl chloride (10.1 mL,78.5 mmol) was dissolved in 50mL of dichloromethane and then slowly added dropwise to the reaction solution, stirred at room temperature for about 4 hours, filtered, and the filtrate was collected and concentrated in vacuo to give a brown solid. Pulping with appropriate amount of methanol to give 4-chloro-1- (benzenesulfonyl) -1H-pyrazolo [3,4-b ] ]Pyridine was an off-white solid (17.0 g, 89%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₂ H ₉ ClN ₃ O ₂ S calculated 294.0099, found 293.0089.

Step 2: 4-chloro-1- (benzenesulfonyl) -1H-pyrazolo [3,4-b]Pyridine (15.0 g,51.2 mmol) was dissolved in 150mL of dichloromethane and tetramethyl ammonium nitrate (13.9 g,102.3 mmol) was added to the solution at 25℃and stirred. Trifluoroacetic anhydride (28.6 ml,204.8 mmol) was slowly added dropwise while maintaining the reaction temperature below 30 ℃. After the addition, the mixture was stirred at room temperature for 5 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give a yellow solid. Pulping with appropriate amount of methanol to obtain 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrazolo [2,3-b]Pyridine was a pale yellow solid (12.3 g, 71%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₂ H ₈ ClN ₄ O ₄ S calculated 338.9949, found 338.9930.

Step 3: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrazolo [2,3-b ]Pyridine (5.0 g,14.8 mmol) was dissolved in 50mL of tetrahydrofuran, DIPEA (3.8 g,29.6 mmol) and (S) - (-) -1-Boc-3-aminopyrrolidine (4.2 g,22.2 mmol) were added and the mixture was warmed to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Beating and solidifying with proper amount of methanol to obtain (S) 3- (((5-nitro-1- (benzenesulfonyl) -1H-pyrazolo [3, 4-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester was a yellow solid (5.1 g, 71%). The product was used directly in the next step without further purification. HRMS (E)SI):m/z[M+H] ⁺ .C ₂₁ H ₂₅ N ₆ O ₆ S calculated 489.1551, found 488.1559.

Step 4: (S) 3- (((5-nitro-1- (benzenesulfonyl) -1H-pyrazolo [3, 4-b)]Pyridine-4-yl) amino-pyrrolidine-1-carboxylic acid tert-butyl ester (5.0 g,10.2 mmol) was dissolved in 50mL of methanol, palladium on carbon (0.5 g, 10%) was added, and after three more times the air in the reaction flask was replaced with hydrogen, the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. The filtrate is collected after suction filtration and concentrated in vacuo to obtain (S) 3- (((5-amino-1- (benzenesulfonyl) -1H-pyrazolo [3, 4-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester was a pink foamy solid (4.5 g, 96%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₁ H ₂₇ N ₆ O ₄ S calculated 459.1809, found 459.1813.

Step 5: triethyloxonium tetrafluoroboric acid (5.0 g,26.1 mmol) and (R) -lactamide (2.3 g,26.1 mmol) were dissolved in 50mL tetrahydrofuran, stirred at room temperature for 3 hours and then concentrated in vacuo to give an oil of the mixture, which was then dissolved in 50mL ethanol and added with (S) 3- (((5-amino-1- (benzenesulfonyl) -1H-pyrazolo [3, 4-b))]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (4.0 g,8.7 mmol) was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give (S) -tert-butyl 3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrazolo [3,4-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester was a green oil (2.2 g, 49%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₉ N ₆ O ₅ S calculated 513.1915, found 513.1923.

Step 6: (S) -tert-butyl 3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrazolo [3,4-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester (2.0 g,3.9 mmol) was dissolvedTrifluoroacetic acid (4.4 g,39.0 mmol) was slowly added to 20mL of dichloromethane and stirred at room temperature for 12 hours, concentrated in vacuo to afford intermediate-13: (R) -1- (6- (benzenesulfonyl) -1- ((S) -pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrazolo [3,4-b]Pyridin-2-yl) ethanol was a light brown oil (1.5 g, 91%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₉ H ₂₁ N ₆ O ₃ S calculated 413.1390, found 413.1399.

Example 1

3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester

Step 1:3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester (0.4 g,0.8 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS01:3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester (0.2 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.95(s,1H),8.59(s,1H),7.51(s,1H),6.35(s,1H),5.75(t,J＝3.0Hz,2H),5.17-5.21(m,1H),3.82-3.93(m,2H),3.76(t,J＝9.0Hz,1H),3.40-3.47(m,1H),2.58-2.74(m,1H),2.28-2.41(m,1H),1.65(d,J＝9.0Hz,3H),1.45(d,J＝24.0Hz,9H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.23,148.61,148.53,142.1,129.04,127.15,120.71,115.63,99.37,79.85,63.60,58.31,53.58,48.13,28.47,27.05,22.81ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₂₆ N ₅ O ₃ Calculated 372.2030, found 372.2018.

Example 2

4- (3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidine-1-carbonyl) benzonitrile

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and paracyanobenzoyl chloride (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 4- (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carbonyl) benzonitrile was as a brown oil (0.3 g, 76%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₂₅ N ₆ O ₄ S calculated 541.1653, found 541.1643.

Step 2: 4- (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carbonyl) benzonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to make it weakBasic, and the organic phase separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS02:4- (3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carbonyl) benzonitrile (0.1 g, 45%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.96(s,1H),8.87(s,1H),8.21(d,J＝9.0Hz,2H),8.10(d,J＝9.0Hz,2H),7.66(s,1H),6.88(s,1H),4.28-4.69(m,1H),3.81–3.92(m,2H),3.74-3.79(m,1H),3.30-3.45(m,2H),1.93-2.15(m,2H),1.49(d,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ172.53,148.69,148.51,142.16,139.53,132.09,129.04,127.91,127.16,120.75,118.63,115.61,113.69,99.39,63.60,58.45,52.57,47.13,27.11,22.82ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₂ H ₂₁ N ₆ O ₂ Calculated 401.1721, found 401.1723.

Example 3

(4-fluorophenyl) (3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl methanone

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and parafluorobenzoyl chloride (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to give (4-fluorophenyl) ) (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) methanone was a brown oil (0.3 g, 77%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₅ FN ₅ O ₄ S calculated 534.1606, found 534.1619.

Step 2: (4-fluorophenyl) (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) methanone (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, 1M sodium hydroxide was added to the solution, and the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS03: (4-fluorophenyl) (3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl-methanone (0.1 g, 45%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.97(s,1H),8.60(d,J＝6.0Hz,1H),7.74-7-76(m,1H),7.55(d,J＝15.0Hz,2H),7.36(t,J＝9.0Hz,1H),7.22(t,J＝9.0Hz,1H),6.45(d,J＝48.0Hz,1H),5.77(s,2H),5.15-5.23(m,1H),3.97-4.20(m,2H),3.71–3.93(m,2H),2.66-2.73(m,1H),1.67(d,J＝6.0Hz,3H),1.38(t,J＝37.5Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ172.58,163.91,148.83,148.29,142.54,130.84,129.03,128.83,127.29,120.85,115.61,115.33,99.57,63.67,58.49,52.59,47.83,27.29,22.89ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₁ FN ₅ O ₂ Calculated 394.1674, found 394.1682.

Example 4

(1R) -1- (1- (1- (1- (ethylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10 mL tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and ethyl sulfonyl chloride (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (1- (1- (ethylsulfonyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a yellow oil (0.3 g, 82%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₆ N ₅ O ₅ S ₂ Calculated 504.1370, found 504.1389.

Step 2: (1R) -1- (1- (1- (1- (ethylsulfonyl) pyrrolidinyl-3-yl) -6- (phenylsulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5 mL tetrahydrofuran and 5 mL methanol, 1M sodium hydroxide 5 mL was added, and after stirring at room temperature for 5 hours, the reaction was complete by TLC. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS04: (1R) -1- (1- (1- (1- (ethylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g, 93%). ¹ HNMR(300 MHz,DMSO-d ₆ ):δ＝12.03(s,1H),8.97(s,1H),7.69(s,1H),6.78(s,1H),4.18-4.77(m,1H),3.60-3.79(m,1H),3.40-3.51(m,2H),3.11–3.32(m,2H),2.74-2.89(m,2H),1.90-2.15(m,2H),1.49(d,J＝6.0 Hz,3H),1.22(t,J＝9.0 Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.77,148.56,142.77,129.19,127.31,120.77,115.68,113.69,99.48,63.29,57.53,56.10,51.11,50.09,26.20,22.89,2.69ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₆ H ₂₂ N ₅ O ₃ S calculated 364.1438, found 364.1472.

Example 5

(1R) -1- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and propylsulfonyl chloride (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a yellow oil (0.3 g, 80%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₈ N ₅ O ₅ S ₂ Calculated 518.1526, found 518.1536.

Step 2: (1R) -1- (1- (1- (1- (propylsulfonyl) pyrrolidinyl-3-yl) -6- (phenylsulfonyl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.6 mmol) was dissolved in 5mL tetrahydrofuranAfter adding 5mL of 1M sodium hydroxide to a mixed solvent of 5mL of methanol, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS05: (1R) -1- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g, 91%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.93(s,1H),8.77(s,1H),7.58(s,1H),6.67(s,1H),4.21–4.68(m,1H),3.51–3.73(m,1H),3.21–3.28(m,2H),3.18(t,J＝9.0Hz,2H),2.79-2.99(m,2H),1.83-2.25(m,2H),1.52-1.68(m,2H),1.49(d,J＝9.0Hz,3H),0.90(t,J＝6.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.66,148.59,142.19,129.02,127.15,120.73,115.61,113.69,99.31,63.66,60.40,57.59,56.19,50.02,26.28,22.84,13.33,12.44ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₂₄ N ₅ O ₃ S378.1594, found 378.1599.

Example 6

(1R) -1- (1- (1- (1- (butylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and butylsulfonyl chloride (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Adding saturated sodium bicarbonate to the reaction solution to be slightly alkaline, and The organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (1- (1- (butylsulfonyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a pale white oil (0.3 g, 77%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₃₀ N ₅ O ₅ S ₂ Calculated 532.1683, found 532.1703.

Step 2: (1R) -1- (1- (1- (1- (butylsulfonyl) pyrrolidinyl-3-yl) -6- (phenylsulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS06: (1R) -1- (1- (1- (1- (butylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g, 91%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.03(s,1H),8.47(s,1H),7.68(s,1H),6.87(s,1H),4.41–4.62(m,1H),3.50-3.79(m,1H),3.11–3.22(m,2H),3.10(t,J＝6.0Hz,2H),2.77-2.80(m,2H),1.93-2.15(m,2H),1.51-1.61(m,2H),1.48(d,J＝6.0Hz,3H),1.29-1.31(m,2H),0.93(t,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.65,148.51,142.18,129.04,127.11,120.79,115.61,99.39,63.68,57.93,57.58,56.17,50.01,26.28,22.82,21.93,21.05,13.88ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₆ N ₅ O ₃ S calculated 392.1751, found 392.1755.

Example 7

(1R) -1- (1- (1- (1- (((2-fluorophenyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and then o-fluorobenzenesulfonyl chloride (0.2 g,1.1 mmol) was slowly added dropwise thereto, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (1- (1- (((2-fluorophenyl) sulfonyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a pale yellow oil (0.3 g, 72%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₅ FN ₅ O ₅ S ₂ Calculated 570.1276, found 570.1257.

Step 2: (1R) -1- (1- (1- (1- (((2-fluorophenyl) sulfonyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS07: (1R) -1- (1- (1- (1- (((2-fluorophenyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 44%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.16(s,1H),8.87(s,1H),7.80-7.84(m,1H),7.63-7.75(m,1H),7.60(s,1H),7.48-7.52(m,1H),7.21-7.43(m,1H),6.77(s,1H),4.51–4.70(m,1H),3.63-3.81(m,1H),3.09-3.33(m,2H),2.63-2.83(m,2H),1.89-2.19(m,2H),1.93(d,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ158.22,148.66,148.57,142.18,133.53,129.03,128.91,127.11,126.33,124.69,120.74,115.84,115.64,99.38,63.69,57.58,55.70,49.63,26.24,22.89ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₁ FN ₅ O ₃ S calculated 430.1344, found 430.1350.

Example 8

(1R) -1- (1- (1-tosylpyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and p-toluenesulfonyl chloride (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (6- (benzenesulfonyl) -1- (1-toluenesulfonylpyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a yellow oil (0.3 g, 73%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₈ N ₅ O ₅ S ₂ Calculated 566.1526, measured 566.1523。

Step 2: (1R) -1- (6- (benzenesulfonyl) -1- (1-toluenesulfonylpyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS08: (1R) -1- (1- (1-tosylpyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g, 89%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.95(s,1H),8.84(s,1H),7.74(d,J＝7.5Hz,2H),7.68(s,1H),7.40(d,J＝7.5Hz,2H),6.87(s,1H),4.53-4.68(m,1H),3.55-3.81(m,1H),3.10-3.25(m,2H),2.79-2.89(m,2H),2.34(s,3H),1.91–2.25(m,2H),1.43(d,J＝4.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.63,148.59,143.33,142.17,137.66,129.39,129.00,128.33,127.16,120.71,115.65,99.39,63.64,57.58,55.74,49.63,26.23,22.81,21.39ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₄ N ₅ O ₃ S calculated 426.1594, found 426.1596.

Example 9

(1R) -1- (1- (1- (1- ([ (1, 1' -biphenyl ] -4-ylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added thereto, and p-phenylbenzenesulfonyl chloride (0.3 g,1.1 mmol) was slowly added dropwise thereto, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (1- (1- ([ [1,1' -biphenyl))]-4-ylsulfonyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a yellow oil (0.3 g, 66%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₃₂ H ₃₀ N ₅ O ₅ S ₂ Calculated 628.1683, found 628.1686.

Step 2: (1R) -1- (1- (1- ([ [1,1' -biphenyl)]-4-ylsulfonyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS09: (1R) -1- (1- (1- ([ (1, 1' -biphenyl)) biphenyl) ]-4-ylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g, 86%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.35(s,1H),8.74(s,1H),7.88-7.92(m,4H),7.67(s,1H),7.45-7.52(m,4H),7.28-7.41(m,1H),6.87(s,1H),4.43-4.71(m,1H),3.52-3.79(m,1H),3.11–3.35(m,2H),2.77-2.88(m,2H),1.90-2.15(m,2H),1.49(d,J＝6.0Hz,3H)ppm； ¹³ CNMR(75MHz,DMSO-d ₆ )δ148.69,148.53,142.19,140.88,138.62,133.06,129.21,129.04,127.93,127.88,127.11,127.10,120.73,115.63,99.38,63.63,57.58,55.70,49.62,26.25,22.81ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₆ H ₂₆ N ₅ O ₃ S calculated 488.1751, found 488.1757.

Example 10

(1R) -1- (1- (1- (1- (naphthalene-2-ylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridine-2-ethanol

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and naphthalenesulfonyl chloride (0.3 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (1- (1- (1-naphthalen-2-ylsulfonyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a pale yellow oil (0.3 g, 68%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₃₀ H ₂₈ N ₅ O ₅ S ₂ Calculated 602.1526, found 602.1540.

Step 2: (1R) -1- (1- (1- (1-naphthalen-2-ylsulfonyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfateAfter concentration in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS10: (1R) -1- (1- (1- (1- (naphthalene-2-ylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-2-ethanol) (0.2 g, 87%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.04(s,1H),8.87(s,1H),8.80(s,1H),8.30-8.41(m,1H),8.03-8.15(m,1H),8.00(d,J＝7.5Hz,2H),7.59(d,J＝7.5Hz,2H),7.45(s,1H),6.87(s,1H),4.55-4.69(m,1H),3.45-3.91(m,1H),3.15-3.35(m,2H),2.69-2.74(m,2H),1.96-2.28(m,2H),1.49(d,J＝6.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.62,148.51,142.17,137.03,136.71,134.11,129.44,129.09,128.11,127.11,126.25,126.04,123.41,120.74,115.60,99.38,63.69,57.57,55.76,49.60,26.22,22.81ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₄ H ₂₄ N ₅ O ₃ S calculated 462.1594, found 462.1607.

Example 11

(1R) -1- (1- (1- (1- ((4- (trifluoromethoxy) phenyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and p-trifluoromethoxybenzenesulfonyl chloride (0.3 g,1.1 mmol) was slowly added dropwise, and after the addition, the temperature was raised to reflux and stirring for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (6- (benzenesulfonyl) -1- (1- ((4- (trifluoromethoxy))Phenyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrole [2,3-b ]]Pyridin-2-yl) ethanol was a yellow oil (0.3 g, 65%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₅ F ₃ N ₅ O ₆ S ₂ Calculated 636.1193, found 636.1195.

Step 2: (1R) -1- (6- (benzenesulfonyl) -1- (1- ((4- (trifluoromethoxy) phenyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrole [2,3-b ]]Pyridin-2-yl) ethanol (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS11: (1R) -1- (1- (1- (1- ((4- (trifluoromethoxy) phenyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g, 86%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.15(s,1H),8.79(s,1H),7.64(d,J＝7.5Hz,2H),7.59(s,1H),7.12(d,J＝7.5Hz,2H),6.74(s,1H),4.33-4.58(m,1H),3.65-3.83(m,1H),3.15-3.31(m,2H),2.74-2.86(m,2H),1.95-2.35(m,2H),1.46(d,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.88,148.61,148.59,142.10,132.00,129.79,129.04,127.17,126.11,120.73,115.61,114.67,99.38,63.69,57.58,55.70,49.66,26.25,22.81ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₁ F ₃ N ₅ O ₄ S calculated 496.1261, found 496.1262.

Example 12

(1R) -1- (1- (1- (1- (thiophen-2-ylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and thiophenesulfonyl chloride (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (6- (benzenesulfonyl) -1- (1- (thiophen-2-ylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a yellow oil (0.3 g, 74%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₄ N ₅ O ₅ S ₃ Calculated 558.0934, found 558.0949.

Step 2: (1R) -1- (6- (benzenesulfonyl) -1- (1- (thiophen-2-ylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS12: (1R) -1- (1- (1- (1- (thiophene-2-ylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 45%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.02(s,1H),8.84(s,1H),7.70(s,1H),7.20(d,J＝7.5Hz,1H),6.96(d,J＝9.0Hz,2H),6.77(s,1H),4.51–4.69(m,1H),3.57-3.83(m,1H),3.17-3.31(m,2H),2.72-2.85(m,2H),1.93-2.31(m,2H),1.07(d,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.61,148.57,142.11,129.09,127.21,127.11,126.33,120.73,115.60,99.31,63.61,57.59,55.74,49.62,26.22,22.81ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₀ N ₅ O ₃ S ₂ Calculated 418.1002, found 418.1012.

Example 13

2- (1- (ethylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile

Step 1: 2- (3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.3 g,0.5 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.0 mmol) was added thereto, and ethyl sulfonyl chloride (0.1 g,0.8 mmol) was slowly added dropwise thereto, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (1- (ethylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile was a yellow oil (0.2 g, 57%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ Calculated value C ₂₉ H ₂₇ N ₈ O ₆ S ₂ 647.1489, found 647.1482.

Step 2: 2- (1- (ethylsulfonyl)Phenyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.2 g,0.3 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS13:2- (1- (ethylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.1 g, 64%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.94(s,1H),8.90(s,1H),8.69(s,1H),8.14(s,1H),7.37(s,1H),6.41(s,2H),5.95(s,1H),5.43(t,J＝6.0Hz,1H),4.62(d,J＝9.0Hz,2H),4.47(d,J＝6.0Hz,2H),4.34(d,J＝9.0Hz,2H),3.78(s,2H),3.25-3.32(m,2H),1.28(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.88,151.11,148.67,142.16,141.57,130.77,129.79,129.04,127.12,120.74,117.77,115.65,107.93,104.05,100.53,99.38,59.23,57.39,51.60,50.81,23.20,2.62ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₂₃ H ₂₃ N ₈ O ₄ S507.1557, found 507.1549.

Example 14

2- (1- (propylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile

Step 1: 2- (3- (4- (2- (5- (hydroxymethyl)) furan)2-yl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.3 g,0.5 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.0 mmol) was added thereto, and propylsulfonyl chloride (0.1 g,0.8 mmol) was slowly added dropwise thereto, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (1- (propylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile was a yellow oil (0.3 g, 84%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₃₀ H ₂₉ N ₈ O ₆ S ₂ Calculated 661.1646, found 661.1649.

Step 2: 2- (1- (propylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS14:2- (1- (propylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.1 g, 42%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.91(s,1H),8.87(s,1H),8.66(s,1H),8.11(s,1H),7.34(s,1H),6.38(s,2H),5.93(s,1H),5.40(t,J＝6.0Hz,1H),4.58(d,J＝9.0Hz,2H),4.45(d,J＝3.0Hz,2H),4.31(d,J＝9.0Hz,2H),3.75(s,2H),3.24(t,J＝7.5Hz,2H),1.69-1.77(m,2H),1.18-1.30(m,2H),1.00(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ157.85,145.73,143.25,143.07,139.10,135.78,135.68,134.04,128.63,124.75,119.74,117.03,113.11,109.22,104.52,96.44,58.75,57.15,56.11,50.29,27.30,16.89,13.16ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₄ H ₂₅ N ₈ O ₄ S calculated 521.1714, found 521.1695.

Example 15

2- (1- (butylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile

Step 1: 2- (3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.3 g,0.5 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.0 mmol) was added thereto, and then butylsulfonyl chloride (0.1 g,0.8 mmol) was slowly added dropwise thereto, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (1- (butylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile was a yellow oil (0.2 g, 55%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₃₁ H ₃₁ N ₈ O ₆ S ₂ Calculated 675.1802, found 675.1811.

Step 2: 2- (1- (butylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6)- (phenylsulfonyl) imidazo [4,5-d ]]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.2 g,0.3 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS15:2- (1- (butylsulfonyl) -3- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.1 g, 63%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.95(s,1H),8.90(s,1H),8.69(s,1H),8.14(s,1H),7.37(s,1H),6.41(s,2H),5.96(s,1H),5.44(t,J＝6.0Hz,1H),4.62(d,J＝9.0Hz,2H),4.48(d,J＝6.0Hz,2H),4.35(d,J＝9.0Hz,2H),3.78(s,2H),3.29(t,J＝7.5Hz,2H),2.53(s,2H),1.66-1.76(m,2H),1.38-1.50(m,2H),0.92(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ157.86,145.75,143.27,143.09,139.10,135.80,135.69,134.05,128.65,124.76,119.77,117.06,113.13,109.23,104.54,96.46,58.78,57.16,56.13,48.45,27.33,25.08,21.36,13.94ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₅ H ₂₇ N ₈ O ₄ S calculated 535.1870, found 535.1870.

Example 16

(5- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) furan-2-yl) methanol

Step 1: (5- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-di-Hydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-methanol (0.3 g,0.6 mmol) was dissolved in 10mL tetrahydrofuran, DIPEA (0.2 g,1.2 mmol) was added and then propylsulfonyl chloride (0.1 g,0.9 mmol) was slowly added dropwise, and after the addition, the temperature was raised to reflux and stirring for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (5- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-ylfuran-2-yl) methanol was a yellow oil (0.2 g, 54%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₆ H ₂₈ N ₅ O ₆ S ₂ Calculated 570.1476, found 570.1488.

Step 2: (5- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-ylfuran-2-yl) methanol (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS16: (5- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-yl) methanol (0.1 g, 66%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.11(s,1H),8.69(s,1H),7.62(s,1H),7.20(d,J＝3.0Hz,1H),6.83(s,1H),6.64(d,J＝3.0Hz,1H),5.58-5.92(m,1H),5.52(t,J＝6.0Hz,1H),4.59(d,J＝6.0Hz,2H),4.04(t,J＝10.5Hz,1H),3.79-3.87(m,2H),3.53-3.62(m,1H),3.24-3.29(m,2H),2.69-2.83(m,1H),1.76-1.88(m,2H),1.07(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ158.09,144.98,143.27,143.04,136.34,135.19,132.29,125.05,114.29,109.37,105.02,98.97,56.21,54.67,49.36,48.97,46.90,30.36,16.90,13.35ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₄ N ₅ O ₄ S calculated 430.1544, found 430.1550.

Example 17

Cyclopropyl (3- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) methanone

Step 1: (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b ]Pyridin-2-yl) furan-2-methanol (0.3 g,0.6 mmol) was dissolved in 10mL tetrahydrofuran, DIPEA (0.2 g,1.2 mmol) was added and cyclopropanecarbonyl chloride (0.1 g,0.9 mmol) was slowly added dropwise, and after the addition, the temperature was raised to reflux and stirring for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give cyclopropyl (3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) methanone was a brown oil (0.2 g, 58%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₆ N ₅ O ₅ S calculated 532.1649, found 532.1661.

Step 2: cyclopropyl (3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) methanone (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, 1M sodium hydroxide was added to the solution, and the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. Water and its preparation method The phases were extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS17: cyclopropyl (3- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) methanone (0.1 g, 68%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.10(s,1H),8.69(d,J＝3.0Hz,1H),7.60(t,J＝4.5Hz,1H),7.22(dd,J ₁ ＝9.0Hz,J ₂ ＝3.0Hz,1H),6.61(t,J＝4.5Hz,1H),6.46(d,J＝9.0Hz,1H),5.84-6.03(m,1H),5.50(t,J＝4.5Hz,1H),4.57(d,J＝6.0Hz,2H),4.20-4.42(m,1H),4.02-4.12(m,1H),3.81–3.95(m,1H),2.65-2.86(m,1H),1.72-2.01(m,1H),1.25(s,2H),0.84(t,J＝7.5Hz,2H),0.74(d,J＝9.0Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ171.92,158.10,158.05,144.98,143.47,142.97,136.41,135.27,132.40,125.22,114.32,109.43,105.09,105.01,98.67,56.20,45.58,12.55,7.68ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₂ N ₅ O ₃ Calculated 392.1717, found 392.1727.

Example 18

2- (1H-imidazol-2-yl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridine

Step 1: 2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added thereto, and propylsulfonyl chloride (0.2 g,1.0 mmol) was slowly added dropwise thereto, and the mixture was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The water phase is twoThe chloromethane extraction was performed twice. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ]Pyrrolo [2,3-b]Pyridine was a yellow oil (0.2 g, 54%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₆ N ₇ O ₄ S ₂ Calculated 540.1482, found 540.1485.

Step 2: 2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS18:2- (1H-imidazol-2-yl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine (0.1 g, 68%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝13.34(s,1H),12.09(d,J＝9.0Hz,1H),8.72(d,J＝6.0Hz,1H),7.58(t,J＝12.0Hz,2H),7.41(s,1H),7.25(d,J＝6.0Hz,2H),6.83(s,1H),4.08(s,2H),3.83-3.97(m,3H),3.20-3.32(m,2H),2.79(t,J＝9.0Hz,1H),2.11(s,2H),1.76-1.86(m,2H),1.25(s,1H),1.08(t,J＝6.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ157.04,148.61,142.46,138.11,129.09,127.92,122.74,120.71,115.15,99.49,60.42,56.83,56.19,50.01,36.27,13.20,12.62ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₂ N ₇ O ₂ S calculated 400.1550, found 400.1561.

Example 19

2- (1H-imidazol-2-yl) -1- (1- (((trifluoromethyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridine

Step 1: 2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added thereto, and then trifluoromethylsulfonyl chloride (0.2 g,1.0 mmol) was slowly added dropwise thereto, and the mixture was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (1H-imidazol-2-yl) -6- (phenylsulfonyl) -1- (1- (((trifluoromethyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrole [2,3-b ]]Pyridine was a yellow oil (0.3 g, 77%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₁₉ F ₃ N ₇ O ₄ S ₂ Calculated 566.0887, found 566.0894.

Step 2: 2- (1H-imidazol-2-yl) -6- (phenylsulfonyl) -1- (1- (((trifluoromethyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrole [2,3-b ]]Pyridine (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS19:2- (1H-imidazol-2-yl) -1- (1- (((trifluoromethyl) sulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridine (0.1 g, 44%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝13.36(s,1H),12.16(s,1H),8.72(s,1H),7.66(s,1H),7.41(s,1H),7.26(s,2H),6.65(s,1H),4.17(d,J＝9.0Hz,2H),3.90(d,J＝6.0Hz,1H),2.57-2.72(m,1H),1.25(s,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ144.80,142.52,138.37,136.04,134.54,132.85,125.37,119.82,104.82,98.39,48.52ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₆ H ₁₅ F ₃ N ₇ O ₂ S calculated 426.0955, found 426.0959.

Example 20

(R) -3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((R-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, carbonyldiimidazole (0.2 g,1.4 mmol) was added thereto, and then trifluoromethylethylamine (0.2 g,1.4 mmol) was slowly added dropwise thereto, and the mixture was stirred at room temperature for 3 hours after the addition. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide was a pale yellow oil (0.2 g, 51%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₄ F ₃ N ₆ O ₄ S calculated 537.1526, found 537.1511.

Step 2: (R) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS20: (R) -3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide (0.1 g, 44%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.96(s,1H),8.62(s,1H),7.51(s,1H),7.09(s,1H),6.37(s,1H),5.80(d,J＝6.0Hz,2H),5.22(t,J＝6.0Hz,1H),3.87-3.96(m,5H),3.49(d,J＝6.0Hz,1H),2.64-2.76(m,1H),2.43(s,1H),1.68(d,J＝3.0Hz,3H),1.53(s,1H),1.26(s,3H),0.89(d,J＝6.0Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ155.73,148.66,148.57,142.76,129.09,127.12,124.28,120.70,115.65,99.38,63.64,57.99,54.17,48.74,41.88,26.60,22.82ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₂₀ F ₃ N ₆ O ₂ Calculated 397.1594, found 397.1603.

Example 21

(R) -1- (1- ((R) -1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridine-2-one

Radical) ethanol

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((R-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL tetrahydrofuran DIPEA (0.2 g,1.4 mmol) was added and propanesulfonyl chloride (0.2 g,1.1 mmol) was slowly added dropwise, after which the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -1- (6- (benzenesulfonyl) -1- ((R) -1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a yellow oil (0.3 g, 80%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₈ N ₅ O ₅ S ₂ Calculated 518.1526, found 518.1534.

Step 2: (R) -1- (6- (benzenesulfonyl) -1- ((R) -1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS21: (R) -1- (1- ((R) -1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g, 91%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.97(s,1H),8.62(s,1H),7.56(s,1H),6.72(s,1H),5.81(d,J＝6.0Hz,2H),5.22(t,J＝6.0Hz,1H),3.82-3.94(m,2H),3.74(t,J＝9.0Hz,1H),3.51–3.59(m,1H),3.28(t,J＝7.5Hz,2H),2.65-2.75(m,1H),1.78-1.85(m,2H),1.68(d,J＝6.0Hz,3H),1.53(s,1H),1.26(s,1H),1.08(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ155.12,144.83,136.22,134.22,132.43,124.69,104.91,98.76,62.52,53.69,49.72,49.02,46.86,31.15,22.08,16.98,13.32ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₂₄ N ₅ O ₃ S calculated 378.1594, found 378.1609.

Example 22

Trans-4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) and 5-hydroxymethylfurfural (0.2 g,1.1 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give trans-4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow solid (0.2 g, 53%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₄ N ₅ O ₄ S calculated 502.1544, found 502.1556.

Step 2: trans-4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified by silica gel chromatography (petroleum ether: acetic acid)Ethyl=1:1) to afford LXS22: trans-4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.99(s,1H),8.60(s,1H),7.51(s,1H),7.03(s,1H),6.87(s,1H),6.57(s,1H),5.47(s,1H),4.88(s,1H),4.55(s,1H),3.11(s,1H),2.35(d,J＝9.0Hz,2H),2.24(d,J＝12.0Hz,2H),1.98(s,3H),1.88(d,J＝12.0Hz,2H),1.19(t,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.81,150.11,146.67,144.93,142.06,129.05,127.92,122.75,120.71,115.65,105.93,104.75,99.68,64.56,57.69,30.22,26.91,24.60ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₀ N ₅ O ₂ Calculated 362.1612, found 362.1625.

Example 23

(R) -3- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide

Step 1: (R) - (5- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-yl methanol (0.3 g,0.6 mmol) was dissolved in 10mL tetrahydrofuran, carbonyldiimidazole (0.2 g,1.2 mmol) was added, and after dropwise addition, trifluoromethylethylamine (0.2 g,1.2 mmol) was slowly added, and after dropwise addition, stirring was carried out at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide was a pale yellow oil (0.2 g,52%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₄ F ₃ N ₆ O ₅ S calculated 589.1475, found 589.1482.

Step 2: (R) -3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide (0.2 g,0.3 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS23: (R) -3- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide (0.1 g, 66%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.08(s,1H),8.66(s,1H),7.57(s,1H),7.19(s,1H),7.09(s,1H),6.61(s,1H),6.47(s,1H),5.94(d,J＝9.0Hz,1H),5.49(s,1H),4.57(d,J＝6.0Hz,2H),3.95(d,J＝9.0Hz,6H),2.71(t,J＝12.0Hz,1H),1.26(s,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ155.75,153.18,151.71,148.07,144.94,142.96,129.54,127.72,124.74,120.77,115.35,107.53,104.35,99.68,57.79,54.88,53.59,48.73,41.81,26.20ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₀ F ₃ N ₆ O ₃ Calculated 449.1543, found 449.1550.

Example 24

(R) -3- (2- (1H-imidazol-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide

Step 1: (R) -2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, carbonyldiimidazole (0.2 g,1.4 mmol) was added thereto, and then trifluoromethylethylamine (0.2 g,1.4 mmol) was slowly added dropwise thereto, and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -3- (2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide was a pale yellow oil (0.2 g, 52%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₂ F ₃ N ₈ O ₃ S calculated 559.1482, found 559.1479.

Step 2: (R) -3- (2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS24: (R) -3- (2- (1H-imidazol-2-yl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide (0.1 g, 67%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝13.34(s,1H),12.10(s,1H),8.72(s,1H),7.58(s,1H),7.41(s,1H),7.25(s,2H),7.10(s,1H),6.47(s,1H),3.89-4.00(m,6H),2.77(t,J＝12.0Hz,1H),2.12(s,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ157.08,155.78,148.66,142.49,138.11,129.00,127.19,124.27,122.77,120.75,115.68,99.33,57.26,54.17,48.70,41.80,26.63ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₁₈ F ₃ N ₈ O calculated 419.1550, found 419.1551.

Example 25

(R) -1- (3- (2- (1H-imidazol-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) prop-2-en-1-one

Step 1: (R) -2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added thereto, and then acryloyl chloride (0.1 g,1.4 mmol) was slowly added dropwise thereto, and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -1- (3- (2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) prop-2-en-1-one was a pale yellow oil (0.2 g, 59%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₂ N ₇ O ₃ S calculated 488.1499, found 488.1511.

Step 2: (R) -1- (3- (2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) prop-2-en-1-one (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, 1M sodium hydroxide was added to the solution, and the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate is added until the reaction liquid is slightly alkaline,and the organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS25: (R) -1- (3- (2- (1H-imidazol-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) prop-2-en-1-one (0.1 g, 70%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝13.34(s,1H),12.10(s,1H),8.72(s,1H),7.58(d,J＝9.0Hz,1H),7.41(s,1H),7.25(s,1H),6.46(s,1H),4.02-4.22(m,2H),3.95(t,J＝9.0Hz,1H),3.67(d,J＝6.0Hz,2H),3.61(d,J＝6.0Hz,1H),3.34(s,2H),3.23(s,1H),2.74-2.88(m,1H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ166.30,157.05,148.66,142.96,138.17,131.16,129.05,127.17,126.88,122.75,120.74,115.65,99.38,57.73,52.07,46.68,27.17ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₁₈ N ₇ O calculated 348.1567, found 348.1557.

Example 26

Trans-4- (2- (2-methylthiazol-5-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) 5-aldehyde-2-methylthiazole (0.2 g,1.1 mmol) was added thereto, and the mixture was stirred for 12 hours after the completion of the dropping, and the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (2-methyl) Thiazol-5-yl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.2 g, 52%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₂₃ N ₆ O ₂ S ₂ 503.1318, found 503.1322.

Step 2: trans-4- (2- (2-methylthiazol-5-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS26: trans-4- (2- (2-methylthiazol-5-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.05(s,1H),8.65(s,1H),8.10(s,1H),7.56(s,1H),6.89(s,1H),4.76(s,1H),3.20(t,J＝12.0Hz,1H),2.80(s,3H),2.43(t,J＝12.0Hz,2H),2.27(d,J＝12.0Hz,2H),2.10(d,J＝15.0Hz,2H),1.86-1.98(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ168.60,144.99,143.26,143.05,136.18,135.29,132.94,127.33,124.63,123.32,104.45,100.98,54.58,31.18,29.48,29.16,28.49,26.19,19.36ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₁₉ N ₆ S calculated 363.1386, found 363.1395.

Example 27

Trans-4- (2- (2-aminothiazol-5-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) was followed by addition of 2-aminothiazole-5-carbaldehyde (0.2 g,1.1 mmol), and the mixture was stirred for 12 hours at 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (2-aminothiazol-5-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.2 g, 52%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₂ N ₇ O ₂ S ₂ Calculated 504.1271, found 504.1277.

Step 2: trans-4- (2- (2-aminothiazol-5-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS27: trans-4- (2- (2-aminothiazol-5-yl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.95(s,1H),8.57(s,1H),7.51(s,2H),7.45(s,1H),6.84(s,1H),4.78(s,1H),3.22(d,J＝12.0Hz,1H),2.44(t,J＝13.5Hz,2H),2.28(d,J＝12.0Hz,2H),1.01(d,J＝12.0Hz,2H),1.91(t,J＝13.5Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ168.94,148.64,144.94,142.16,137.74,129.05,127.15,122.75,122.29,120.75,115.67,99.39,65.97,30.88,26.95,24.66ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₁₈ N ₇ S calculated 364.1339, found 364.1365.

Example 28

Trans-4- (2- (2-methylthiophene-5-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) 5-methyl-2-thiophenecarboxaldehyde (0.2 g,1.1 mmol) was added thereto, and the mixture was stirred for 12 hours after the completion of the dropping, the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (5-methylthiophene-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.2 g, 53%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₄ N ₅ O ₂ S ₂ Calculated 502.1366, found 502.1377.

Step 2: trans-4- (2- (5-methylthiophene-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified by silica gel chromatography (petroleum ether: ethyl acetate=1:1) to give LXS28: trans-4- (2- (2-methylthiophene-5-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.00(s,1H),8.63(s,1H),7.54(s,1H),7.38(d,J＝3.0Hz,1H),7.02(s,1H),6.87(s,1H),4.84(d,J＝12.0Hz,1H),3.21(t,J＝12.0Hz,1H),2.58(s,3H),2.45(t,J＝12.0Hz,2H),2.29(d,J＝12.0Hz,2H),2.03(d,J＝6.0Hz,2H),1.81-1.93(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ145.90,144.93,143.26,136.04,135.11,132.96,129.68,129.49,127.19,124.51,123.28,104.53,100.88,54.70,31.17,29.17,28.65,26.21,15.41ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₀ N ₅ S calculated 362.1434, found 362.1432.

Example 29

Trans-4- (2- (2-methylfuran-5-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) 5-methyl-2-furaldehyde (0.2 g,1.1 mmol) was added thereto, and the mixture was stirred for 12 hours after the completion of the addition, the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (5-methylfuran-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.2 g, 54%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₄ N ₅ O ₃ S calculationValue 486.1594, found 486.1601.

Step 2: trans-4- (2- (5-methylfuran-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS29: trans-4- (2- (2-methylfuran-5-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 70%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.00(s,1H),8.62(s,1H),7.53(s,1H),7.01(s,1H),6.89(s,1H),6.41(s,1H),4.89(t,J＝10.5Hz,1H),3.15(t,J＝12.0Hz,1H),2.53(s,3H),2.40(d,J＝12.0Hz,2H),2.29(d,J＝12.0Hz,2H),2.00(d,J＝10.0Hz,2H),1.91(d,J＝12.0Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ154.49,145.07,143.04,142.81,136.20,135.14,132.90,124.49,123.34,114.47,108.68,104.57,100.44,54.96,31.17,29.36,28.78,26.41,22.57,13.91ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₀ N ₅ O calculated 346.1662, found 346.1664.

Example 30

2- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) phenol

Step 1: 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (0.3 g,0.7 mmol)) Dissolved in 10mL of DMF and added with Na ₂ S ₂ O ₅ After addition of o-hydroxybenzaldehyde (0.2 g,1.4 mmol) (0.7 g,3.5 mmol), the mixture was stirred for 12 hours at 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give 3- (2- (2-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4,5-d ]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester was a yellow solid (0.2 g, 55%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₉ H ₃₀ N ₅ O ₅ S calculated 560.1962, found 560.1965.

Step 2: 3- (2- (2-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester (0.2 g,0.4 mmol) was dissolved in 10mL of dichloromethane, trifluoroacetic acid (0.5 g,4.0 mmol) was slowly added and stirred at room temperature for 12 hours, and concentrated in vacuo to give 2- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) phenol was a pale yellow oil (0.1 g, 61%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₂ N ₅ O ₃ S calculated 460.1438, found 460.1441.

Step 3: 2- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) phenol (0.1 g,0.2 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.1 g,0.4 mmol) was added thereto, and propanesulfonyl chloride (0.1 g,0.3 mmol) was slowly added dropwise thereto, and the mixture was stirred at room temperature for 3 hours after the addition. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) phenol was a pale yellow oil (0.1 g,81%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₈ N ₅ O ₅ S ₂ Calculated 566.1526, found 566.1533.

Step 4: 2- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) phenol (0.1 g,0.2 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS30:2- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) phenol (65.0 mg, 86%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.06(s,1H),8.67(s,1H),7.59(t,J＝3.0Hz,1H),7.49-7.52(m,1H),7.41-7.47(m,1H),7.19(d,J＝9.0Hz,1H),7.01(t,J＝7.5Hz,1H),6.80(d,J＝3.0Hz,1H),5.12-5.24(m,1H),3.98-4.10(m,1H),3.74-3.87(m,2H),3.19-3.25(m,2H),2.69-2.83(m,1H),2.33-2.42(m,1H),1.77-1.84(m,2H),1.05(t,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ170.82,156.82,150.94,144.75,136.04,135.50,132.54,131.85,131.74,124.82,119.58,117.92,116.59,104.91,98.80,60.22,55.10,49.24,46.75,30.10,21.24,16.91,14.55,13.32ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₄ N ₅ O ₃ S calculated 426.1594, found 426.1462.

Example 31

4- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) benzene-1, 3-diol

Step 1: 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) and 2, 4-dihydroxybenzaldehyde (0.2 g,1.4 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give 3- (2, 4-dihydroxyphenyl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidine-1-tert-butyl carboxylate was a yellow solid (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₉ H ₃₀ N ₅ O ₆ S calculated 576.1911, found 576.1919.

Step 2: 3- (2, 4-dihydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-tert-butyl carboxylate (0.3 g,0.5 mmol) was dissolved in 10mL of dichloromethane, trifluoroacetic acid (0.6 g,5.0 mmol) was slowly added and stirred at room temperature for 12 hours, and concentrated in vacuo to give 4- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) benzene-1, 3-diol was a pale yellow oil (0.2 g, 81%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₂ N ₅ O ₄ S476.1387, found 476.1391.

Step 3: 4- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) benzene-1, 3-diol (0.2 g,0.4 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.1 g,0.8 mmol) was added and propanesulfonyl chloride (0.1 g,0.6 mmol) was slowly added dropwise, and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Adding saturated sodium bicarbonate to the reaction solutionWeakly basic and the organic phase separated off. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 4- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-ylbenzene-1, 3-diol was a pale yellow oil (0.2 g, 82%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₈ N ₅ O ₆ S ₂ Calculated 582.1476, found 582.1501.

Step 4: 4- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridine-2-yl-benzene-1, 3-diol (0.2 g,0.3 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS31:4- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) benzene-1, 3-diol (0.1 g, 66%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.97(s,1H),10.15(s,1H),9.84(s,1H),8.63(s,1H),7.57(s,1H),7.29(d,J＝9.0Hz,1H),6.76(d,J＝3.0Hz,1H),6.53(d,J＝3.0Hz,1H),6.42–6.46(m,1H),5.12-5.34(m,1H),3.95(t,J＝9.0Hz,1H),3.73-3.81(m,2H),3.17-3.23(m,2H),2.66-2.80(m,1H),2.30-2.38(m,1H),1.72-1.85(m,2H),1.28-1.31(m,2H),1.08-1.19(m,2H),1.02(t,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ160.74,157.62,151.30,144.70,135.81,135.33,133.33,131.70,124.76,108.69,107.72,104.91,102.94,98.78,54.98,53.91,49.43,46.70,18.47,16.95,13.34ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₄ N ₅ O ₄ S calculated 442.1544, found 442.1405.

Example 32

3- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) phenol

Step 1: 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) and 3-hydroxybenzaldehyde (0.2 g,1.4 mmol) were added thereto, and the mixture was stirred for 12 hours after the completion of the dropping, the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give 3- (2- (3-hydroxyphenyl) -6- (phenylsulfonyl) imidazo [4,5-d ]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester was a yellow solid (0.3 g, 82%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₉ H ₃₀ N ₅ O ₅ S calculated 560.1962, found 560.1969.

Step 2: 3- (2- (3-hydroxyphenyl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester (0.3 g,0.5 mmol) was dissolved in 10mL of dichloromethane, trifluoroacetic acid (0.6 g,5.0 mmol) was slowly added and stirred at room temperature for 12 hours, and concentrated in vacuo to give 3- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) phenol was a pale yellow oil (0.2 g, 81%). The product can be purified without further purificationDirectly used in the next step. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₂ N ₅ O ₃ S calculated 460.1438, found 460.1441.

Step 3: 3- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) phenol (0.2 g,0.4 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.1 g,0.8 mmol) was added thereto, and propanesulfonyl chloride (0.1 g,0.6 mmol) was slowly added dropwise thereto, and the mixture was stirred at room temperature for 3 hours after the addition. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-ylphenol was a pale yellow oil (0.2 g, 81%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₈ N ₅ O ₅ S ₂ Calculated 566.1526, found 566.1529.

Step 4: 3- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine-2-yl phenol (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS32:3- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) phenol (0.1 g, 66%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.06(s,1H),10.04(s,1H),8.68(s,1H),7.60(t,J＝3.0Hz,1H),7.43(t,J＝7.5Hz,1H),7.20(t,J＝6.0Hz,1H),7.00-7.03(m,1H),6.80(d,J＝3.0Hz,1H),5.41-5.53(m,1H),3.99-4.09(m,1H),3.76-3.89(m,2H),3.46-3.55(m,1H),3.16-3.32(m,2H),2.71–2.85(m,1H),2.40-2.49(m,1H),1.72-1.84(m,2H),1.05(t,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ158.03,152.38,144.82,136.27,135.14,132.22,131.63,130.44,120.62,117.30,116.85,111.64,105.14,55.07,49.05,30.03,16.88,13.35ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₄ N ₅ O ₃ S calculated 426.1594, found 426.1464.

Example 33

1- (3- (2, 4-dihydroxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) prop-2-en-1-one

Step 1: 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) and 2, 4-dihydroxybenzaldehyde (0.2 g,1.4 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give 3- (2, 4-dihydroxyphenyl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidine-1-tert-butyl carboxylate was a yellow solid (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₉ H ₃₀ N ₅ O ₆ S calculated 576.1911, found 576.1918.

Step 2: 3- (2, 4-dihydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Dissolution of pyridin-1 (6H) -yl) pyrrolidine-1-tert-butyl carboxylate (0.3 g,0.5 mmol)Trifluoroacetic acid (0.6 g,5.0 mmol) was slowly added to 10mL of dichloromethane and stirred at room temperature for 12 hours, and concentrated in vacuo to give 4- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) benzene-1, 3-diol was a pale yellow oil (0.2 g, 81%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₂ N ₅ O ₄ S calculated 476.1387, found 476.1375.

Step 3: 4- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) benzene-1, 3-diol (0.2 g,0.4 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.1 g,0.8 mmol) was added and then acryloyl chloride (0.1 g,0.6 mmol) was slowly added dropwise and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 1- (3- (2, 4-dihydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) prop-2-en-1-one was a pale yellow oil (0.2 g, 90%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₄ N ₅ O ₅ S calculated 530.1493, found 530.1488.

Step 4: 1- (3- (2, 4-dihydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) prop-2-en-1-one (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, 1M sodium hydroxide was added to the solution, and the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS33:1- (3- (2, 4-dihydroxyphenyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) prop-2-ene1-ketone (0.1 g, 68%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.96(s,1H),8.62(s,1H),7.52(d,J＝6.0Hz,1H),7.26(d,J＝6.0Hz,1H),6.55(s,1H),6.42(d,J＝9.0Hz,1H),4.03-4.10(m,4H),3.55-3.66(m,3H),2.68-2.79(m,1H),2.32(s,1H),2.02(s,4H),1.21(t,J＝6.0Hz,4H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ166.39,159.94,156.62,153.78,148.64,142.18,131.16,130.11,129.05,127.14,126.89,120.74,115.69,110.95,109.05,105.64,99.38,57.77,52.05,46.69,27.17ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₀ N ₅ O ₃ Calculated 390.1561, found 390.1692.

Example 34

3- (2- (3-hydroxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide

Step 1: 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) and 3-hydroxybenzaldehyde (0.2 g,1.4 mmol) were added thereto, and the mixture was stirred for 12 hours after the completion of the dropping, the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give 3- (2- (3-hydroxyphenyl) -6- (phenylsulfonyl) imidazo [4,5-d ]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester was a yellow solid (0.3 g, 82%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₉ H ₃₀ N ₅ O ₅ S calculated 560.1962, found 560.1977.

Step 2: 3- (2- (3-hydroxyphenyl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid tert-butyl ester (0.3 g,0.5 mmol) was dissolved in 10mL of dichloromethane, trifluoroacetic acid (0.6 g,5.0 mmol) was slowly added and stirred at room temperature for 12 hours, and concentrated in vacuo to give 3- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) phenol was a pale yellow oil (0.2 g, 81%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₂ N ₅ O ₃ S calculated 460.1438, found 460.1441.

Step 3: (R) -2- (1H-imidazol-2-yl) -6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine (0.2 g,0.4 mmol) was dissolved in 10mL of tetrahydrofuran, carbonyldiimidazole (0.2 g,1.0 mmol) was added thereto, and then trifluoromethylethylamine (0.2 g,1.0 mmol) was slowly added dropwise thereto, and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide was a pale yellow oil (0.2 g, 79%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₄ F ₃ N ₆ O ₄ S calculated 585.1526, found 585.1531.

Step 4:3- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide (0.2 g,0.3 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and saturated brine was usedWashing, drying over anhydrous sodium sulfate, concentrating in vacuo, and purifying the residue using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS34:3- (2- (3-hydroxyphenyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -N- (2, 2-trifluoroethyl) pyrrolidine-1-carboxamide (0.1 g, 66%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.04(s,1H),8.69(s,1H),7.56(t,J＝3.0Hz,1H),7.43(t,J＝7.5Hz,1H),7.15(t,J＝4.5Hz,2H),6.99-7.08(m,2H),6.43(d,J＝3.0Hz,1H),5.46(t,J＝9.0Hz,1H),3.86-3.98(m,6H),2.71–2.78(m,1H),2.30-2.41(m,1H),1.26(s,1H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ158.03,156.37,152.81,152.40,144.80,136.37,135.20,132.31,131.66,130.50,125.03,120.61,117.57,117.33,116.78,111.67,105.18,98.76,91.18,76.29,73.64,73.34,67.45,30.10ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₀ F ₃ N ₆ O ₂ Calculated 445.1594, found 445.1459.

Example 35

Trans-4- (2- (3-hydroxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) and 3-hydroxybenzaldehyde (0.2 g,1.6 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated.The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₄ N ₅ O ₃ S calculated 498.1594, found 498.1588.

Step 2: trans-4- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS35: trans-4- (2- (3-hydroxyphenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.98(s,1H),9.86(s,1H),8.64(s,1H),7.54(t,J＝3.0Hz,1H),7.41(t,J＝7.5Hz,2H),7.10(t,J＝4.5Hz,2H),6.98-7.01(m,1H),6.87(s,1H),4.48-4.56(m,1H),3.21(s,1H),3.19(s,1H),2.41(t,J＝12.0Hz,2H),2.26(d,J＝12.0Hz,2H),2.02(t,J＝4.5Hz,2H),1.67-1.79(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ157.90,152.05,144.92,136.19,135.11,132.69,132.29,130.35,124.39,123.15,120.52,117.15,116.76,104.60,100.64,55.37,54.78,49.05,29.34,28.75,26.27ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₀ N ₅ O calculated 358.1662, found 358.1655.

Example 36

Trans-4- (2, 4-dihydroxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) was followed by addition of 2, 4-dihydroxybenzaldehyde (0.2 g,1.6 mmol), and the mixture was stirred at 90℃for 12 hours after completion of the dropwise addition. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2, 4-dihydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.3 g, 77%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₄ N ₅ O ₄ S calculated 514.1544, found 514.1560.

Step 2: trans-4- (2, 4-dihydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS36: trans-4- (2, 4-dihydroxyphenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.92(s,1H),8.58(s,1H),7.49(s,1H),7.19(d,J＝9.0Hz,1H),6.84(s,1H),6.58(s,1H),6.41–6.44(m,1H),4.23(d,J＝9.0Hz,1H),3.14(t,J＝12.0Hz,1H),2.79(d,J＝18.0Hz,1H),2.36(d,J＝9.0Hz,2H),2.26(d,J＝15.0Hz,2H),2.02(s,1H),1.62-1.74(m,2H),1.18-1.26(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ160.50,157.73,150.96,144.77,135.36,133.04,132.21,124.09,123.21,109.32,107.49,104.42,85.32,73.67,60.22,54.89,29.20,28.95,26.39,14.55ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₀ N ₅ O ₂ Calculated 374.1612, found 374.1600.

Example 37

Trans-4- (2- (4- (trifluoromethyl) phenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) followed by 4-trifluoromethylbenzaldehyde (0.3 g,1.6 mmol) was added thereto, and the mixture was stirred at 90℃for 12 hours after the completion of the dropwise addition. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (6- (benzenesulfonyl) -2- (4- (trifluoromethyl) phenyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.3 g, 72%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₂₃ F ₃ N ₅ O ₂ S calculated 550.1519, found 550.1521.

Step 2: trans-4- (6- (benzenesulfonyl) -2- (4- (trifluoromethyl) phenyl)) Imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS37: trans-4- (2- (4- (trifluoromethyl) phenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 45%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.04(s,1H),8.68(s,1H),7.97(d,J＝3.0Hz,4H),7.56(t,J＝3.0Hz,1H),6.89(s,1H),4.45-4.53(m,1H),3.17(t,J＝13.5Hz,1H),2.40(t,J＝10.5Hz,2H),2.23(d,J＝12.0Hz,2H),2.03(t,J＝10.5Hz,2H),1.74-1.86(m,2H),1.25(s,1H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ150.58,145.02,136.44,135.27,132.89,131.00,130.63,129.90,126.38,126.10,124.55,123.21,104.58,100.85,72.19,54.92,29.32,28.50,26.22ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₂ H ₁₉ F ₃ N ₅ Calculated 410.1587, found 410.1590.

Example 38

Trans-4- (2- (2-hydroxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) and then 2-hydroxybenzaldehyde (0.2 g,1.6 mmol) were added thereto, and the mixture was warmed toStirring is carried out at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (2-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₄ N ₅ O ₃ S calculated 498.1594, found 498.1600.

Step 2: trans-4- (2- (2-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS38: trans-4- (2- (2-hydroxyphenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.94(s,1H),10.17(s,1H),8.62(s,1H),7.52(t,J＝3.0Hz,1H),7.40-7.46(m,2H),6.98-7.08(m,2H),6.87(d,J＝3.0Hz,1H),4.18-4.26(m,1H),3.14(t,J＝12.0Hz,1H),2.38(t,J＝12.0Hz,2H),2.26(d,J＝10.5Hz,2H),1.60-1.72(m,2H),1.18-1.26(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ156.49,150.28,144.85,135.95,135.45,132.47,132.24,131.75,124.19,123.16,119.68,118.54,116.23,104.41,100.53,72.30,55.03,29.22,28.89,26.37ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₀ N ₅ O calculated 358.1662, found 358.1658.

Example 39

Trans-4- (2- (2-fluoro-4-hydroxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) was followed by addition of 2-fluoro-4-hydroxybenzaldehyde (0.2 g,1.6 mmol), and the mixture was stirred for 12 hours at 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (2-fluoro-4-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a pale yellow oil (0.3 g, 77%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₃ FN ₅ O ₃ S calculated 516.1500, found 516.1511.

Step 2: trans-4- (2- (2-fluoro-4-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS39: trans-4- (2- (2-fluoro-4-hydroxyphenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.99(s,1H),8.63(s,1H),7.54(t,J＝3.0Hz,1H),7.43-7.49(m,1H),6.88(d,J＝3.0Hz,1H),6.82–6.85(m,1H),6.80(d,J＝3.0Hz,1H),4.24(d,J＝12.0Hz,1H),3.13(t,J＝13.5Hz,1H),2.34(d,J＝12.0Hz,2H),2.23(d,J＝12.0Hz,2H),2.02(s,1H),1.94(d,J＝9.0Hz,2H),1.70-1.82(m,2H),1.18-1.26(m,1H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ160.11,159.75,153.77,148.62,142.15,130.54,129.04,127.16,122.75,120.77,116.16,115.64,112.04,104.54,99.38,65.93,30.88,26.91,23.69ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₁₉ FN ₅ O calculated 376.1568, found 376.1562.

Example 40

Trans-4- (2- (2-fluorophenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) was followed by addition of 2-fluorobenzaldehyde (0.2 g,1.6 mmol), and the mixture was stirred for 12 hours after the completion of the dropping, and the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (2-fluorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a pale yellow oil (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₃ FN ₅ O ₂ S calculated 500.1551, found 500.1563.

Step 2: trans-4- (2- (2-fluorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, After adding 5mL of 1M sodium hydroxide, stirring was performed at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS40: trans-4- (2- (2-fluorophenyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.06(s,1H),8.70(s,1H),7.70(t,J＝6.0Hz,2H),7.57(s,1H),7.49(t,J＝9.0Hz,2H),6.91(s,1H),4.27(s,1H),3.13(s,1H),2.35(d,J＝12.0Hz,2H),2.24(d,J＝9.0Hz,2H),2.01(d,J＝6.0Hz,2H),1.75(d,J＝12.0Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ162.07,158.80,146.49,145.00,136.27,135.41,133.08,132.92,132.42,125.44,124.54,123.11,119.40,119.19,116.62,116.34,104.40,100.51,60.22,55.18,29.42,28.59,26.29,14.51ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₁₉ FN ₅ Calculated 360.1619, found 360.1615.

Example 41

Trans-4- (2- (2-hydroxy-4-methoxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) was added 2-fluoro-4-methoxybenzaldehyde (0.2 g,1.6 mmol), and the mixture was stirred at 90℃for 12 hours after completion of the dropwise addition. TLC monitored reaction was complete. Adding saturated sodium bicarbonate to the reaction solution to make the reaction solution alkalescent, and separating out an organic phase. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (2-hydroxy-4-methoxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.3 g, 75%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₂₆ N ₅ O ₄ S calculated 528.1700, found 528.1711.

Step 2: trans-4- (2- (2-hydroxy-4-methoxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS41: trans-4- (2- (2-hydroxy-4-methoxyphenyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.91(s,1H),10.26(s,1H),8.60(s,1H),7.51(t,J＝3.0Hz,1H),7.34(d,J＝9.0Hz,1H),6.86(d,J＝3.0Hz,1H),6.58-6.61(m,2H),4.24(t,J＝13.5Hz,1H),3.83(s,3H),3.15(t,J＝12.0Hz,1H),2.39(t,J＝12.0Hz,2H),2.25(d,J＝12.0Hz,2H),2.01(d,J＝12.0Hz,2H),1.62-1.74(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ162.03,157.72,150.38,144.83,135.83,135.37,133.21,132.24,124.14,123.19,111.08,105.80,104.42,101.63,55.60,54.94,29.20,28.92,26.38ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₂ H ₂₂ N ₅ O ₂ Calculated 388.1768, found 366.1782.

Example 42

Trans-4- (2- (4- (methylthio) phenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) followed by 4-methylthiobenzaldehyde (0.2 g,1.6 mmol) was added thereto, and the mixture was stirred at 90℃for 12 hours after the completion of the dropwise addition. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (4- (methylthio) phenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.3 g, 75%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₂₆ N ₅ O ₂ S ₂ Calculated 528.1522, found 528.1533.

Step 2: trans-4- (2- (4- (methylthio) phenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS42: trans-4- (2- (4- (methylthio) phenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.98(s,1H),8.65(s,1H),7.66(d,J＝9.0Hz,2H),7.54(t,J＝3.0Hz,1H),7.48(d,J＝9.0Hz,2H),6.88(d,J＝3.0Hz,1H),4.49(t,J＝13.5Hz,1H),3.17(t,J＝12.0Hz,1H),2.61(s,3H),2.45(t,J＝12.0Hz,2H),2.25(d,J＝12.0Hz,2H),2.03(d,J＝6.0Hz,2H),1.71-1.83(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.77,148.43,142.89,139.43,129.04,127.77,127.32,127.17,127.01,122.74,120.73,115.64,99.49,65.93,31.96,26.94,24.68,14.88ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₂ H ₂₂ N ₅ O ₂ Calculated 388.1590, found 388.1599.

Example 43

Trans-4- (2- (4-fluorophenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) followed by 4-fluorobenzaldehyde (0.2 g,1.6 mmol) was added thereto, and the mixture was stirred for 12 hours after the completion of the dropping, the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (4-fluorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₃ FN ₅ O ₂ S calculated 500.1551, found 500.1559.

Step 2: trans-4- (2- (4-fluorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction All of them. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS43: trans-4- (2- (4-fluorophenyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.99(s,1H),8.65(s,1H),7.74-7.79(m,2H),7.54(t,J＝3.0Hz,1H),7.46(t,J＝9.0Hz,2H),6.88(d,J＝3.0Hz,1H),4.44(t,J＝12.0Hz,1H),3.15(t,J＝12.0Hz,1H),2.34-2.47(m,2H),2.24(d,J＝12.0Hz,2H),2.04(d,J＝9.0Hz,2H),1.70-1.81(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ162.99,153.74,148.65,142.11,129.19,129.03,127.43,126.22,122.74,120.75,116.43,115.64,99.40,65.93,30.82,26.94,21.54ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₁₉ FN ₅ Calculated 360.1619, found 360.1683.

Example 44

Trans-4- (2- (4- (methylsulfonyl) phenyl) -2, 3-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) followed by 4-methylsulfonylbenzaldehyde (0.3 g,1.6 mmol) was added thereto, and the mixture was stirred for 12 hours after the completion of the dropwise addition, and the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brineDrying over anhydrous sodium sulfate, and vacuum concentrating to obtain trans-4- (2- (4- (methylsulfonyl) phenyl) -6- (phenylsulfonyl) -2, 3-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.3 g, 70%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₂₈ N ₅ O ₄ S ₂ Calculated 562.1577, found 562.1588.

Step 2: trans-4- (2- (4- (methylsulfonyl) phenyl) -6- (phenylsulfonyl) -2, 3-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS44: trans-4- (2- (4- (methylsulfonyl) phenyl) -2, 3-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.2 g, 89%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.40(s,1H),8.93(s,1H),8.22(d,J＝9.0Hz,2H),8.14(s,1H),8.06(d,J＝6.0Hz,2H),7.22(t,J＝3.0Hz,1H),6.63(d,J＝3.0Hz,1H),6.07(d,J＝9.0Hz,1H),4.02-4.10(m,1H),3.30(s,3H),2.73-2.81(m,1H),2.12(d,J＝9.0Hz,2H),2.03(s,2H),1.76-1.87(m,2H),1.44-1.55(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ144.28,139.38,138.74,134.46,131.18,128.94,128.11,127.19,123.38,122.74,108.17,99.36,83.56,61.28,47.74,28.48,26.94,24.93ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₂ H ₂₄ N ₅ O ₂ S calculated 422.1645, found 422.1679.

Example 45

(5- (1- (1- (1- (cyclopropylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) furan-2-yl methanol

Step 1: (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-methanol (0.3 g,0.6 mmol) was dissolved in 10mL tetrahydrofuran, DIPEA (0.2 g,1.2 mmol) was added and cyclopropylsulfonyl chloride (0.1 g,0.9 mmol) was slowly added dropwise, and after the addition, the temperature was raised to reflux and stirring for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (5- (6- (benzenesulfonyl) -1- (1- (cyclopropylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-ylfuran-2-yl) methanol was a yellow oil (0.3 g, 82%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₆ N ₅ O ₆ S ₂ Calculated 568.1319, found 568.1321.

Step 2: (5- (6- (benzenesulfonyl) -1- (1- (cyclopropylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-ylfuran-2-yl) methanol (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS45: (5- (1- (1- (1- (cyclopropylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-yl methanol (0.1 g, 44%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.09(s,1H),8.67(s,1H),7.61(t,J＝3.0Hz,1H),7.19(d,J＝3.0Hz,1H),6.85(s,1H),6.63(d,J＝3.0Hz,1H),5.80-5.92(m,1H),5.51(t,J＝6.0Hz,1H),4.58(d,J＝6.0Hz,2H),4.04-4.10(m,1H),3.81–3.90(m,2H),3.58-3.67(m,1H),2.89-2.97(m,1H),2.71–2.80(m,2H),1.26(s,1H),1.06(t,J＝6.0Hz,4H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.88,151.18,148.60,144.53,142.17,129.04,127.16,120.88,115.63,107.95,104.05,99.38,57.39,56.43,54.43,49.75,37.55,24.66,4.07ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₂ N ₅ O ₄ S calculated 428.1387, found 428.1384.

Example 46

3- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile

Step 1: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) and 5-hydroxymethylfurfural (0.2 g,1.4 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a yellow oil (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₂₀ N ₇ O ₄ S calculated 514.1292, found 514.1299.

Step 2: 3- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3 ] b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS46:3- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.96(s,1H),8.79(s,1H),8.06(s,1H),7.94(s,1H),7.59(s,1H),7.02(d,J＝6.0Hz,1H),6.78(s,1H),6.59(d,J＝6.0Hz,1H),5.04(t,J＝7.5Hz,2H),4.39(s,2H),3.28(t,J＝7.5Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.89,151.18,148.69,142.17,141.89,130.74,129.74,129.04,127.17,120.73,117.77,115.63,107.94,104.05,100.05,99.49,57.40,49.27,15.93ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₁₆ N ₇ O ₂ Calculated 374.1360, found 374.1377.

Example 47

3- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) pyridin-2-amine

Step 1: 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) was added followed by 2-amino-3-pyridinecarbaldehyde (0.2 g,1.4 mmol), and the mixture was stirred for 12 hours at 90 ℃. TL (TL) C monitoring the reaction to completion. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give tert-butyl 3- (2- (2-aminopyridin-3-yl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid ester was a yellow solid (0.3 g, 82%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₃₀ N ₇ O ₄ S calculated 560.2074, found 560.2077.

Step 2: tert-butyl 3- (2- (2-aminopyridin-3-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid ester (0.3 g,0.5 mmol) was dissolved in 10mL of dichloromethane, trifluoroacetic acid (0.6 g,5.0 mmol) was slowly added and stirred at room temperature for 12 hours, and concentrated in vacuo to give 3- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) pyridin-2-amine was a pale yellow oil (0.2 g, 81%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₂ N ₇ O ₂ S calculated 460.1550, found 460.1566.

Step 3: 3- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) pyridin-2-amine (0.2 g,0.4 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.1 g,0.8 mmol) was added and propanesulfonyl chloride (0.1 g,0.6 mmol) was slowly added dropwise and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-ylpyridin-2-amine was a pale yellow oil (0.2 g, 81%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₈ N ₇ O ₄ S ₂ Calculated 566.1639, found 566.1645.

Step 4: 3- (6- (benzenesulfonyl) -1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-ylpyridin-2-amine (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS47:3- (1- (1- (1- (propylsulfonyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) pyridin-2-amine (0.1 g, 67%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.06(s,1H),8.83(s,1H),8.03(t,J＝7.5Hz,1H),7.74(s,2H),7.66(d,J＝6.0Hz,1H),7.56(s,1H),6.81(s,1H),6.68(t,J＝7.5Hz,1H),3.65-3.79(m,1H),3.12-3.36(m,2H),3.10(t,J＝9.0Hz,2H),2.70-2.81(m,2H),1.85-2.14(m,2H),1.69(m,2H),0.93(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ156.68,153.77,148.64,146.69,142.19,134.84,129.04,127.16,120.74,118.74,115.63,113.59,99.49,60.47,56.83,56.18,50.04,26.25,13.38,12.48ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₄ N ₇ O ₂ S calculated 426.1707, found 426.1705.

Example 48

2- (3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (picolide)Pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 2-bromoacetonitrile (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile was a pale yellow oil (0.2 g, 61%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₃ N ₆ O ₃ S calculated 451.1547, found 451.1550.

Step 2: 2- (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours and monitored by TLC to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS48:2- (3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile (0.1 g, 73%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.86(s,1H),8.87(s,1H),7.59(s,1H),6.89(s,1H),4.53-4.68(m,1H),3.68-3.78(m,1H),3.48(s,2H),2.56-2.81(m,2H),2.20-2.30(m,2H),1.90-2.15(m,2H),1.93(t,J＝6.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.59,142.17,129.04,127.16,120.75,115.63,114.78,99.28,63.69,58.18,57.39,54.83,50.04,26.97,22.86ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₆ H ₁₉ N ₆ O calculated 311.1615, found 311.1618.

Example 49

3- (3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 3-bromopropionitrile (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile was a pale yellow oil (0.2 g, 59%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₅ N ₆ O ₃ S calculated 465.1703, found 465.1709.

Step 2: 2- (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours and monitored by TLC to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS49:2- (3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile (0.1 g, 72%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.14(s,1H),8.97(s,1H),7.53(s,1H),6.91(s,1H),4.58-4.72(m,1H),3.69-3.81(m,1H),3.01(t,J＝9.0Hz,2H),2.72-2.85(m,2H),2.70(t,J＝9.0Hz,2H),2.22-2.36(m,2H),1.93-2.19(m,2H),1.58(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.66,142.98,129.03,127.17,120.77,119.04,115.69,99.38,63.69,58.94,57.69,55.16,27.64,22.85,17.17ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₂₁ N ₆ O calculated 325.1771, found 325.1777.

Example 50

3- (4- (2- (5-methylfuran-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl propionitrile

Step 1: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) and 5-methylfurfural (0.2 g,1.4 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (4- (2- (5-methylfuran-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a yellow oil (0.3 g, 82%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₂₀ N ₇ O ₃ S calculated 498.1343, found 498.1350.

Step 2: 3- (4- (2- (5-methylfuran-2-yl) -6- (phenylsulphone)Acyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS50:3- (4- (2- (5-methylfuran-2-yl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl-propionitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.87(s,1H),8.65(s,1H),8.48(s,1H),7.95(s,1H),7.34(s,1H),6.32(d,J＝3.0Hz,1H),6.21(s,1H),5.95(s,1H),4.61(t,J＝4.5Hz,2H),3.26(t,J＝6.0Hz,2H),2.36(s,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ154.31,145.68,143.29,142.72,138.24,135.85,135.54,134.05,129.75,124.57,118.82,118.75,113.43,108.51,104.57,96.45,48.05,19.20,13.73ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₁₆ N ₇ O calculated 358.1411, found 358.1414.

Example 51

3- (3- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl propionitrile

Step 1: (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-methanol (0.3 g,0.6 mmol) was dissolved in 10mL tetrahydrofuran, DIPEA (0.2 g,1.2 mmol) was added and 3-bromopropionitrile (0.2 g,0.9 mmol) was slowly added dropwise, and after the addition, the temperature was raised to reflux and stirring was continued for 3 hours. TLC monitoring reaction completion. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile was a pale yellow oil (0.2 g, 60%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₅ N ₆ O ₄ S calculated 517.1653, found 517.1659.

Step 2: 3- (3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours and monitored by TLC to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS51:3- (3- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile (0.1 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.03(s,1H),8.88(s,1H),7.59(s,1H),7.02(d,J＝9.0Hz,1H),6.84(s,1H),6.59(d,J＝9.0Hz,1H),4.39(s,2H),3.64-3.78(m,1H),3.03(t,J＝9.0Hz,2H),2.74-2.86(m,2H),2.73(t,J＝9.0Hz,2H),2.20-2.35(m,2H),1.90-2.15(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.88,151.18,148.64,144.94,142.17,129.04,127.18,120.79,119.04,115.63,107.94,104.06,99.38,57.39,57.01,55.84,55.19,27.05,17.16ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₁ N ₆ O ₂ Calculated 377.1721, found 377.1728.

Example 52

2- (3- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-ylacetonitrile

Step 1: (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-methanol (0.3 g,0.6 mmol) was dissolved in 10mL tetrahydrofuran, DIPEA (0.2 g,1.2 mmol) was added and 2-bromoacetonitrile (0.2 g,0.9 mmol) was slowly added dropwise, and after the addition, the temperature was raised to reflux and stirring for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile was a pale yellow oil (0.2 g, 61%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₂₃ N ₆ O ₄ S calculated 503.1496, found 503.1500.

Step 2:3- (3- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours and monitored by TLC to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS52:3- (3- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile (0.1 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.99(s,1H),8.67(s,1H),7.58(s,1H),7.06(d,J＝7.5Hz,1H),6.88(s,1H),6.54(d,J＝7.5Hz,1H),4.33(s,2H),3.69-3.83(m,1H),3.48(s,2H),2.56-2.81(m,2H),2.20-2.30(m,2H),1.93-2.18(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.97,151.19,148.63,144.95,142.18,129.03,127.17,120.75,115.69,114.84,107.94,104.05,99.39,57.36,56.72,55.09,54.81,50.05,26.29ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₁₉ N ₆ O ₂ Calculated 363.1564, found 363.1569.

Example 53

2- (3- (2- (3-hydroxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile

Step 1: 3- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) phenol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 2-bromoacetonitrile (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (3- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile was a yellow oil (0.2 g, 61%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₃ N ₆ O ₃ S calculated 499.1547, found 499.1550.

Step 2: (3- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1Acetonitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS53:2- (3- (2- (3-hydroxyphenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) acetonitrile (0.1 g, 70%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.09(s,1H),8.83(s,1H),7.84(d,J＝6.0Hz,1H),7.66(s,1H),7.34(t,J＝6.0Hz,1H),7.04(s,1H),6.91(d,J＝6.0Hz,1H),6.83(s,1H),3.71–3.82(m,1H),3.49(s,2H),2.58-2.83(m,2H),2.17-2.36(m,2H),1.90-2.16(m,2H)ppm； ¹³ CNMR(75MHz,DMSO-d ₆ )δ157.59,153.75,148.63,142.17,132.05,130.65,129.05,127.16,120.75,120.11,115.94,115.65,114.85,112.94,99.38,57.3,54.84,50.04,26.84ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₁₉ N ₆ O calculated 359.1615, found 359.1619.

Example 54

(R) -4- (2- (1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) benzonitrile

Step 1: triethyloxonium tetrafluoroboric acid (0.5 g,2.4 mmol) and (R) -lactamide (0.2 g,2.4 mmol) were dissolved in 10mL tetrahydrofuran and after stirring at room temperature for 3 hours the mixture was concentrated in vacuo to give an oil which was then dissolved in 10mL ethanol and 4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) was added]Pyridin-4-yl) amino) benzonitrile (0.3 g,0.8 mmol) was heated to reflux and stirred for 3 hours. TLC monitoring reverseShould be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -4- (2- (1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile was a pale green oil (0.3 g, 88%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₁₈ N ₅ O ₃ S calculated 444.1125, found 444.1129.

Step 2: (R) -4- (2- (1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile (0.3 g,0.7 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS54: (R) -4- (2- (1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile (0.1 g, 49%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.01(s,1H),8.91(s,1H),7.80(d,J＝9.0Hz,2H),7.64(d,J＝9.0Hz,2H),7.56(s,1H),6.88(s,1H),3.98-4.68(m,1H),1.49(d,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ151.75,148.69,142.16,140.48,134.27,129.04,127.18,122.84,120.73,118.64,115.67,112.17,99.38,62.95,22.84ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₁₄ N ₅ O calculated 304.1193, found 304.1203.

Example 55

4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) benzonitrile

Step 1: 4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) benzonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) and 5-hydroxymethylfurfural (0.2 g,1.6 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile was a yellow oil (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₁₈ N ₅ O ₄ S calculated 496.1074, found 496.1080.

Step 2: 4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS55:4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile (0.1 g, 47%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.91(s,1H),8.73(s,1H),7.83(d,J＝6.0Hz,2H),7.68(d,J＝6.0Hz,2H),7.56(s,1H),7.02(d,J＝9.0Hz,1H),6.83(s,1H),6.59(d,J＝9.0Hz,1H),4.39(s,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.85,151.17,148.64,142.59,142.31,134.27,129.05,127.17,122.85,120.73,118.65,115.69,112.15,107.94,104.06,99.38,57.39ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₁₄ N ₅ O ₂ 356.1142, found 356.1149.

Example 56

4- (2- (3-hydroxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) benzonitrile

Step 1: 4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) benzonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) and 3-hydroxybenzaldehyde (0.2 g,1.6 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 4- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile was a yellow oil (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₁₈ N ₅ O ₃ S calculated 492.1125, found 492.1134.

Step 2: 4- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS56:4- (2- (3-hydroxyphenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile (0.1 g, 47%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.06(s,1H),8.83(s,1H),7.84-7.93(m,1H),7.81(d,J＝7.5Hz,2H),7.64(d,J＝7.5Hz,2H),7.58(s,1H),7.34(t,J＝9.0Hz,1H),7.08(s,1H),6.91(d,J＝9.0Hz,1H),6.88(s,1H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ157.89,148.99,144.47,142.59,142.16,134.27,132.04,130.64,129.05,127.49,122.84,120.75,120.16,118.69,115.96,115.61,112.94,112.15,99.54ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₁₄ N ₅ O calculated 352.1193, found 352.1199.

Example 57

4- (2- (4- (methylsulfonyl) phenyl) -2, 3-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) benzonitrile

Step 1: 4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) benzonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) followed by 4-methylsulfonylbenzaldehyde (0.3 g,1.6 mmol) was added thereto, and the mixture was stirred for 12 hours after the completion of the dropwise addition, and the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 4- (2- (4- (methylsulfonyl) phenyl) -6- (phenylsulfonyl) -2, 3-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile was a yellow oil (0.3 g, 70%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₂₂ N ₅ O ₄ S ₂ Calculated 556.1108, found 556.1113.

Step 2: 4- (2- (4- (methylsulfonyl) phenyl) -6- (phenylsulfonyl) -2, 3-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzylNitrile (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS57:4- (2- (4- (methylsulfonyl) phenyl) -2, 3-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) benzonitrile (0.1 g, 45%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.86(s,1H),7.89(s,1H),7.74(d,J＝6.0Hz,2H),7.63(s,1H),7.54(d,J＝6.0Hz,2H),7.42(d,J＝9.0Hz,2H),6.88(s,1H),6.78(d,J＝9.0Hz,2H),5.08(s,1H),3.32(s,1H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.77,149.47,139.04,138.79,134.41,133.05,131.18,128.15,127.93,127.16,123.38,118.66,114.28,108.15,101.04,99.37,87.84,47.72ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₂ H ₁₈ N ₅ O ₂ S calculated 416.1176, found 416.1180.

Example 58

3- ((R) -3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((R-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 3-bromopropionitrile (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated.The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- ((R) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl propionitrile was a pale yellow oil (0.2 g, 59%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₅ N ₆ O ₃ S calculated 465.1703, found 465.1709.

Step 2: 3- ((R) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl propionitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours and monitored by TLC to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS58:3- ((R) -3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile (0.1 g, 72%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.98(s,1H),8.73(s,1H),7.56(s,1H),6.78(s,1H),4.61–4.75(m,1H),3.65-3.83(m,1H),3.04(t,J＝6.0Hz,2H),2.70-2.83(m,2H),2.73(t,J＝6.0Hz,2H),2.20-2.31(m,2H),1.90-2.15(m,2H),1.49(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.64,148.59,142.19,129.03,127.16,120.74,119.04,115.69,99.39,63.62,58.91,57.63,55.16,27.63,22.84,17.19ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₂₁ N ₆ O calculated 325.1771, found 325.1777.

Example 59

3- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 3-bromopropionitrile (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl propionitrile was a pale yellow oil (0.2 g, 59%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₅ N ₆ O ₃ S calculated 465.1703, found 465.1711.

Step 2: 3- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl propionitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours and monitored by TLC to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS59:3- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile (0.1 g, 72%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.99(s,1H),8.83(s,1H),7.59(s,1H),6.88(s,1H),4.51–4.69(m,1H),3.65-3.85(m,1H),3.05(t,J＝9.0Hz,2H),2.76-2.89(m,2H),2.73(t,J＝9.0Hz,2H),2.20-2.41(m,2H),1.95-2.22(m,2H),1.43(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.61,148.57,142.11,128.64,126.11,120.73,118.57,115.62,99.38,63.62,58.93,57.62,55.17,27.64,22.89,16.14ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₂₁ N ₆ O calculated 325.1771, found 325.1780.

Example 60

3- (3- (2- (4- (methylsulfonyl) phenyl) -2, 3-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile

Step 1: 3- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester (0.3 g,0.7 mmol) was dissolved in 10 mL DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) and 4-methylsulfonylbenzaldehyde (0.2 g,1.4 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give 3- (2- (4- (methylsulfonyl) phenyl) -6- (benzenesulfonyl) -2, 3-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester was a yellow solid (0.2 g, 49%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₃₀ H ₃₄ N ₅ O ₆ S ₂ Calculated 624.1945, found 624.1955.

Step 2: 3- (2- (4- (methylsulfonyl) phenyl) -6- (phenylsulfonyl) -2, 3-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -pyrrolidine-1-carboxylic acid ester (0.2 g,0.3 mmol) was dissolved in 10 mL dichloromethane and slowlyTrifluoroacetic acid (0.4 g,3.0 mmol) was added and stirred at room temperature for 12 hours, concentrated in vacuo to give 2- (4- (methylsulfonyl) phenyl) -6- (phenylsulfonyl) -1- (pyrrolidin-3-yl) -1,2,3, 6-tetrahydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridine was a pale yellow oil (0.1 g, 60%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₂₆ N ₅ O ₄ S ₂ Calculated 524.1421, found 524.1427.

Step 3: 2- (4- (methylsulfonyl) phenyl) -6- (phenylsulfonyl) -1- (pyrrolidin-3-yl) -1,2,3, 6-tetrahydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridine (0.1 g,0.2 mmol) was dissolved in 10 mL tetrahydrofuran, DIPEA (0.1 g,0.4 mmol) was added thereto, 3-bromopropionitrile (0.1 g,0.3 mmol) was slowly added dropwise thereto, and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (3- (2- (4- (methylsulfonyl) phenyl) -6- (benzenesulfonyl) -2, 3-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl propionitrile was a pale yellow oil (0.1 g, 91%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₂₉ N ₆ O ₄ S ₂ Calculated 577.1686, found 577.1688.

Step 4: 3- (3- (2- (4- (methylsulfonyl) phenyl) -6- (phenylsulfonyl) -2, 3-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl propionitrile (0.1 g,0.2 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours and monitored by TLC to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS60:3- (3- (2- (4- (methylsulfonyl) phenyl) -2, 3-dihydroimidazo [4, 5-d)]Pyrrolo-o[2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) propionitrile (60.0 mg, 79%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.46(s,1H),7.89(s,1H),7.74(d,J＝9.0Hz,2H),7.56(s,1H),7.51(d,J＝9.0Hz,2H),6.88(s,1H),5.04(s,1H),3.32(s,3H),3.03(t,J＝9.0Hz,2H),2.75(t,J＝9.0Hz,2H),2.66-2.71(m,1H),2.31–2.56(m,2H),2.19-2.33(m,2H),1.66-2.02(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ144.28,139.28,138.73,134.49,131.18,128.95,128.15,127.15,123.38,119.04,108.16,99.38,83.28,62.18,59.28,55.41,55.14,47.72,33.58,17.10ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₂ H ₂₅ N ₆ O ₂ S calculated 437.1754, found 437.1759.

Example 61

1- (3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidine-1-carbonyl) cyclopropanecarbonitrile

Step 1: (1R) -1- (6- (benzenesulfonyl) -1- (pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 3-bromopropyl cyanide (0.2 g,1.1 mmol) was slowly added dropwise, and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 1- (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carbonyl) cyclopropanecarbonitrile was a yellow oil (0.3 g, 82%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₂₅ N ₆ O ₄ S calculated 505.1653, found 505.1660.

Step 2: 1- (3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carbonyl) cyclopropanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and the reaction was complete as monitored by TLC. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS61:1- (3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carbonyl) cyclopropanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.06(s,1H),7.55(s,1H),6.87(s,1H),4.33-4.68(m,1H),3.89-4.17(m,1H),3.77-4.03(m,2H),3.41–3.51(m,2H),2.29-2.54(m,2H),1.48(d,J＝9.0Hz,3H),0.67-0.92(m,4H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ180.77,148.66,148.53,142.17,129.00,127.17,120.73,115.63,114.47,99.39,63.69,58.42,51.88,46.48,27.15,22.84,13.63,10.06ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₂₁ N ₆ O ₂ Calculated 365.1721, found 365.1711.

Example 62

2- (1- (ethylsulfonyl) -3- (4- (2- (5-methylthiophene-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile

Step 1: tert-butyl 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl) -3- & gto(cyanomethyl) azetidine-1-carboxylic acid ester (0.3 g,0.6 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.6 g,3.0 mmol) of 5-methyl-2-thiophenecarboxaldehyde (0.2 g,0.9 mmol) was added thereto, and the mixture was stirred at 90℃for 12 hours after the completion of the dropping. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give tert-butyl 3- (cyanomethyl) -3- (4- (2- (5-methylthiophene-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidine-1-carboxylic acid ester was a yellow solid (0.2 g, 56%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₃₂ H ₃₁ N ₈ O ₄ S ₂ Calculated 655.1904, found 655.1909.

Step 2: tert-butyl 3- (cyanomethyl) -3- (4- (2- (5-methylthiophene-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) -1H-pyrazol-1-yl) azetidine-1-carboxylic acid ester (0.2 g,0.3 mmol) was dissolved in 10mL of dichloromethane, trifluoroacetic acid (0.4 g,3.0 mmol) was slowly added thereto, and after stirring at room temperature for 12 hours, vacuum concentration was carried out to give 2- (3- (4- (2- (5-methylthiophene-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile was a pale yellow oil (0.1 g, 59%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₃ N ₈ O ₂ S ₂ Calculated 555.1380, found 555.1390.

Step 3: 2- (3- (4- (2- (5-methylthiophene-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.1 g,0.2 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.1 g,0.4 mmol) was added thereto, and ethyl sulfonyl chloride (0.1 g,0.3 mmol) was slowly added dropwise thereto, and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. Water and its preparation methodThe phases were extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (1- (ethylsulfonyl) -3- (4- (2- (5-methylthiophene-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile was a pale yellow oil (0.1 g, 86%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₉ H ₂₇ N ₈ O ₄ S ₃ Calculated 647.1312, found 647.1318.

Step 4: 2- (1- (ethylsulfonyl) -3- (4- (2- (5-methylthiophene-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.1 g,0.2 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS62:2- (1- (ethylsulfonyl) -3- (4- (2- (5-methylthiophene-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (65.0 mg, 83%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.03(s,1H),8.89(s,1H),8.08(s,2H),7.65(s,1H),7.49(d,J＝9.0Hz,1H),6.89(s,1H),6.84(d,J＝9.0Hz,1H),3.89-4.06(m,4H),3.45(m,2H),2.81(s,2H),2.36(s,3H),1.22(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.69,142.17,141.66,141.61,134.33,130.77,129.73,129.01,127.49,127.11,120.73,117.74,115.63,100.54,99.31,59.29,51.66,50.83,23.28,15.22,2.69ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₃ H ₂₃ N ₈ O ₂ S ₂ Calculated 507.1380, found 507.1390.

Example 63

2- (1- (ethylsulfonyl) -3- (4- (2- (thiophen-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile

Step 1: tert-butyl 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) -1H-pyrazol-1-yl) -3- (cyanomethyl) azetidine-1-carboxylic acid ester (0.3 g,0.6 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.6 g,3.0 mmol) and 2-thiophenecarboxaldehyde (0.2 g,0.9 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give tert-butyl 3- (cyanomethyl) -3- (4- (6- (benzenesulfonyl) -2- (thiophen-2-yl) imidazo [4,5-d]Pyrrolo [2,3-b]pyridin-1H) -yl) -1H-pyrazol-1-yl-azetidine-1-carboxylic acid ester was a yellow solid (0.2 g, 57%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₃₁ H ₂₉ N ₈ O ₄ S ₂ Calculated 641.1748, found 641.1751.

Step 2: tert-butyl 3- (cyanomethyl) -3- (4- (6- (benzenesulfonyl) -2- (thiophen-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 6H) -yl) -1H-pyrazol-1-yl azetidine-1-carboxylate (0.2 g,0.3 mmol) was dissolved in 10mL of dichloromethane, trifluoroacetic acid (0.4 g,3.0 mmol) was slowly added thereto, and after stirring at room temperature for 12 hours, vacuum concentration was carried out to give 2- (3- (4- (6- (benzenesulfonyl) -2- (thiophen-2-yl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile was a pale yellow oil (0.1 g, 59%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₁ N ₈ O ₂ S ₂ Calculated 541.1223, found 541.1230.

Step 3: 2- (3- (4- (6- (benzenesulfonyl) -2- (thiophen-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.1 g,0.2 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.1 g,0.4 mmol) was added thereto, and ethyl sulfonyl chloride (0.1 g,0.3 mmol) was slowly added dropwise thereto, and the mixture was stirred at room temperature for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (3- (4- (6- (benzenesulfonyl) -2- (thiophen-2-yl) imidazo [4,5-d ])]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile was a pale yellow oil (0.1 g, 85%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₈ H ₂₅ N ₈ O ₄ S ₃ Calculated 633.1155, found 633.1160.

Step 4: 2- (3- (4- (6- (benzenesulfonyl) -2- (thiophen-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl acetonitrile (0.1 g,0.2 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS63:2- (1- (ethylsulfonyl) -3- (4- (2- (thiophen-2-yl) imidazo [4,5-d ])]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (60.0 mg, 77%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.96(s,1H),8.74(s,1H),8.10(s,2H),7.85(d,J＝7.5Hz,1H),7.69(d,J＝7.5Hz,1H),7.67(s,1H),7.13-7.21(m,1H),6.79(s,1H),3.88-4.16(m,4H),3.55(m,2H),2.86(s,2H),1.22(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.67,143.88,142.19,141.53,130.77,129.73,129.04,128.63,128.04,127.17,120.73,117.72,115.69,100.53,99.38,59.28,51.64,50.88,23.37,5.77ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₂ H ₂₁ N ₈ O ₂ S ₂ Calculated 493.1223, found 493.1230.

Example 64

3- (4- (2- (trifluoromethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile

Step 1: triethyloxonium tetrafluoroboric acid (0.4 g,2.1 mmol) and 2, 2-trifluoroacetamide (0.2 g,2.1 mmol) were dissolved in 10mL tetrahydrofuran and the mixture was concentrated in vacuo after stirring at room temperature for 3 hours to give an oil, which was then dissolved in 10mL ethanol and 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) was added ]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.3 g,0.7 mmol) was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (4- (6- (benzenesulfonyl) -2- (trifluoromethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a milky oil (0.3 g, 84%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₁ H ₁₅ F ₃ N ₇ O ₂ S calculated 486.0955, found 486.0961.

Step 2: 3- (4- (6- (benzenesulfonyl) -2- (trifluoromethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl-propionitrile (0.3 g,0.6 mmol) was dissolved in a mixed solution of 5mL tetrahydrofuran and 5mL methanolAfter adding 5mL of 1M sodium hydroxide to the reaction mixture, the mixture was stirred at room temperature for 5 hours, and the reaction was completed by TLC. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS64:3- (4- (2- (trifluoromethyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.1 g, 47%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.96(s,1H),8.89(s,1H),8.06(s,1H),7.94(s,1H),7.56(s,1H),6.86(s,1H),5.04(t,J＝9.0Hz,2H),3.24(t,J＝9.0Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.69,144.57,142.18,130.77,129.84,129.04,127.11,120.73,117.77,116.73,115.69,100.52,99.67,49.28,16.88ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₅ H ₁₁ F ₃ N ₇ Calculated 346.1023, found 346.1029.

Example 65

4- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) butyronitrile

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 4-bromobutyronitrile (0.2 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 4- ((S)-3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-ylbutyronitrile was a pale yellow oil (0.2 g, 57%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₇ N ₆ O ₃ S calculated 479.1860, found 479.1871.

Step 2: 4- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-ylbutyronitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours and monitored by TLC to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS65:4- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) butyronitrile (0.1 g, 71%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.16(s,1H),8.89(s,1H),7.69(s,1H),6.88(s,1H),4.53-4.69(m,1H),3.69-3.80(m,1H),2.56-2.81(m,2H),2,43(t,J＝7.5Hz,2H),2.21–2.31(m,2H),1.92-2.16(m,2H),1.87(t,J＝7.5Hz,2H),1.66-1.78(m,2H),1.44(d,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.65,148.51,142.17,129.04,127.19,120.77,119.37,115.62,99.74,63.67,58.92,58.49,55.91,55.53,27.63,22.81,15.92,15.19ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₃ N ₆ O calculated 339.1928, found 339.1931.

Example 66

3-cyclopentyl-3- (4- (2- (trifluoromethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile

Step 1: 4-nitropyrazole (0.5 g,4.4 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (1.2 g,8.8 mmol) was added thereto, 3-bromo-3-cyclopentylpropanenitrile (1.3 g,6.6 mmol) was slowly added dropwise thereto, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3-cyclopentyl-3- (4-nitro-1H-pyrazol-1-yl) propionitrile as a pale yellow oil (0.8 g, 77%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₁₁ H ₁₅ N ₄ O ₂ Calculated 235.1190, found 235.1194.

Step 2: 3-cyclopentyl-3- (4-nitro-1H-pyrazol-1-yl) propionitrile (0.8 g,3.4 mmol) was dissolved in 10mL of methanol, palladium on carbon (0.1 g, 10%) was added, the air in the reaction flask was replaced with hydrogen three or more times, and the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. The filtrate was collected after suction filtration and concentrated in vacuo to give 3-cyclopentyl-3- (4-amino-1H-pyrazol-1-yl) propionitrile as a pink foamy solid (0.7 g, 100%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₁ H ₁₇ N ₄ Calculated 205.1448, found 205.1552.

Step 3: 3-cyclopentyl-3- (4-amino-1H-pyrazol-1-yl) propionitrile (0.7 g,3.4 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.9 g,6.8 mmol) was added followed by 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridine (0.8 g,2.3 mmol), after which the mixture was stirred at reflux for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and slurried with methanol to give 3-cyclopentyl-3- (4- ((5-nitro-1- (benzenesulfonyl) group) ) -1H-pyrrolo [2,3-b]Pyridin-4-yl) amino) -1H-pyrazol-1-yl-propionitrile was a pale yellow oil (0.6 g, 50%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₄ N ₇ O ₄ S calculated 506.1605, found 506.1613.

Step 4: 3-cyclopentyl-3- (4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.6 g,1.2 mmol) was dissolved in 10mL of methanol, palladium on carbon (0.1 g, 10%) was added, the air in the reaction flask was replaced with hydrogen three or more times, and the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. The filtrate is collected after suction filtration and concentrated in vacuo to obtain 3-cyclopentyl-3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl-propionitrile was a pink foamy solid (0.5 g, 88%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₆ N ₇ O ₂ S calculated 476.1863, found 476.1870.

Step 5: triethyloxonium tetrafluoroboric acid (0.6 g,3.3 mmol) and 2, 2-trifluoroacetamide (0.1 g,3.3 mmol) were dissolved in 10mL tetrahydrofuran and the mixture was concentrated in vacuo after stirring at room temperature for 3 hours to give an oil, which was then dissolved in 10mL ethanol and 3-cyclopentyl-3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) was added ]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.5 g,1.1 mmol) was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=2:1) to give 3-cyclopentyl-3- (4- (6- (benzenesulfonyl) -2- (trifluoromethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a pale green oil (0.2 g, 34%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₃ F ₃ N ₇ O ₂ S calculated 554.1581, trueMeasured 554.1593.

Step 6: 3-cyclopentyl-3- (4- (6- (benzenesulfonyl) -2- (trifluoromethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS66: 3-cyclopentyl-3- (4- (2- (trifluoromethyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.1 g, 67%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.96(s,1H),8.79(s,1H),8.06(s,1H),7.94(s,1H),7.58(s,1H),6.77(s,1H),3.53-3.70(m,1H),2.80(d,J＝9.0Hz,2H),1.35-1.60(m,9H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.66,144.67,142.19,130.78,129.77,129.03,127.16,120.74,117.74,116.74,115.64,100.58,99.39,63.95,34.28,30.95,25.16,18.88ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₁₉ F ₃ N ₇ Calculated 414.1649, found 414.1654.

Example 67

3- (4- (2- (4- (methylsulfonyl) phenyl) -2, 3-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile

Step 1: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7g，3.5mmAfter ol) 4-methylsulfonylbenzaldehyde (0.2 g,0.9 mmol) was added and the mixture was stirred for 12 hours at 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate to give 3- (4- (2- (4- (methylsulfonyl) phenyl) -6- (benzenesulfonyl) -2, 3-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a yellow solid (0.2 g, 47%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₄ N ₇ O ₄ S ₂ Calculated 574.1326, found 574.1331.

Step 2: 3- (4- (2- (4- (methylsulfonyl) phenyl) -6- (phenylsulfonyl) -2, 3-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.2 g,0.3 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS67:3- (4- (2- (4- (methylsulfonyl) phenyl) -2, 3-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.1 g, 66%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.06(s,1H),7.89(s,1H),7.86(s,1H),7.74(d,J＝9.0Hz,2H),7.58(s,1H),7.51(d,J＝9.0Hz,2H),7.18(s,1H),6.87(s,1H),5.04(t,J＝7.5Hz,3H),3.34(s,3H),3.20(t,J＝7.5Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ149.78,139.07,138.77,134.44,131.17,130.48,130.15,128.19,127.94,127.18,123.34,117.79,115.75,108.15,99.43,87.59,49.22,47.78,17.88ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₀ N ₇ O ₂ S calculated 434.1394, found 434.1400.

Example 68

5- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) valeronitrile

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and then 5-bromovaleronitrile (0.2 g,1.1 mmol) was slowly added dropwise, and after that, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 5- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-ylvaleronitrile was a pale yellow oil (0.2 g, 56%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₂₉ N ₆ O ₃ S calculated 493.2016, found 493.2020.

Step 2: 5- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl-valeronitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, 1M sodium hydroxide was added to the solution, and the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS68:5- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) valeronitrile (0.1 g, 70%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.03(s,1H),8.87(s,1H),7.58(s,1H),6.85(s,1H),4.59-4.68(m,1H),3.65-3.79(m,1H),2.58-2.83(m,2H),2,44(t,J＝9.0Hz,2H),2.19-2.28(m,2H),1.90-2.13(m,2H),1.90(t,J＝9.0Hz,2H),1.63-1.77(m,2H),1.48(d,J＝9.0Hz,3H),1.25-1.30(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.94,148.51,142.11,129.75,127.63,120.71,119.39,115.67,99.52,62.68,58.93,58.41,55.96,55.81,27.63,27.21,23.22,22.84,17.18ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₂₅ N ₆ O calculated 353.2084, found 353.2088.

Example 69

4- ((S) -7- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -5-azaspiro [2.4] heptyl-5-yl) butyronitrile

Step 1: (S) 5-azaspiro [2.4 ]]Tert-butyl hept-7-carbamate (0.3 g,1.4 mmol) was dissolved in 10mL of DMF, and after addition of potassium carbonate (0.4 g,2.8 mmol) and 4-bromobutyronitrile (0.3 g,2.1 mmol) the reaction was stirred at room temperature for 12 hours and monitored by MS for completion. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted three times with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (S) -tert-butyl (5- (3-cyanopropyl) -5-azaspiro [ 2.4)]Heptyl-7-yl) carbamate was a pale yellow oil (0.3 g, 76%) and the product was used in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₁₅ H ₂₆ N ₃ O ₂ Calculated 280.2020, found 280.2029.

Step 2: (S) -tert-butyl (5- (3-cyanopropyl) -5-azaspiro [2.4 ]]Heptyl-7-yl) carbamate (0.3 g,1.1 mmol) was dissolved in 10mL dichloromethane and slowly addedTrifluoroacetic acid (1.3 g,11.0 mmol) was stirred at room temperature for 12 hours and concentrated in vacuo to give (S) -4- (7-amino-5-azaspiro [ 2.4)]Hept-5-yl) butyronitrile is a pale yellow oil (0.2 g, 100%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₁₀ H ₁₈ N ₃ Calculated 180.1495, found 180.1499.

Step 3: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (0.3 g,0.9 mmol) was dissolved in 100mL of tetrahydrofuran and DIPEA (0.7 g,5.5 mmol) and (S) -4- (7-amino-5-azaspiro [2.4 ] were added]Hept-5-yl) butyronitrile (0.2 g,1.1 mmol) was then warmed to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Curing with a suitable amount of methanol to give (S) -4- (7- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -5-azaspiro [2.4]Hept-5-yl) butyronitrile is a yellow solid (0.3 g, 70%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₅ N ₆ O ₄ S calculated 481.1653, found 481.1659.

Step 4: (S) -4- (7- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -5-azaspiro [2.4]Hept-5-yl) butyronitrile (0.3 g,0.6 mmol) was dissolved in 10mL of methanol, palladium on carbon (0.1 g, 10%) was added, and after three more times the air in the flask was replaced with hydrogen, the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC monitored the reaction was complete. The filtrate is collected after suction filtration and concentrated in vacuo to give (S) -4- (7- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)) ]Pyridin-4-yl) amino) -5-azaspiro [2.4]Hept-5-yl) butyronitrile is a pale pink foamy solid (0.3 g, 100%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₇ N ₆ O ₂ S calculated 451.1911, found 451.1922.

Step 5: triethyloxonium tetrafluoroboric acid (0.4 g,2.0 mmol) and (R) -lactamide (0.2 g,2.0 mmol) were dissolved in 20mL tetrahydrofuran, stirred at room temperature for 3 hours and concentrated in vacuo to give an oil of the mixture, which was then dissolved in 20mL ethanolAnd (S) -4- (7- (((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)) is added]Pyridin-4-yl) amino) -5-azaspiro [2.4]Hept-5-yl) butyronitrile (0.3 g,0.7 mmol), and the reaction mixture was stirred at reflux for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give 4- ((S) -7- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -5-azaspiro [2.4 ]Hept-5-yl) butyronitrile is a pale yellow oil (0.2 g, 60%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₉ N ₆ O ₃ S calculated 505.2016, found 505.2020.

Step 6: 4- ((S) -7- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -5-azaspiro [2.4]Hept-5-yl) butyronitrile (0.2 g,0.4 mmol) was dissolved in a mixture of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS69:4- ((S) -7- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -5-azaspiro [2.4]Heptyl-5-yl) butyronitrile (0.1 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.96(s,1H),8.79(s,1H),7.59(s,1H),6.85(s,1H),4.58-4.71(m,1H),3.70-3.77(m,1H),2.66-2.83(m,2H),2,47(t,J＝7.5Hz,2H),2.12-2.22(m,2H),1.88(t,J＝9.0Hz,2H),1.76-1.80(m,2H),1.48(d,J＝9.0Hz,3H),0.05-0.27(m,4H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ149.33,148.58,141.66,129.05,127.99,120.78,119.38,115.64,99.56,71.22,68.47,63.68,56.19,53.48,25.59,22.83,15.98,15.11,4.22ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₅ N ₆ The calculated value of O365.2084,found 365.2089.

Example 70

(R) -1- (1- ((S) -5- (4, 4-trifluorobutyl) -5-azaspiro [2.4] heptan-7-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

LXS70 was prepared in analogy to the preparation of example 69, the crude product was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS70: (R) -1- (1- ((S) -5- (4, 4-trifluorobutyl) -5-azaspiro [ 2.4) ]Heptane-7-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 66%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.03(s,1H),8.77(s,1H),7.61(s,1H),6.93(s,1H),4.60-4.73(m,1H),3.73-3.79(m,1H),2.56-2.81(m,2H),2,43(t,J＝9.0Hz,2H),2.15-2.26(m,2H),1.77-1.81(m,2H),1.43(d,J＝4.5Hz,3H),1.26-1.38(m,2H),0.02-0.22(m,4H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.93,148.51,142.16,129.04,127.11,126.83,120.77,115.61,99.78,71.21,67.54,62.59,56.93,53.76,37.74,25.78,22.81,10.16,5.83ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₅ F ₃ N ₅ O calculated 408.2006, found 408.2010.

Example 71

(R) -1- (1- ((S) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 1To 0mL of tetrahydrofuran was added DIPEA (0.2 g,1.4 mmol) and 4, 4-trifluoro-1-iodobutane (0.3 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -1- (6- (benzenesulfonyl) -1- ((S) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a pale yellow oil (0.3 g, 79%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₄ H ₂₇ F ₃ N ₅ O ₃ S calculated 522.1781, found 522.1788.

Step 2: (R) -1- (6- (benzenesulfonyl) -1- ((S) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS71: (R) -1- (1- ((S) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.04(s,1H),8.83(s,1H),7.56(s,1H),6.89(s,1H),4.61–4.74(m,1H),3.71–3.79(m,1H),2.56-2.81(m,2H),2,41(t,J＝4.5Hz,2H),2.20-2.32(m,2H),1.90-2.15(m,2H),1.80-1.87(m,2H),1.44(d,J＝6.0Hz,3H),1.35-1.40(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ150.11,149.33,144.34,129.88,127.19,126.53,120.77,116.53,98.57,64.78,58.93,58.42,56.32,55.93,37.77,27.61,22.84,10.56ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₃ F ₃ N ₅ O calculated 382.1849, found 382.1852.

Example 72

5- ((S) -7- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -5-azaspiro [2.4] heptyl-5-yl) valeronitrile

LXS72 was prepared in analogy to the preparation of example 69, the crude product was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS72:5- ((S) -7- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -5-azaspiro [2.4]Heptyl-5-yl) valeronitrile (0.1 g, 45%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.99(s,1H),8.87(s,1H),7.59(s,1H),6.72(s,1H),4.63-4.77(m,1H),3.73-3.82(m,1H),2.52-2.74(m,2H),2,47(t,J＝6.0Hz,2H),2.12-2.23(m,2H),1.87(t,J＝6.0Hz,2H),1.59-1.68(m,2H),1.48(d,J＝9.0Hz,3H),1.33-1.41(m,2H),0.08-0.22(m,4H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ150.68,149.47,142.19,129.33,127.86,120.73,119.39,115.62,98.56,71.29,68.40,65.27,56.44,53.49,27.28,25.58,23.29,22.81,17.11,5.88ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₂₇ N ₆ O379.2241, found 379.2243.

Example 73

(R) -1- (1- ((S) -1- (5-fluoropentyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL tetrahydrofuran and DIPEA (0.2 g,1.4 mmol) was added slowly1-bromo-5-fluoropentane (0.2 g,1.1 mmol) was added dropwise, and after the addition, the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -1- (1- ((S) -1- (5-fluoropentyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a pale yellow oil (0.3 g, 82%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₃₁ FN ₅ O ₃ S calculated 500.2126, found 500.2130.

Step 2: (R) -1- (1- ((S) -1- (5-fluoropentyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS73: (R) -1- (1- ((S) -1- (5-fluoropentyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.98(s,1H),8.88(s,1H),7.63(s,1H),6.84(s,1H),4.68-4.76(m,1H),4.09-4.13(m,2H),3.74-3.79(m,1H),2.59-2.84(m,2H),2,49(t,J＝9.0Hz,2H),2.19-2.30(m,2H),1.91–2.18(m,2H),1.49(d,J＝9.0Hz,3H),1.40-1.45(m,2H),1.36-1.40(m,2H),1.27-1.31(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ151.08,148.53,142.19,129.04,127.88,120.78,115.62,98.67,83.69,64.55,58.92,58.44,56.61,55.92,30.71,28.09,27.66,19.45ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₂₇ FN ₅ O calculated 360.2194, found 360.2199.

Example 74

2- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) acetamide

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and then 2-bromo-N- (2, 2-trifluoroethyl) acetamide (0.3 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) acetamide was a pale yellow oil (0.3 g, 75%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₆ F ₃ N ₆ O ₄ S551.1683, found 552.1688.

Step 2: 2- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) acetamide (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified by silica gel chromatography (petroleum ether: acetic acid)Ethyl=1:1) to afford LXS74:2- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) acetamide (0.1 g, 45%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.11(s,1H),8.89(s,1H),8.03(s,1H),7.58(s,1H),6.91(s,1H),4.65-4.78(m,1H),3.72-3.79(m,3H),3.25(s,2H),2.58-2.83(m,2H),2.21–2.34(m,2H),1.94-2.18(m,2H),1.49(d,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ170.55,152.67,148.55,143.18,129.04,127.84,124.79,120.76,115.69,98.47,64.87,59.54,58.28,57.48,54.94,39.41,27.88,22.81ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₂ F ₃ N ₆ O ₂ Calculated 411.1751, found 411.1777.

Example 75

2- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) propionamide

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and then 2-bromo-N- (2, 2-trifluoroethyl) propionamide (0.3 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) propionamide was a pale yellow oil (0.3 g,73%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₅ H ₂₈ F ₃ N ₆ O ₄ S calculated 565.1839, found 565.1841.

Step 2: 2- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) propionamide (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS75:2- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) propionamide (0.1 g, 44%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.91(s,1H),8.77(s,1H),8.05(s,1H),7.68(s,1H),6.86(s,1H),4.67-4.79(m,1H),3.65-3.79(m,4H),2.56-2.81(m,2H),2.18-2.31(m,2H),1.90-2.15(m,2H),1.41(d,J＝7.5Hz,3H),1.28(d,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ171.96,148.67,148.51,142.18,129.04,127.18,124.75,120.75,115.64,97.56,69.29,63.64,58.59,54.92,52.48,39.47,27.36,22.86,18.44ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₂₄ F ₃ N ₆ O ₂ Calculated 425.1907, found 425.1911.

Example 76

2- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) butanamide

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S-pyrrolidinyl-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 2-bromo-N- (2, 2-trifluoroethyl) butanamide (0.3 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) butanamide was a pale yellow oil (0.3 g, 71%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₆ H ₃₀ F ₃ N ₆ O ₄ S calculated 579.1996, found 579.2001.

Step 2: 2- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) butyramide (0.3 g,0.5 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC monitored the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS76:2- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) -N- (2, 2-trifluoroethyl) butanamide (0.1 g, 44%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.01(s,1H),8.78(s,1H),8.08(s,1H),7.53(s,1H),6.79(s,1H),4.68-4.74(m,1H),3.56-3.79(m,4H),2.57-2.85(m,2H),2.20-2.30(m,2H),1.93-2.17(m,2H),1.57-1.64(m,2H),1.48(d,J＝7.5Hz,3H),0.91(t,J＝9.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ173.88,151.77,148.53,142.11,129.04,127.17,124.77,120.71,115.63,98.56,75.93,64.65,58.53,55.22,52.71,39.48,27.63,23.66,22.84,12.89ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₂₆ F ₃ N ₆ O ₂ Calculated 439.2064, found 439.2072.

Example 77

2- (1- (ethylsulfonyl) -3- (4- (2- (5-methylfuran-2-yl) imidazol [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile

LXS77 was prepared in analogy to the preparation of example 63, the crude product was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS77:2- (1- (ethylsulfonyl) -3- (4- (2- (5-methylfuran-2-yl) imidazolyl) 4,5-d ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) azetidin-3-yl) acetonitrile (0.1 g, 53%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.07(s,1H),8.88(s,1H),8.08(s,2H),7.58(s,1H),6.95(d,J＝7.5Hz,1H),6.83(s,1H),6.08(d,J＝7.5Hz,1H),4.80-4.14(m,4H),3.45(t,J＝9.0Hz,2H),2.85(s,2H),2.30(s,3H),1.22(t,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ152.28,151.49,149.11,143.19,141.55,130.75,129.78,129.01,128.66,121.67,117.78,115.61,107.81,107.62,100.57,99.56,59.27,51.63,50.83,23.27,15.98,4.77ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₃ H ₂₃ N ₈ O ₃ S491.1608, found 491.1612.

Example 78

2- (4- (2- (trifluoromethyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) acetonitrile

Step 1: triethyloxonium tetrafluoroboric acid (0.5 g,2.4 mmol) and 2, 2-trifluoroacetamide (0.2 g,2.4 mmol) were dissolved in 10mL tetrahydrofuran and the mixture was concentrated in vacuo after stirring at room temperature for 3 hours to give an oil, which was then dissolved in 10mL ethanol and 2- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) was added]Pyridin-4-yl) amino) -1H-pyrazol-1-yl acetonitrile (0.3 g,0.8 mmol) was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (4- (6- (benzenesulfonyl) -2- (trifluoromethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) acetonitrile was a milky oil (0.3 g, 83%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₀ H ₁₃ F ₃ N ₇ O ₂ S calculated 472.0798, found 472.0802.

Step 2: 2- (4- (6- (benzenesulfonyl) -2- (trifluoromethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) acetonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS78:2- (4- (2- (trifluoromethyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) acetonitrile (0.1 g, 47%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.97(s,1H),8.87(s,1H),8.05(s,1H),7.91(s,1H),7.56(s,1H),6.83(s,1H),4.85(s,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.11,144.33,130.74,129.74,129.04,127.65,120.73,116.73,116.32,115.62,100.53,98.45,45.65ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₄ H ₉ F ₃ N ₇ Calculated 332.0866, found 332.0871.

Example 79

3- (4- (imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile

Step 1: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.3 g,0.7 mmol) was dissolved in 10mL of toluene, followed by addition of triethyl orthoformate (0.2 g,1.4 mmol), p-toluenesulfonic acid (30.0 mg, 10%) and heating to reflux with stirring for reaction for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 3- (4- (6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a pale yellow oil (0.3 g, 98%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₀ H ₁₆ N ₇ O ₂ S calculated 418.1081, found 418.1088.

Step 2: 3- (4- (6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.3 g,0.7 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS79:3- (4- (imidazo)[4,5-d]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.1 g, 50%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.99(s,1H),8.89(s,1H),8.15(s,1H),7.95(s,1H),7.56(s,1H),7.15(s,1H),6.89(s,1H),5.04(t,J＝7.5Hz,2H),3.21(t,J＝7.5Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ150.44,142.88,134.58,130.74,129.73,129.04,127.16,120.74,117.73,115.60,100.54,98.62,49.37,17.50ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₄ H ₁₂ N ₇ Calculated 278.1149, found 278.1151.

Example 80

3- (4- (2- (2-chlorophenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile

Step 1: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) and 2-chlorobenzaldehyde (0.2 g,1.0 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours after the completion of the addition. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate to give 3- (4- (2- (2-chlorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a yellow solid (0.3 g, 77%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₁₉ ClN ₇ O ₂ S calculated 528.1004, found 528.1014.

Step 2: 3- (4- (2- (2-chlorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS80:3- (4- (2- (2-chlorophenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.1 g, 45%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.03(s,1H),8.78(s,1H),8.08(s,1H),7.99(s,1H),7.73(d,J＝7.5Hz,1H),7.58(s,1H),7.55(d,J＝7.5Hz,1H),7.35-7.39(m,2H),6.85(s,1H),5.09(t,J＝9.0Hz,2H),3.28(t,J＝9.0Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ149.21,143.48,142.19,138.56,132.27,130.77,130.16,129.75,129.38,129.05,127.30,127.17,120.77,117.74,115.64,100.63,98.56,50.45,17.54ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₁₅ ClN ₇ Calculated 388.1072, found 388.1077.

Example 81

2- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) acetonitrile

Step 1: 2- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl acetonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4.0 mmol) and 5-hydroxymethylfurfural (0.3 g,1.6 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Adding saturated sodium bicarbonate to the reaction solution to make it slightly alkaline, and separating outAn organic phase. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) acetonitrile was a pale yellow oil (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₁₈ N ₇ O ₄ S calculated 500.1135, found 500.1140.

Step 2: 2- (4- (2- (5- (hydroxymethyl) furan-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) acetonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL of tetrahydrofuran and 5mL of methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS81:2- (4- (2- (5- (hydroxymethyl) furan-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) acetonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.93(s,1H),8.91(s,1H),8.05(s,1H),7.91(s,1H),7.56(s,1H),7.02(d,J＝7.5Hz,1H),6.89(s,1H),6.59(d,J＝7.5Hz,1H),4.85(s,2H),4.39(s,2H)3.65(s,1H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.88,151.17,149.67,142.18,141.33,130.75,129.75,129.07,127.19,120.77,116.36,115.63,107.96,104.07,100.58,98.67,57.38,46.17ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₁₄ N ₇ O ₂ Calculated 360.1203, found 360.1211.

Example 82

3- (4- (2- (3-hydroxyphenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile

Step 1: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) and 3-hydroxybenzaldehyde (0.2 g,1.0 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate to give 3- (4- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a yellow solid (0.3 g, 79%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₂₀ N ₇ O ₃ S510.1343, found 510.1351.

Step 2:3- (4- (2- (3-hydroxyphenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS82:3- (4- (2- (3-hydroxyphenyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.79(s,1H),8.83(s,1H),8.06(s,1H),7.94(s,1H),7.84(d,J＝9.0Hz,1H),7.59(s,1H),7.34(t,J＝9.0Hz,1H),7.04(s,1H),6.91(d,J＝9.0Hz,1H),6.89(s,1H),5.35(s,1H),5.03(t,J＝7.5Hz,2H),3.29(t,J＝7.5Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ157.59,149.56,143.43,142.19,132.08,130.75,130.61,129.77,120.06,127.18,120.74,120.15,117.74,115.97,115.61,112.95,100.59,98.65,50.65,18.66ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₁₆ N ₇ O calculated 370.1411, found 370.1419.

Example 83

3- (4- (2- (2-fluorophenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile

Step 1: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) and 2-fluorobenzaldehyde (0.2 g,1.0 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours after the completion of the addition. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate to give 3- (4- (2- (2-fluorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a yellow solid (0.3 g, 80%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₆ H ₁₉ FN ₇ O ₂ S calculated 512.1299, found 512.1301.

Step 2: 3- (4- (2- (2-fluorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, anhydrous After drying over sodium sulfate, concentration in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS83:3- (4- (2- (2-fluorophenyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.07(s,1H),8.78(s,1H),8.05(s,1H),7.96(s,1H),7.71-7.77(m,2H),7.56(s,1H),7.49(d,J＝7.5Hz,1H),7.28(t,J＝7.5Hz,1H),6.88(s,1H),5.04(t,J＝9.0Hz,2H),3.21(t,J＝9.0Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ158.39,148.63,143.39,142.17,130.77,130.38,129.76,129.16,129.06,127.17,124.88,123.59,120.74,117.74,115.69,114.74,101.76,100.43,51.98,22.51ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₀ H ₁₅ FN ₇ 372.1367, found 372.1377.

Example 84

3- (4- (2- (5-methylthiophene-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl propionitrile

Step 1: 3- (4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) -1H-pyrazol-1-yl propionitrile (0.3 g,0.7 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.5 mmol) of 5-methyl-2-thiophenecarboxaldehyde (0.2 g,1.0 mmol) was added thereto, and the mixture was stirred at 90℃for 12 hours after the completion of the dropping. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate to give 3- (4- (2- (5-methylthiophene-2-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile was a yellow solid (0.3 g, 80%). HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₅ H ₂₀ N ₇ O ₂ S ₂ Calculated 514.1114, found 514.1119.

Step 2: 3- (4- (2- (5-methylthiophene-2-yl) -6- (phenylsulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, stirring was carried out at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS84:3- (4- (2- (5-methylthiophene-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl-propionitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.93(s,1H),8.83(s,1H),8.06(s,1H),7.99(s,1H),7.56(s,1H),7.51(d,J＝7.5Hz,1H),6.89(s,1H),6.83(d,J＝7.5Hz,1H),5.10(t,J＝6.0Hz,2H),3.26(t,J＝6.0Hz,2H),2.36(s,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ151.63,142.17,141.63,141.30,134.38,130.74,129.74,129.06,127.59,127.50,127.14,120.79,117.78,115.62,101.86,99.38,51.96,15.93,15.22ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₁₆ N ₇ S calculated 374.1182, found 374.1189.

Example 85

4- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrazolo [3,4-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) butyronitrile

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S) -pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrazolo [3,4-b]Pyridine compound2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 4-bromobutyronitrile (0.2 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 4- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d) ]Pyrazolo [3,4-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) butyronitrile was a pale yellow oil (0.2 g, 57%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₆ N ₇ O ₃ S calculated 480.1812, found 480.1825.

Step 2: 4- ((S) -3- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrazolo [3,4-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) butyronitrile (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, 1M sodium hydroxide was added to the solution, and the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS85:4- ((S) -3- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrazolo [3,4-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) butyronitrile (0.1 g, 71%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.54(s,1H),8.89(s,1H),7.55(s,1H),4.65-4.70(m,1H),3.64-3.81(m,1H),2.56-2.83(m,2H),2.43(t,J＝9.0Hz,2H),2.23-2.31(m,2H),1.90-2.15(m,2H),1.87(t,J＝9.0Hz,2H),1.66-1.76(m,2H),1.41(d,J＝6.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ154.79,148.53,140.85,140.53,132.46,125.49,119.39,104.75,63.68,58.52,58.41,55.92,55.51,27.61,22.85,15.94,15.11ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₂₂ N ₇ O calculated 340.1880, found 340.1888.

Example 86

(1R) -1- (1- (((3R) -4-fluoro-1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b]Pyridine (1.0 g,3.0 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.8 g,6.0 mmol) and (3R) 3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester (0.9 g,4.5 mmol) were added, and the mixture was heated to reflux and stirred for 4 hours. TLC monitored reaction was complete. Concentrated in vacuo to give a yellow oil. Beating solidification using an appropriate amount of methanol gives (4R) -tert-butyl 3-fluoro-4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid ester was a yellow solid (1.2 g, 80%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₅ FN ₅ O ₆ S calculated 506.1504, found 506.1509.

Step 2: (4R) -tert-butyl 3-fluoro-4- ((5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b)]Pyridine-4-yl) amino) pyrrolidine-1-carboxylic acid ester (1.2 g,2.4 mmol) was dissolved in 20mL of methanol, palladium on carbon (0.1 g, 10%) was added, and after three more times the air in the reaction flask was replaced with hydrogen, the reaction was kept under a hydrogen atmosphere and stirred at room temperature for 12 hours, and TLC monitored the reaction was complete. The filtrate is collected after suction filtration and concentrated in vacuo to obtain (4R) -tert-butyl 3-fluoro-4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) ]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid ester was a pale pink foamy solid (1.1 g, 97%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₂ H ₂₇ FN ₅ O ₄ S calculated 476.1762, found 476.1770.

Step 3: will be triethylOxonium tetrafluoroboric acid (1.2 g,6.3 mmol) and (R) -lactamide (0.6 g,6.3 mmol) were dissolved in 10mL tetrahydrofuran and after stirring at room temperature for 3 hours the mixture was concentrated in vacuo to give an oil, which was then dissolved in 10mL ethanol and (4R) -tert-butyl 3-fluoro-4- ((5-amino-1- (benzenesulfonyl) -1H-pyrrolo [2, 3-b) was added]Pyridin-4-yl) amino) pyrrolidine-1-carboxylic acid ester (1.0 g,2.1 mmol) was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo, the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give (4R) -tert-butyl 3-fluoro-4- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid ester was as a green oil (0.5 g, 45%). HRMS (ESI) M/z [ M+H ] ] ⁺ .C ₂₅ H ₂₉ FN ₅ O ₅ S calculated 530.1868, found 530.1870.

Step 4: (4R) -tert-butyl 3-fluoro-4- (2- ((R) -1-hydroxyethyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-1 (6H) -yl) pyrrolidine-1-carboxylic acid ester (0.5 g,0.9 mmol) was dissolved in 10mL of dichloromethane, trifluoroacetic acid (1.0 g,9.0 mmol) was slowly added and stirred at room temperature for 12 hours, and concentrated in vacuo to give (1R) -1- (1- (((3R) -4-fluoropyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a light brown oil (0.4 g, 99%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₀ H ₂₁ FN ₅ O ₃ S calculated 430.1344, found 430.1350.

Step 5: (1R) -1- (1- (((3R) -4-fluoropyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 4, 4-trifluoro-1-iodobutane (0.3 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Adding saturated sodium bicarbonate to the reaction solution to make it slightly alkaline, and separating out the mixtureAnd (3) an organic phase. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (1R) -1- (1- (((3R) -4-fluoro-1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a pale yellow oil (0.2 g, 53%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₄ H ₂₆ F ₄ N ₅ O ₃ S calculated 540.1687, found 540.1689.

Step 6: (1R) -1- (1- (((3R) -4-fluoro-1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS86: (1R) -1- (1- (((3R) -4-fluoro-1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrole [2,3-b ]]Pyridin-2-yl) ethanol (0.1 g, 68%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.94(s,1H),8.68(s,1H),7.54(s,1H),6.77(s,1H),4.68-4.72(m,1H),3.91–4.06(m,1H),3.30-3.41(m,1H),2.56-2.81(m,2H),2.54(t,J＝4.5Hz,2H),2.29-2.51(m,2H),1.64-1.81(m,2H),1.46(d,J＝9.0Hz,3H),1.36-1.42(m,2H)ppm； ¹³ CNMR(75MHz,DMSO-d ₆ )δ151.89,148.53,142.19,129.06,127.18,126.84,120.77,115.69,98.56,91.20,63.91,61.77,56.33,54.88,51.67,37.71,22.86,11.67ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₂ F ₄ N ₅ O calculated 400.1755, found 400.1770.

Example 87

(R) -1- (1- (((3R, 4R) -4-fluoro-1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

LXS87 was prepared by analogy with the preparation of example 86 using (3R, 4R) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester instead of (3R) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester and purification of the crude product using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS87: (R) -1- (1- (((3R, 4R) -4-fluoro-1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 60%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.99(s,1H),8.78(s,1H),7.58(s,1H),6.75(s,1H),4.64-4.71(m,1H),3.90-4.05(m,1H),3.31–3.55(m,1H),2.53-2.87(m,2H),2.50(t,J＝6.0Hz,2H),2.23-2.47(m,2H),1.73-1.88(m,2H),1.41(d,J＝6.0Hz,3H),1.33-1.44(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.97,148.53,142.19,129.00,127.65,126.88,120.73,115.69,97.63,91.28,63.63,61.79,56.39,54.85,51.63,37.77,22.81,11.65ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₂ F ₄ N ₅ O calculated 400.1755, found 400.1768.

Example 88

(R) -1- (1- (((3R, 4S) -4-fluoro-1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

LXS88 was prepared by analogy with the preparation of example 86 using (3R, 4 s) 3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester instead of (3R) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester and purification of the crude product using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS88: (R) -1- (1- (((3R, 4S) -4-fluoro-1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 50%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.13(s,1H),8.81(s,1H),7.60(s,1H),6.57(s,1H),4.58-4.70(m,1H),3.90-4.05(m,1H),3.33-3.42(m,1H),2.51–2.86(m,2H),2.42(t,J＝9.0Hz,2H),2.30-2.41(m,2H),1.66-1.82(m,2H),1.49(d,J＝9.0Hz,3H),1.39-1.46(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ151.45,158.55,142.19,129.05,127.16,126.86,120.74,115.64,98.56,91.55,63.65,61.75,56.38,54.85,51.68,37.77,22.89,11.56ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₂ F ₄ N ₅ O calculated 400.1755, found 400.1763.

Example 89

(R) -1- (1- ((3S, 5S) -5- (hydroxymethyl) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

LXS89 was prepared by analogy with the preparation of example 86 using (2 s,4 s) -4-amino-2- (hydroxymethyl) pyrrolidine-1-carboxylic acid tert-butyl ester instead of (3R) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester, crude product was purified using silica gel chromatography column (petroleum ether: ethyl acetate=1:1) to give LXS89: (R) -1- (1- ((3S, 5S) -5- (hydroxymethyl) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 51%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.98(s,1H),8.78(s,1H),7.59(s,1H),6.88(s,1H),4.68-4.74(m,1H),3.79-3.85(m,1H),3.34(d,J＝6.0Hz,2H),2.59-2.82(m,2H),2.43(t,J＝4.5Hz,2H),2.33-2.41(m,1H),1.87-2.12(m,2H),1.64-1.81(m,2H),1.47(d,J＝6.0Hz,3H),1.36-1.40(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.94,148.57,142.19,129.04,127.11,126.88,120.75,115.63,98.67,68.74,63.67,62.55,56.71,56.21,54.18,37.79,28.31,22.84,10.49ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₂₅ F ₃ N ₅ O ₂ Calculated 412.1955, found 412.1961.

Example 90

(R) -1- (1- ((S) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrazolo [3,4-b ] pyridin-2-yl) ethanol

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S) -pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrazolo [3,4-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 4, 4-trifluoro-1-iodobutane (0.3 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -1- (6- (benzenesulfonyl) -1- ((S) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d) ]Pyrazolo [3,4-b]Pyridin-2-yl) ethanol was a pale yellow oil (0.2 g, 52%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₃ H ₂₆ F ₃ N ₆ O ₃ S calculated 523.1734, found 523.1740.

Step 2: (R) -1- (6- (benzenesulfonyl) -1- ((S) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrazolo [3,4-b]Pyridin-2-yl) ethanol (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS90: (R) -1- (1- ((S) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d]Pyrazolo [3,4-b]Pyridine compound-2-yl) ethanol (0.1 g, 68%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝13.54(s,1H),8.82(s,1H),7.58(s,1H),4.65-4.73(m,1H),3.64-3.79(m,2H),2.53-2.81(m,2H),2.41(t,J＝6.0Hz,2H),2.20-2.33(m,2H),1.91–2.14(m,2H),1.85(m,2H),1.41(d,J＝9.0Hz,3H),1.27-1.37(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ154.75,148.52,140.88,140.51,132.48,126.84,125.47,105.37,63.68,58.51,58.43,56.38,55.91,38.88,27.91,22.86,9.56ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₂₂ F ₃ N ₆ O calculated 383.1802, found 383.1800.

Example 91

(R) -1- (1- (((3 s, 5R) -5- (hydroxymethyl) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

LXS91 was prepared by analogy with the preparation of example 86 using (2R, 4 s) -4-amino-2- (hydroxymethyl) pyrrolidine-1-carboxylic acid tert-butyl ester instead of (3R) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester and purification of the crude product using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS91: (R) -1- (1- (((3S, 5R) -5- (hydroxymethyl) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 43%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝11.68(s,1H),8.73(s,1H),7.61(s,1H),6.89(s,1H),4.65-4.71(m,1H),3.76-3.89(m,1H),3.35(d,J＝6.0Hz,2H),2.64-2.81(m,2H),2.45(t,J＝7.5Hz,2H),2.37-2.39(m,1H),1.89-2.15(m,2H),1.60-1.84(m,2H),1.43(d,J＝9.0Hz,3H),1.33-1.41(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ151.87,148.54,142.19,129.05,127.18,126.84,120.77,115.69,98.56,68.74,63.69,62.57,56.71,56.38,54.18,38.96,28.54,22.85,13.74ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₉ H ₂₅ F ₃ N ₅ O ₂ Calculated 412.1955, found 412.1963.

Example 92

(R) -1- (1- (((3 s, 5R) -5- (hydroxymethyl) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4,5-d ] pyrazolo [3,4-b ] pyridin-2-yl) ethanol

LXS92 was prepared by analogy with the preparation of example 86 using (2R, 4 s) -4-amino-2- (hydroxymethyl) pyrrolidine-1-carboxylic acid tert-butyl ester instead of (3R) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester, crude product was purified using silica gel chromatography column (petroleum ether: ethyl acetate=1:1) to give LXS92: (R) -1- (1- (((3S, 5R) -5- (hydroxymethyl) -1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) -1, 6-dihydroimidazo [4, 5-d)]Pyrazolo [3,4-b]Pyridin-2-yl) ethanol (0.1 g, 33%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝13.78(s,1H),8.87(s,1H),7.54(s,1H),4.69-4.72(m,1H),3.83-3.89(m,1H),3.37(d,J＝6.0Hz,2H),2.61–2.80(m,2H),2.47(t,J＝9.0Hz,2H),2.36-2.43(m,1H),1.88-2.15(m,2H),1.58-1.79(m,2H),1.44(d,J＝10.5Hz,3H),1.38-1.43(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ155.75,148.56,140.83,140.51,132.48,126.84,125.42,104.74,68.75,63.61,62.51,56.39,56.29,54.17,38.67,28.56,22.87,11.65ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₄ F ₃ N ₆ O ₂ Calculated 413.1907, found 413.1914.

Example 93

4- ((4R) -3-fluoro-4- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrazolo [3,4-b ] pyridin-1 (6H) -yl) pyrrolidin-1-yl) butyronitrile

LXS93 was prepared in analogy to the preparation of example 86, the crude product was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS93:4- ((4R) -3-fluoro-4- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrazolo [3,4-b]Pyridin-1 (6H) -yl) pyrrolidin-1-yl) butyronitrile (0.1 g, 31%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝13.73(s,1H),8.89(s,1H),7.61(s,1H),4.57-4.71(m,1H),3.91–4.08(m,1H),3.33-3.45(m,1H),2.57-2.81(m,2H),2.47(t,J＝6.0Hz,2H),2.40-2.43(m,2H),1.90(t,J＝9.0Hz,2H),1.70-1.76(m,2H),1.43(d,J＝7.5Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ154.76,148.54,141.65,140.51,132.78,125.47,119.38,104.78,91.38,64.89,61.33,55.59,54.86,51.69,22.85,17.56,16.45ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₇ H ₂₁ FN ₇ O calculated 358.1786, found 358.1789.

Example 94

4- ((2S, 4S) -4- (2- ((R) -1-hydroxyethyl) imidazo [4,5-d ] pyrazolo [3,4-b ] pyridin-1 (6H) -yl) -2- (hydroxymethyl) pyrrolidin-1-yl) butyronitrile

LXS94 was prepared by analogy with the preparation of example 86 using (2 s,4 s) -4-amino-2- (hydroxymethyl) pyrrolidine-1-carboxylic acid tert-butyl ester instead of (3R) -3-amino-4-fluoropyrrolidine-1-carboxylic acid tert-butyl ester, crude product was purified using silica gel chromatography column (petroleum ether: ethyl acetate=1:1) to give LXS94:4- ((2S, 4S) -4- (2- ((R) -1-hydroxyethyl) imidazo [4, 5-d)]Pyrazolo [3,4-b]Pyridin-1 (6H) -yl) -2- (hydroxymethyl) pyrrolidin-1-yl) butyronitrile (0.1 g, 27%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝13.68(s,1H),8.89(s,1H),7.58(s,1H),4.63-4.71(m,1H),3.85-3.91(m,1H),3.39(d,J＝9.0Hz,2H),2.66-2.81(m,2H),2.39(t,J＝6.0Hz,2H),2.38-2.45(m,1H),1.79-2.23(m,2H),1.56-1.72(m,2H),1.41(d,J＝10.5Hz,3H),1.33-1.39(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ155.78,149.65,140.89,140.32,132.89,124.23,119.38,104.73,69.65,63.65,62.56,57.76,56.21,53.39,29.65,22.89,18.56,14.65ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₁₈ H ₂₄ N ₇ O ₂ Calculated 370.1986, found 370.1990.

Example 95

Trans-4- (2- (3, 4-difluorophenyl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) cyclohexanecarbonitrile

Step 1: trans-4- ((5-amino-1- (phenylsulfonyl) -1H-pyrrolo [2, 3-b)]Pyridin-4-yl) amino) cyclohexanecarbonitrile (0.3 g,0.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.8 g,4 mmol) and 3, 4-difluorobenzaldehyde (0.2 g,1.6 mmol) were added thereto, and the mixture was stirred at 90℃for 12 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give trans-4- (2- (3, 4-difluorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile was a yellow oil (0.3 g, 76%). HRMS (ESI) M/z [ M+H ]] ⁺ .C ₂₇ H ₂₂ F ₂ N ₅ O ₂ S calculated 518.1457, found 518.1461.

Step 2: trans-4- (2- (3, 4-difluorophenyl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.3 g,0.6 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to be complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS95: trans-4- (2- (3, 4-difluorophenyl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) cyclohexanecarbonitrile (0.1 g, 46%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.02(s,1H),8.66(s,1H),7.77-7.84(m,1H),7.56-7.73(m,1H),7.55(d,J＝3.0Hz,2H),6.88(s,1H),4.41–4.49(m,1H),3.15(t,J＝12.0Hz,1H),2.32-2.44(m,2H),2.23(d,J＝12.0Hz,2H),2.04(d,J＝12.0Hz,2H),1.73-1.85(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.78,150.05,149.64,148.69,142.19,129.05,127.83,127.16,124.74,122.75,120.75,117.52,115.63,115.18,97.58,65.94,31.89,28.78,22.63ppm；HRMS(ESI):m/z[M+H] ⁺ .C ₂₁ H ₁₈ F ₂ N ₅ Calculated 378.1525, found 378.1529.

Example 96

(R) -1- (1- ((S) -1- (3, 3-trifluoropropyl) pyrrolidin-3-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S) -pyrrolidin-3-yl) imidazo [4,5-d]Pyrrolo [3,4-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 4, 4-trifluoro-1-iodopropane (0.2 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -1- (6- (benzenesulfonyl) -1- ((S) -1- (3, 3-trifluoropropyl) pyrrolidin-3-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a pale yellow oil (0.2 g, 54%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ Calculated value C ₂₃ H ₂₅ F ₃ N ₅ O ₃ S508.1625, found 508.1630.

Step 2: (R) -1- (6- (benzenesulfonyl) -1- ((S) -1- (3, 3-trifluoropropyl) pyrrolidin-3-yl) imidazo [4, 5-d) ]Pyrrolo-o[2,3-b]Pyridin-2-yl) ethanol (0.2 g,0.4 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS96: (R) -1- (1- ((S) -1- (3, 3-trifluoropropyl) pyrrolidin-3-yl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.09(s,1H),8.87(s,1H),7.53(s,1H),6.83(s,1H),4.60-4.75(m,1H),3.73-3.78(m,1H),2.56-2.87(m,2H),2,42(t,J＝4.5Hz,2H),2.15-2.32(m,2H),1.90-2.11(m,2H),1.41(d,J＝6.0Hz,3H),1.35-1.40(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.67,148.51,142.18,129.02,127.11,124.88,120.74,115.65,99.35,63.64,58.94,58.41,55.95,40.25,38.45,27.69,22.81ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₁₇ H ₂₁ F ₃ N ₅ O368.1693, found 368.1670.

Example 97

(R) -1- (1- ((S) -1- (3, 4-pentafluorobutyl) pyrrolidin-3-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

Step 1: (R) -1- (6- (benzenesulfonyl) -1- ((S) -pyrrolidin-3-yl) imidazo [4,5-d]Pyrrolo [3,4-b]Pyridin-2-yl) ethanol (0.3 g,0.7 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.2 g,1.4 mmol) was added and 1, 2-pentafluoro-4-iodobutane (0.3 g,1.1 mmol) was slowly added dropwise, and the mixture was warmed to reflux and stirred for 3 hours. TLC monitored reaction was complete. Addition of saturated bicarbonate The reaction solution was slightly alkaline from sodium, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give (R) -1- (1- ((S) -1- (3, 4-pentafluorobutyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) imidazole [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol was a pale yellow oil (0.2 g, 49%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ Calculated value C ₂₄ H ₂₅ F ₅ N ₅ O ₃ S558.1593, found 558.1602.

Step 2: (R) -1- (1- ((S) -1- (3, 4-pentafluorobutyl) pyrrolidin-3-yl) -6- (benzenesulfonyl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g,0.36 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the reaction was stirred at room temperature for 5 hours, and TLC monitored the completion of the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS97: (R) -1- (1- ((S) -1- (3, 4-pentafluorobutyl) pyrrolidin-3-yl) imidazo [4, 5-d) ]Pyrrole [2,3-b ]]Pyridin-2-yl) ethanol (0.1 g, 67%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.85(s,1H),8.77(s,1H),7.56(s,1H),6.89(s,1H),4.60-4.75(m,1H),3.73-3.78(m,1H),2.56-2.87(m,2H),2,47(t,J＝4.5Hz,2H),2.15-2.32(m,2H),1.90-2.11(m,2H),1.45(d,J＝6.0Hz,3H),1.34-1.40(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.67,148.51,142.18,131.88,129.02,127.11,120.93,119.74,114.65,97.35,68.64,53.94,51.41,50.95,41.55,37.40,22.68,21.40ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₁₈ H ₂₁ F ₅ N ₅ O418.1661, found 418.1666.

Example 98

(S) - (5- (1- (1- (1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) furan-2-yl) methanol

Step 1: 98-1 (0.5 g,2.7 mmol) was dissolved in 10mL of DMF and K was added ₂ CO ₃ (0.7 g,5.4 mmol) and 4, 4-trifluoro-1-iodobutane (0.7 g,3.0 mmol) were slowly added dropwise, and the mixture was stirred at room temperature for 12 hours. MS monitors the reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 98-2 as a white oil (0.7 g, 88%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ]] ⁺ Calculated value C ₁₃ H ₂₄ F ₃ N ₂ O ₂ 297.1784, found 297.1788.

Step 2: 98-2 (0.7 g,2.4 mmol) was dissolved in 10mL of dichloromethane, and trifluoroacetic acid (2.7 g,24.0 mmol) was added thereto and stirred at room temperature for 12 hours. MS monitors the reaction was complete. Concentration in vacuo gave 98-3 as a pale yellow oil (0.4 g, 99%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ Calculated value C ₈ H ₁₆ F ₃ N ₂ 197.1260, found 197.1266.

Step 3: 98-3 (0.4 g,2.0 mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.5 g,4.0 mmol) was added followed by 4-chloro-5-nitro-1- (benzenesulfonyl) -1H-pyrrolo [2,3-b ]]Pyridine (0.6 g,1.8 mmol) was heated to reflux and stirred for 3 hours. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 98-4 as a yellow oil (0.6 g, 68%). The product was used directly in the next step without further purification. HRMS (ESI):m/z[M+H] ⁺ calculated value C ₂₁ H ₂₃ F ₃ N ₅ O ₄ S498.1417, found 498.1420.

Step 4: 98-4 (0.6 g,1.2 mmol) was dissolved in 10mL of methanol, palladium on carbon (0.1 g, 10%) was added, and the reaction was maintained in a hydrogen atmosphere by replacing the air in the reaction flask with hydrogen three or more times, and stirred at room temperature for 12 hours, and TLC was monitored to complete the reaction. The filtrate was collected after suction filtration and concentrated in vacuo to give 98-5 as a white foamy solid (0.5 g, 89%). The product was used directly in the next step without further purification. HRMS (ESI) M/z [ M+H ] ] ⁺ Calculated value C ₂₁ H ₂₅ F ₃ N ₅ O ₂ S468.1676, found 468.1680.

Step 5: 98-5 (0.5 g,1.8 mmol) was dissolved in 10mL of DMF and Na was added ₂ S ₂ O ₅ (0.7 g,3.6 mmol) and 5-hydroxymethylfurfural (0.4 g,3.2 mmol) were added thereto, and the mixture was stirred for 12 hours after the completion of the dropping, the temperature was raised to 90 ℃. TLC monitored reaction was complete. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 98-6 as a yellow oil (0.3 g, 49%). HRMS (ESI) M/z [ M+H ]] ⁺ Calculated value C ₂₇ H ₂₇ F ₃ N ₅ O ₄ S574.1730, found 574.1739.

Step 6: 98-6 (0.2 g,0.3 mmol) was dissolved in a mixed solvent of 5mL tetrahydrofuran and 5mL methanol, and after adding 5mL of 1M sodium hydroxide, the mixture was stirred at room temperature for 5 hours, and TLC was monitored to complete the reaction. Saturated sodium bicarbonate was added to the reaction solution to be weakly alkaline, and an organic phase was separated. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS98: (S) - (5- (1- (1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-2-yl) furan-2-yl) methanol (0.1 g, 66%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.98(s,1H),8.87(s,1H),7.51(s,1H),7.02(d,J＝6.0Hz,1H),6.84(s,1H),6.59(d,J＝6.0Hz,1H),4.39(s,1H),3.79-3.88(m,1H),2.53-2.81(m,2H),2.43(t,J＝6.0Hz,2H),2.20-2.30(m,2H),1.90-2.15(m,2H),1.81(d,J＝6.0Hz,2H),1.36(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ153.84,151.12,148.62,144.95,142.19,129.08,127.15,126.84,120.74,115.64,107.95,104.08,99.35,57.85,57.34,56.38,55.97,55.84,37.75,27.08,10.18ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₂₁ H ₂₃ F ₃ N ₅ O ₂ 434.1798, found 434.1788.

Example 99

(S) -3- (1- (1- (1- (1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) phenol

LXS99 was prepared by analogy with the preparation of example 98 and starting 3-hydroxybenzaldehyde, and the crude product was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS99: (S) -3- (1- (1- (1- (1- (4, 4-trifluorobutyl) pyrrolidin-3-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-2-yl) phenol (0.1 g, 54%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.17(s,1H),8.89(s,1H),7.84(t,J＝3.0Hz,1H),7.58(s,1H),7.34(t,J＝7.5Hz,1H),7.04(s,1H),6.90-7.02(m,1H),6.91(d,J＝3.0Hz,1H),6.08(d,J＝7.5Hz,1H),3.79-3.81(m,2H),2.50-2.80(m,2H),2.45(t,J＝6.0Hz,2H),2.21-2.37(m,2H),1.93-2.19(m,2H),1.83(d,J＝6.0Hz,2H),1.34(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ157.54,153.74,148.62,142.18,132.08,130.68,129.08,127.10,126.85,120.77,120.65,115.95,115.64,112.97,99.34,58.46,58.21,56.37,55.94,37.77,27.62,10.18ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₂₂ H ₂₃ F ₃ N ₅ O430.1849, found 430.1933.

Example 100

(R) -1- (1- ((S) -1- (2, 3, 4-heptafluorobutyl) pyrrolidin-3-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

LXS100 was prepared by analogy with the preparation of example 97 and starting materials 2,3, 4-heptafluoroiodobutane, and the crude product was purified using silica gel chromatography (petroleum ether: ethyl acetate=1:1) to give LXS100: (R) -1- (1- ((S) -1- (2, 3, 4-heptafluorobutyl) pyrrolidin-3-yl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.1 g, 43%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.35(s,1H),8.87(s,1H),7.54(s,1H),6.63(s,1H),4.60-4.70(m,1H),3.73-3.79(m,1H),2.56-2.81(m,2H),2,68(s,2H),2.20-2.30(m,2H),1.90-2.15(m,2H),1.49(d,J＝6.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.79,148.59,129.16,127.19,120.88,120.71,118.74,115.65,104.35,99.65,63.64,58.94,58.41,55.91,51.95,27.55,22.40ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₁₈ H ₁₉ F ₇ N ₅ O454.1472, found 454.1488.

Example 101

(R) -1- (1- ((S) -1- (perfluorobutyl) pyrrolidin-3-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-ethanol)

LXS101 was prepared by analogy with the preparation of example 97 and starting perfluoroiodobutane, and the crude product was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS101: (R) -1- (1- ((S) -1- (perfluorobutyl) pyrrolidin-3-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridine-2-ethanol) (0.1 g, 64%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.45(s,1H),8.91(s,1H),7.39(s,1H),6.68(s,1H),4.60-4.74(m,1H),3.73-3.82(m,1H),2.54-2.88(m,2H),1.90-2.30(m,4H),1.51(d,J＝6.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ156.61,148.61,148.51,142.18,129.01,127.34,120.78,118.20,115.28,107.24,99.33,63.88,58.99,44.84,42.38,27.65,22.81ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₁₈ H ₁₇ F ₉ N ₅ O490.1284, found 490.1288.

Example 102

(R) -1- (1- ((S) -1- ((3, 3-trifluoropropyl) sulfonyl) pyrrolidin-3-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-2-yl) ethanol

LXS102 was prepared in analogy to the preparation of example 97 and starting material trifluoromethylpropanesulfonyl chloride and the crude was purified using silica gel chromatography (petroleum ether: ethyl acetate=1:1) to give LXS102: (R) -1- (1- ((S) -1- ((3, 3-trifluoropropyl) sulfonyl) pyrrolidin-3-yl) imidazo [4,5-d]Pyrrolo [2,3-b]Pyridin-2-yl) ethanol (0.2 g, 69%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.71(s,1H),8.56(s,1H),7.38(s,1H),6.74(s,1H),4.68-4.78(m,1H),3.73-3.84(m,1H),3.20(d,J＝4.5Hz,2H),3.11(t,J＝6.0Hz,2H),2.70-2.84(m,2H),2.37(t,J＝6.0Hz,2H),1.91-2.15(m,2H),1.43(d,J＝6.0Hz,3H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.66,148.51,142.15,129.05,127.10,125.47,120.71,115.64,99.34,63.64,57.58,56.14,50.04,40.08,29.87,26.27,22.87ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₁₇ H ₂₁ F ₃ N ₅ O ₃ S432.1312, found 432.1318.

Example 103

4- (4- (imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) butyronitrile

LXS103 was prepared by analogy with the preparation of intermediate 10 and example 79 and starting material 4-bromopropionitrile, and the crude product was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS103:4- (4- (imidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) butyronitrile (0.1 g, 57%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.13(s,1H),8.88(s,1H),8.06(s,1H),7.94(s,1H),7.55(s,1H),7.15(s,1H),6.68(s,1H),4.46(t,J＝6.0Hz,2H),2.10-2.21(m,2H),1.87(t,J＝6.0Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.77,142.11,134.58,130.77,129.71,129.08,127.88,120.74,119.34,115.67,100.57,99.37,52.38,22.74,14.97ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₁₅ H ₁₄ N ₇ 292.1305, found 292.1316.

Example 104

4- (4- (2- (5-methylfuran-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl-butyronitrile LXS104 was prepared using a procedure analogous to the preparation of example 103 starting 5-methylfuran-2-carbaldehyde, crude using a silica gel column (petroleum ether: ethyl acetate=1:1) to afford LXS104:4- (4- (2- (5-methylfuran-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl-butyronitrile (0.2 g, 67%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.33(s,1H),8.85(s,1H),8.11(s,1H),7.98(s,1H),7.55(s,1H),6.95(d,J＝6.0Hz,1H),6.68(s,1H),6.08(d,J＝6.0Hz,1H),4.38(t,J＝6.0Hz,2H),2.30(s,3H),2.14-2.25(m,2H),1.91(t,J＝4.5Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ152.21,151.47,148.65,142.18,141.28,130.75,129.70,129.08,127.18,120.78,119.58,115.68,107.88,107.67,100.51,99.34,52.38,22.74,14.95,13.77ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₂₀ H ₁₈ N ₇ O372.1567, found 352.1588.

Example 105

4- (4- (2- (5-methylthiophene-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Preparation of pyridin-1 (6H) -yl) -1H-pyrazol-1-yl-butyronitrile Using example 103Preparation method and starting material 5-methylthiophene-2-carbaldehyde to LXS105, crude product was purified using silica gel column (petroleum ether: ethyl acetate=1:1) to afford LXS105:4- (4- (2- (5-methylthiophene-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl-butyronitrile (0.1 g, 45%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.28(s,1H),8.68(s,1H),8.06(s,1H),7.94(s,1H),7.63(s,1H),7.49(d,J＝6.0Hz,1H),6.83(d,J＝6.0Hz,1H),6.61(s,1H),4.46(t,J＝6.0Hz,2H),2.36(s,3H),2.11-2.23(m,2H),1.87(t,J＝4.5Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.66,142.18,141.68,141.24,134.38,130.75,129.75,129.04,127.54,127.45,120.77,119.35,115.67,100.57,99.35,52.38,22.75,15.29,14.95ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₂₀ H ₁₈ N ₇ S388.1339, found 388.1345.

Example 106

3- (4- (2- (thiophen-2-yl) imidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile

LXS106 was prepared in analogy to the preparation of example 79 and starting thiophene-2-carbaldehyde and crude was purified using silica gel chromatography (petroleum ether: ethyl acetate=1:1) to give LXS106:3- (4- (2- (thiophen-2-yl) imidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) propionitrile (0.1 g, 64%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.34(s,1H),8.84(s,1H),8.34(s,1H),7.98(s,1H),7.85(d,J＝4.5Hz,1H),7.69(d,J＝4.5Hz,1H),7.63(s,1H),7.19(m,1H),6.56(s,1H),5.08(t,J＝6.0Hz,2H),3.20(t,J＝6.0Hz,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.68,143.98,142.18,141.28,130.74,129.72,129.10,129.00,128.61,128.07,127.15,120.75,117.77,115.65,100.58,99.38,49.25,15.92ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₁₈ H ₁₄ N ₇ S360.1026, found 360.1038.

Example 107

4- (4- (2-cyclobutylimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) butyronitrile

LXS107 was prepared by analogy with the preparation of example 103 and starting cyclobutylformaldehyde, and the crude product was purified using silica gel chromatography (petroleum ether: ethyl acetate=1:1) to give LXS107:4- (4- (2-cyclobutylimidazo [4, 5-d)]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) butyronitrile (0.1 g, 57%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.34(s,1H),8.89(s,1H),8.06(s,1H),7.96(s,1H),7.63(s,1H),6.56(s,1H),4.46(t,J＝6.0Hz,2H),3.19-3.24(m,1H),2.15-2.38(m,4H),2.10-2.14(m,2H),1.91-2.01(m,2H),1.77-1.87(m,2H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.60,144.89,142.18,130.77,129.71,129.08,127.18,120.75,119.37,115.67,100.59,99.38,52.38,32.69,26.28,22.78,18.93,14.92ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₁₉ H ₂₀ N ₇ 346.1775, found 346.1778.

Example 108

4- (4- (2-cyclopropylimidazo [4,5-d ] pyrrolo [2,3-b ] pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) butyronitrile

LXS108 was prepared in analogy to the preparation of example 103 and starting cyclopropylaldehyde and the crude product was purified using a silica gel column (petroleum ether: ethyl acetate=1:1) to give LXS108:4- (4- (2-Cyclopropylimidazo [4, 5-d) ]Pyrrolo [2,3-b]Pyridin-1 (6H) -yl) -1H-pyrazol-1-yl) butyronitrile (0.1 g, 62%). ¹ HNMR(300MHz,DMSO-d ₆ ):δ＝12.11(s,1H),8.69(s,1H),8.11(s,1H),7.94(s,1H),7.58(s,1H),6.41(s,1H),4.51(t,J＝6.0Hz,2H),2.10-2.18(m,2H),1.77-1.87(m,2H),1.35-1.52(m,1H),0.99-1.24(m,4H)ppm； ¹³ C NMR(75MHz,DMSO-d ₆ )δ148.68,144.51,142.98,130.77,129.75,129.05,127.15,120.77,119.35,115.68,100.54,99.35,52.38,22.74,14.95,8.59,3.48ppm；HRMS(ESI):m/z[M+H] ⁺ Calculated value C ₁₈ H ₁₈ N ₇ 332.1618, found 332.1624.

In vitro activity assay for JAK1 and JAK2 kinases

Experimental materials

1. Reagent and consumable

Reagent name	Suppliers of goods	Goods number	Lot number
				JAK1	Carna	08-114	11CBS-0144M
JAK2	Carna	08-045	10CBS-0289R
				Kinase substrate22	GL	112393	P190917-CL112393
Kinase JAK1 peptide	GL	758318	P191104-TL758318
				DMSO	Sigma	D8418-1L	SHBG3288V
384-well plate	Corning	3573	12619003

2. Experimental instrument

Centrifuge (manufacturer: eppendorf type 5430)

Enzyme label instrument (manufacturer: perkin Elmer model Caliper EZ Reader II)

Echo550 (manufacturer: labcyte, model: echo 550)

Experimental method

1. Kinase reaction process

(1) 1 XKinase buffer was prepared.

(2) Preparing a compound concentration gradient: test compounds were tested at 1000nM, 3-fold dilution, 10 concentrations, double well assay, and 100-fold final concentration of compound was prepared in 384 well plates. Then 250nl was transferred to 384 reaction plates with Echo550 for use. 250nl of 100% DMSO was added to each of the negative control wells and the positive control wells.

(3) A2.5-fold final concentration of Kinase solution was prepared using a 1 XKinase buffer.

(4) Adding 10 mu L of kinase solution with 2.5 times of final concentration to each of the compound well and the positive control well; to the negative control wells, 10. Mu.L of 1 XKinase buffer was added.

(5) Centrifuge at 1000rpm for 30 seconds, mix well with shaking and incubate at room temperature for 10 minutes.

(6) A mixed solution of ATP and Kinase substrate was prepared at 25/15 times the final concentration using a 1 XKinase buffer.

(7) The reaction was initiated by adding 15. Mu.L of a 25/15-fold final concentration of the mixed solution of ATP and substrate.

(8) The 384-well plate was centrifuged at 1000rpm for 30 seconds, and after shaking and mixing, incubated at room temperature for a corresponding period of time.

(9) The kinase reaction was stopped by adding 30. Mu.L of stop detection solution, centrifuging at 1000rpm for 30 seconds, and shaking and mixing.

(10) The conversion was read with Caliper EZ Reader.

2. Data analysis

Calculation formula

Wherein: conversion% _sample is a Conversion reading of the sample; convertion% _min: negative control Kong Junzhi, representing conversion reading without enzyme wells; convesion% _max: positive control Kong Junzhi, represents a conversion reading without compound inhibition wells.

Fitting dose-response curve

The log value of the concentration is taken as an X axis, the percent inhibition rate is taken as a Y axis, and a log (inhibitor) vs. response-Variable slope fit quantitative effect curve of analysis software GraphPad Prism 5 is adopted, so that the IC of each compound on the enzyme activity is obtained ₅₀ Values.

The formula is Y=bottom+ (Top-Bottom)/(1+10++LogIC 50-X HillSlope)

IC ₅₀ The data are specifically shown in Table 1.

TABLE 1

A<10nM；10nM<B<100nM；100nM<C<1000nM；D>1000nM。

Claims

1. A compound of formula I:

or a tautomer, stereoisomer, racemate or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing;

Wherein X is CH or N;

R ¹ and R is ² Is defined as (i), (ii) or (iii):

(i)R ¹ is thatR ² Is->

Ring B is a benzene ring or a 5-6 membered heteroaromatic ring;

R ^1a is C _1–3 An alkyl group;

each R ³ Independently halogen, cyano, C _1–4 Alkyl, C _1–4 Haloalkyl, -O-C _1–4 Alkyl or-O-C _1–4 A haloalkyl group;

each R ⁴ Independently is halogen, hydroxy, C _1–4 Alkyl, C _1–4 Haloalkyl, -O-C _1–4 Alkyl, -O-C _1–4 Haloalkyl or C _1–4 A hydroxyalkyl group;

alternatively, two R's on the same carbon atom or on different carbon atoms ⁴ Are connected with each other to form-CH ₂ -or- (CH) ₂ ) ₂ –；

R ^5a Is C _2–6 Alkyl, C _2–6 Haloalkyl, -L ¹ –R ^5f Unsubstituted or substituted 6-10 membered aryl or unsubstituted or substituted 5-10 membered heteroaryl, said substituted 6-10 membered aryl and substituted 5-10 membered heteroaryl referring to 1, 2, 3 or 4 hydrogen atoms in the 6-10 membered aryl and 5-10 membered heteroaryl being independently replaced by R ^5g Substitution;

R ^5b 、R ^5c 、R ^5d 、R ^5e and R is ^5k Each independently is C _1–6 Alkyl, C _1–6 Haloalkyl, -L ¹ –R ^5f Unsubstituted or substituted 6-10 membered aryl, or unsubstituted or substituted 5-10 membered heteroaryl, said substituted 6-10 membered aryl and substituted 5-10 membered heteroaryl referring to 1, 2, 3 or 4 hydrogen atoms in the 6-10 membered aryl and 5-10 membered heteroaryl being independently replaced by R ^5h Substitution;

each R ^5g And R is ^5h Each independently is halogen, cyano, C _1–4 Alkyl, C _1–4 Haloalkyl, -O-C _1–4 Alkyl, -O-C _1–4 Haloalkyl or phenyl;

each L ¹ Independently is- [ C (R) ^a R ^b )] _1-5 –、–[C(R ^a R ^b )] _1–2 –C(O)–[C(R ^a R ^b )] _1–2 –、–[C(R ^a R ^b )] _1–2 –C(O)NH–[C(R ^a R ^b )] _1–2 –、–[C(R ^a R ^b )] _1–2 –NHC(O)–[C(R ^a R ^b )] _1–2 –、–[C(R ^a R ^b )] _1–2 –S(O) ₂ –[C(R ^a R ^b )] _1–2 –、–[C(R ^a R ^b )] _1–2 –NHS(O) ₂ –[C(R ^a R ^b )] _1–2 -or- [ C (R) ^a R ^b )] _1–2 –S(O) ₂ NH–[C(R ^a R ^b )] _1–2 –；

Each R ^5f H, F, CHF independently ₂ 、CH ₂ F、CF ₃ Or CN;

each R ^a Independently H, halogen or C _1–3 An alkyl group;

each R ^b Independently H, halogen or C _1–3 An alkyl group;

m is 0, 1, 2, 3 or 4;

n is 0, 1, 2, 3 or 4;

(ii)R ¹ is thatR ² Is->

Ring C is a benzene ring or a 5-6 membered heteroaromatic ring;

each R ⁶ Independently halogen, hydroxy, amino, cyano, C _1–4 Alkyl, C _1–4 Haloalkyl, -O-C _1–4 Alkyl, -O-C _1–4 Haloalkyl, -S-C _1–4 Alkyl, -S (O) ₂ –C _1–4 Alkyl or C _1–4 A hydroxyalkyl group;

each R ⁷ Independently R is ⁴ ；

Or, in the same placeTwo R's on carbon atoms or on different carbon atoms ⁷ Are connected with each other to form-CH ₂ -or- (CH) ₂ ) ₂ –；

R ⁸ Is R ⁵ 、–S(O) ₂ R ^8a 、–C(O)R ^8b 、–C(O)NR ^8c R ^8d 、–C(O)OR ^8e or-C (O) NHR ^8k ；

R ^8a 、R ^8b 、R ^8c 、R ^8d 、R ^8e And R is ^8k Each independently is methyl, -CF ₃ 、C _2–6 Alkenyl or C _3–6 Cycloalkyl;

each R ⁹ Independently R is ⁴ ；

z is 0, 1, 2, 3 or 4;

y is 0, 1, 2, 3 or 4;

t is 0, 1, 2, 3 or 4;

(iii)R ¹ h, CF of a shape of H, CF ₃ Or (b)R ² Is->

Ring D is C _3–6 Cycloalkyl, benzene ring or 5-6 membered heteroaryl ring;

ring E is a benzene ring or a 5-6 membered heteroaromatic ring;

each R ¹⁰ And R is ¹¹ Independently halogen, hydroxy, amino, cyano, C _1–4 Alkyl, C _1–4 Haloalkyl, -O-C _1–4 Alkyl, -O-C _1–4 Haloalkyl, -S-C _1–4 Alkyl, -S (O) ₂ –C _1–4 Alkyl or C _1–4 A hydroxyalkyl group;

R ¹² is cyano, -L ³ –R ^12f Or (b)

Each R ^14a Independently halogen, cyano, C _1–4 Alkyl-and cyano-substituted C _1–4 Alkyl, C _1–4 Haloalkyl, -O-C _1–4 Alkyl, -O-C _1–4 Haloalkyl or C _1–4 A hydroxyalkyl group;

R ^14b is R ⁵ or-S (O) ₂ –C _1–4 An alkyl group;

L ³ is- [ C (R) ^e R ^f )] ₁₅ –、–C(O)–、–C(O)NH–、–NHC(O)–、–S(O) ₂ –、–NHS(O) ₂ –、–S(O) ₂ NH–、–[C(R ^e R ^f )] ₁₂ –C(O)–[C(R ^e R ^f )] _1–2 –、–[C(R ^e R ^f )] _1–2 –C(O)NH–[C(R ^e R ^f )] _1–2 –、–[C(R ^e R ^f )] _1–2 –NHC(O)–[C(R ^e R ^f )] _1–2 –、–[C(R ^e R ^f )] _1–2 –S(O) ₂ –[C(R ^e R ^f )] _1–2 –、–[C(R ^e R ^f )] _1–2 –NHS(O) ₂ –[C(R ^e R ^f )] _1–2 -or- [ C (R) ^e R ^f )] _1–2 –S(O) ₂ NH–[C(R ^e R ^f )] _1–2 –；

R ^12f H, F, CHF of a shape of H, F, CHF ₂ 、CH ₂ F、CF ₃ Or CN;

each R ^e And R is ^f Independently H, halogen, C _1–3 Alkyl or C _3–6 Cycloalkyl;

p is 0, 1, 2, 3 or 4;

q is 0, 1, 2, 3 or 4;

v is 0, 1, 2 or 3;

u is 0, 1 or 2;

2. The compound of claim 1, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, characterized in that: r is R ^1a Is methyl;

and/or, ring B is a benzene ring;

and/or R ^5a C in the definition _2–6 Alkyl is ethyl, n-propyl or n-butyl;

and/or R ⁴ Halogen in the definition is fluorine;

and/or R ⁴ C in the definition _1–4 Alkyl is methyl;

and/or R ⁴ C in the definition _1–4 Haloalkyl is C _1–4 A fluoroalkyl group;

and/or R ⁴ -O-C in the definition _1–4 Alkyl is-O-CH ₃ ；

And/or R ⁴ -O-C in the definition _1–4 Haloalkyl is-O-C _1–4 A fluoroalkyl group;

and/or R ⁴ C in the definition _1–4 Hydroxyalkyl is-CH ₂ OH；

And/or R ^5a "unsubstituted or substituted 6-10 membered aryl" in the definition is unsubstituted or substituted phenyl, or unsubstituted or substituted naphthyl;

and/or R ^5a "unsubstituted or substituted 5-10 membered heteroaryl" in the definition is "unsubstituted or substituted 5-or 6-membered heteroaryl";

and/or R ^5g And R is ^5h Halogen in the definition is fluorine;

and/or R ^5g And R is ^5h C in the definition _1–4 Alkyl is methyl;

and/or R ^5g And R is ^5h -O-C in the definition _1–4 Haloalkyl is-OCF ₃ ；

And/or R ^5g And R is ^5h C in the definition _1–4 Haloalkyl is C _1–4 A fluoroalkyl group;

and/or R ^5g And R is ^5h -O-C in the definition _1–4 Alkyl is-O-CH ₃ ；

And/or R ^5b "unsubstituted or substituted 6-10 membered aryl" in the definition is unsubstituted or substituted phenyl, or unsubstituted or substituted naphthyl;

And/or R ^a Halogen in the definition is fluorine;

and/or R ^a C in the definition _1–3 Alkyl is methyl or ethyl;

and/or R ^b Halogen in the definition is fluorine;

and/or R ^b C in the definition _1–3 Alkyl is methyl or ethyl;

and/or each L ¹ Independently is- [ C (R) ^a R ^b )] _1-5 -or- [ C (R) ^a R ^b )] _1–2 –C(O)NH–[C(R ^a R ^b )] _1–2 –；

And/or m is 1;

and/or n is 0, 1 or 2;

and/or the 5-6 membered heteroaromatic ring in the definition of ring C is imidazole, thiazole, furan, thiophene or pyridine;

and/or R ⁶ Halogen in the definition is fluorine;

and/or R ⁶ C in the definition _1–4 Alkyl is methyl;

and/or R ⁶ C in the definition _1–4 Haloalkyl is C _1–4 A fluoroalkyl group;

and/or R ⁶ -O-C in the definition _1–4 Alkyl is-O-CH ₃ ；

And/or R ⁶ -O-C in the definition _1–4 Haloalkyl is-O-C _1–4 A fluoroalkyl group;

and/or R ⁶ In the definition-S-C _1–4 Alkyl is-S-CH ₃ ；

And/or R ⁶ In the definition-S (O) ₂ –C _1–4 Alkyl is-S (O) ₂ –CH ₃ ；

And/or R ⁶ C in the definition _1–4 Hydroxyalkyl is-CH ₂ –OH；

And/or R ^8a 、R ^8b 、R ^8c 、R ^8d 、R ^8e And R is ^8k C in the definition _2–6 Alkenyl is vinyl;

and/or R ^8a 、R ^8b 、R ^8c 、R ^8d 、R ^8e And R is ^8k C in the definition _3–6 Cycloalkyl is cyclopropyl;

and/or the number of the groups of groups,in cis or trans configuration;

and/or, t is 0;

and/or y is 0;

and/or z is 0, 1 or 2;

and/or C in the definition of ring D _3–6 Cycloalkyl is cyclopropyl or cyclobutyl;

and/or the 5-6 membered heteroaromatic ring in the definition of ring D is furan or thiophene;

and/or the 5-6 membered heteroaromatic ring in the definition of ring E is pyrazole;

and/or R ¹⁰ And R is ¹¹ Halogen in the definition is fluorine or chlorine;

and/or R ¹⁰ And R is ¹¹ C in the definition _1–4 Alkyl is methyl;

and/or R ¹⁰ And R is ¹¹ C in the definition _1–4 Haloalkyl is C _1–4 A fluoroalkyl group;

and/or R ¹⁰ And R is ¹¹ -O-C in the definition _1–4 Alkyl is-O-CH ₃ ；

And/or R ¹⁰ And R is ¹¹ -O-C in the definition _1–4 Haloalkyl is-O-C _1–4 A fluoroalkyl group;

and/or R ¹⁰ And R is ¹¹ In the definition-S-C _1–4 Alkyl is-S-CH ₃ ；

And/or R ¹⁰ And R is ¹¹ In the definition-S (O) ₂ –C _1–4 Alkyl is-S (O) ₂ –CH ₃ ；

And/or R ¹⁰ And R is ¹¹ C in the definition _1–4 Hydroxyalkyl is-CH ₂ –OH；

And/or q is 0;

and/or p is 0, 1 or 2;

and/or R ^14b In the definition-S (O) ₂ –C _1–4 Alkyl is-S (O) ₂ –CH ₂ CH ₃ 、–S(O) ₂ –CH ₂ CH ₂ CH ₃ or-S (O) ₂ –CH ₂ CH ₂ CH ₂ CH ₃ ；

And/or R ^e And R is ^f Halogen in the definition is fluorine;

and/or R ^e And R is ^f C in the definition _1–3 Alkyl is methyl or ethyl;

and/or R ^e And R is ^f C in the definition _3–6 Cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl.

3. The compound of claim 1 or 2, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, characterized in that: Is->

And/or each R ⁴ Independently halogen or C _1–4 Hydroxyalkyl, or two R's on the same carbon atom or on different carbon atoms ⁴ Are connected with each other to form-CH ₂ -or- (CH) ₂ ) ₂ –；

And/or R ^5a "unsubstituted or substituted 6-10 membered aryl" in the definition is unsubstituted phenyl, or is substituted with 1, 2, 3 and 4 substituents independently selected from halogen, C _1–4 Alkyl, -O-C _1–4 Haloalkyl and phenyl-substituted phenyl;

and/or R ^5a "unsubstituted or substituted 5-10 membered heteroaryl" in the definition is unsubstituted or substituted thienyl;

and/or R ^5b "unsubstituted or substituted 6-10 membered aryl" in the definition is unsubstituted phenyl, or phenyl substituted with 1, 2, 3, and 4 substituents independently selected from halogen and cyano;

and/or R ^5b -L in the definition ¹ –R ^5f is-C (R) ^a R ^b )–R ^5f ；

And/or R ^5g And R is ^5h C in the definition _1–4 Haloalkyl is-CF ₃ ；

And/or each R ^a Independently H, fluoro, methyl or ethyl; each R ^b Independently H, fluoro, methyl or ethyl; alternatively, R ^a And R is ^b Form a cyclopropyl group together with the carbon atom to which they are attached;

and/or when R ² Is thatWhen ring C is benzene ring, imidazole, furan or pyridine;

and/or when R ² Is thatWhen ring C is benzene ring, thiazole, furan or thiophene;

And/or R ⁸ Is R ⁵ 、–S(O) ₂ R ^8a or-C (O) R ^8b ；

And/or each R ⁶ Independently fluorine, hydroxy, amino, cyano, methyl, CF ₃ 、–O–CH ₃ 、–S–CH ₃ 、–S(O) ₂ –CH ₃ or-CH ₂ –OH；

And/or R ¹² Is cyano, -C (R) ^e R ^f )–R ^12f 、–[C(R ^e R ^f ) ₂ ]–R ^12f 、–[C(R ^e R ^f ) ₃ ]–R ^12f Or (b)

And/or R ^14a C substituted by cyano _1–4 An alkyl group;

and/or v is 0;

and/or u is 1.

4. A compound according to at least one of claims 1-3, or a tautomer, stereoisomer, racemate or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, characterized in that: each R ^5g Independently is halogen, C _1–4 Alkyl, -O-C _1–4 Haloalkyl or phenyl;

and/or R ^5a "unsubstituted or substituted 6-10 membered aryl" in the definition is

And/or R ^5a "unsubstituted or substituted 5-10 membered heteroaryl" in the definition is

And/or R ^5b "unsubstituted or substituted 6-10 membered aryl" in the definition is

And/or R ^5b -L in the definition ¹ –R ^5f Is that

And/or R ^5e C in the definition _1–6 Alkyl is tert-butyl;

and/or R ⁵ -L in the definition ¹ –R ^5f Is- [ C (R) ^a R ^b )] _1-5 –R ^5f Or- [ C (R) ^a R ^b )] _1–2 –C(O)NH–[C(R ^a R ^b )] _1–2 -, preferably-C (R) ^a R ^b )–R ^5f 、–[C(R ^a R ^b )] ₂ –R ^5f 、–[C(R ^a R ^b )] ₃ –R ^5f 、–[C(R ^a R ^b )] ₄ –R ^5f Or- [ C (R) ^a R ^b )] ₅ –R ^5f ；

And/or R ⁸ is-S (O) ₂ C(R ^a R ^b )–C _1–6 Alkyl, -S (O) ₂ –CF ₃ 、–S(O) ₂ C(R ^a R ^b )–R ^5f 、–S(O) ₂ [C(R ^a R ^b ) ₂ ]–R ^5f 、–S(O) ₂ [C(R ^a R ^b ) ₃ ]–R ^5f 、–C(R ^a R ^b )–R ^5f 、–[C(R ^a R ^b ) ₂ ]–R ^5f 、–[C(R ^a R ^b ) ₃ ]–R ^5f 、–C(O)CH＝CH ₂ or-C (O) NHC (R) ^a R ^b )–R ^5f ；

And/or the number of the groups of groups,is->

And/or R ^14a is-CH ₂ CN；

And/or R ^14b is-S (O) ₂ –C _1–4 An alkyl group.

5. The compound of any one of claims 1-4, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a crystalline form or solvate of any one of the foregoing, characterized in that: r is R ^5a Is C _2–6 An alkyl group, an unsubstituted or substituted 6-10 membered aryl group, or an unsubstituted or substituted 5-10 membered heteroaryl group;

and/or R ^5b is-L ¹ –R ^5f Or unsubstituted or substituted phenyl;

and/or R ^5e Is C _1–6 An alkyl group;

and/or R ^5c 、R ^5d And R is ^5k Each independently is-L ¹ –R ^5f ；

And/or each R ^5f F, CF independently ₃ Or CN;

and/or R ⁸ is-S (O) ₂ (CH ₂ ) ₂ –CH ₃ 、–S(O) ₂ –CF ₃ 、–C(O)NHCH ₂ –CF ₃ 、–C(O)CH＝CH ₂ 、 –CH ₂ –CN、–(CH ₂ ) ₂ -CN or–(CH ₂ ) ₃ –CF ₃ ；

And/or the number of the groups of groups,is->

And/or R ^14b is-S (O) ₂ –C _1–4 An alkyl group;

and/or the number of the groups of groups,is->

And/or ring C is a benzene ring,

6. The compound of at least one of claims 1-5, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, characterized in that: r is R ⁵ -C (O) NHR in the definition ^5k is-C (O) NHCH ₂ –CF ₃ ；

And/or R ⁵ In the definition-S (O) ₂ R ^5a is-S (O) ₂ (CH ₂ ) ₂ –CF ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CH ₃ 、–S(O) ₂ CH ₂ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₃ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、 preferably-S (O) ₂ (CH ₂ ) ₂ –CF ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CH ₃ 、–S(O) ₂ CH ₂ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₃ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、

And/or R ⁵ In the definition-C (O) R ^5b Is that

And/or R ⁵ In the definition-C (O) OR ^5e is-C (O) OC (CH) ₃ ) ₂ –CH ₃ ；

And/or R ⁵ -L in the definition ¹ –R ^5f is-C (R) ^a R ^b )–CN、–[C(R ^a R ^b )] ₂ –CN、–[C(R ^a R ^b )] ₃ –CN、–[C(R ^a R ^b )] ₄ –CN、–[C(R ^a R ^b )]–CF ₃ 、–[C(R ^a R ^b )] ₂ –CF ₃ 、–[C(R ^a R ^b )] ₃ –CF ₃ 、–C(R ^a R ^b )C(O)NH–C(R ^a R ^b )CF ₃ Or- [ C (R) ^a R ^b )] ₅ -F, preferably-C (R ^a R ^b )–CN、–[C(R ^a R ^b )] ₂ –CN、–[C(R ^a R ^b )] ₃ –CN、–[C(R ^a R ^b )] ₄ –CN、–[C(R ^a R ^b )]–CF ₃ 、–[C(R ^a R ^b )] ₂ –CF ₃ 、–[C(R ^a R ^b )] ₃ –CF ₃ Or- [ C (R) ^a R ^b )] ₅ –F。

7. The compound of any one of claims 1-6, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a crystalline form or solvate of any one of the foregoing, characterized in that: r is R ⁵ is-CH ₂ –CN、–(CH ₂ ) ₂ –CN、–(CH ₂ ) ₃ –CN、–(CH ₂ ) ₄ –CN、–(CH ₂ ) ₂ –CF ₃ 、–CH ₂ (CF ₂ ) ₂ –CF ₃ 、–(CF ₂ ) ₃ –CF ₃ 、–(CH ₂ ) ₂ CF ₂ –CF ₃ 、–(CH ₂ ) ₃ –CF ₃ 、–CH(CH ₂ CH ₃ )C(O)NH–CH ₂ CF ₃ 、–CH ₂ C(O)NHCH ₂ –CF ₃ 、–CH(CH ₃ )C(O)NHCH ₂ –CF ₃ 、–(CH ₂ ) ₅ –F、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、–C(O)NHCH ₂ –CF ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CH ₃ 、–S(O) ₂ CH ₂ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₃ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、 –C(O)OC(CH ₃ ) ₂ –CH ₃ 、preferably-CH ₂ –CN、–(CH ₂ ) ₂ –CN、–(CH ₂ ) ₃ –CN、–(CH ₂ ) ₄ –CN、–(CH ₂ ) ₂ –CF ₃ 、–CH ₂ (CF ₂ ) ₂ –CF ₃ 、–(CF ₂ ) ₃ –CF ₃ 、–(CH ₂ ) ₂ CF ₂ –CF ₃ 、–(CH ₂ ) ₃ –CF ₃ 、–CH(CH ₂ CH ₃ )C(O)NH–CH ₂ CF ₃ 、–CH ₂ C(O)NHCH ₂ –CF ₃ 、–CH(CH ₃ )C(O)NHCH ₂ –CF ₃ 、–(CH ₂ ) ₅ –F、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、–S(O) ₂ CH ₂ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₃ –CH ₃ 、–S(O) ₂ (CH ₂ ) ₂ –CF ₃ 、

And/or the number of the groups of groups,is->

And/or R ⁸ is-S (O) ₂ C(R ^a R ^b )–CH ₃ 、–S(O) ₂ –CF ₃ 、–C(O)NHC(R ^a R ^b )–CF ₃ 、–C(O)CH＝CH ₂ 、 –C(R ^a R ^b )–CN、–[C(R ^a R ^b ) ₂ ]-CN or- [ C (R) ^a R ^b ) ₃ ]–CF ₃ ；

And/or the number of the groups of groups,is->

And/or R ¹² is-CN, -CH ₂ –CN、–(CH ₂ ) ₂ –CN、–(CH ₂ ) ₃ –CN、 preferably-CH ₂ –CN、–(CH ₂ ) ₂ -CN or- (CH) ₂ ) ₃ –CN；

And/or the number of the groups of groups,is->

8. The compound of claim 1, or a tautomer, stereoisomer, racemate, or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, characterized in that: the compound has a structure shown in the following formula I-1a, I-1B, I-1C, I-1D, I-2, I-3C, I-3D, I-3E, I-3F, I-3G, I-4E, I-4F, I-4J, I-4L, I-4M, I-5, I-6, I-7A, I-7B, I-7C, I-7D, I-7E, I-7F, I-7G or I-7H;

Therein, X, R ^1a 、R ⁴ 、R ^5g 、n、L ¹ 、R ^5f 、R ⁶ 、R ⁷ 、R ⁸ 、y、R ⁹ 、z、t、R ¹⁰ 、R ¹¹ 、R ¹² 、R ^14b P and q are as defined in at least one of claims 1 to 7;

each f is independently 0, 1, 2, 3, or 4.

9. A compound according to claim 1, or a tautomer, stereoisomer, racemate or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, wherein said compound has any of the following structures:

10. a process for the preparation of a compound of formula I comprising the steps of: reacting a compound shown in a formula II with alkali in an organic solvent to obtain the compound shown in a formula I;

wherein X, Y is,R ¹ And R is ² Is as defined in at least one of claims 1 to 9.

11. A compound of formula II:

12. A pharmaceutical composition comprising

(i) A compound of formula I as defined in at least one of claims 1 to 9, or a tautomer, stereoisomer, racemate or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing; and

(ii) A pharmaceutically acceptable carrier.

13. Use of a compound of formula I as defined in at least one of claims 1 to 9, or a tautomer, stereoisomer, racemate or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, or a pharmaceutical composition as defined in claim 12, as a Janus kinase inhibitor.

14. Use of a compound of formula I as defined in at least one of claims 1 to 9, or a tautomer, stereoisomer, racemate or isotopic derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a crystalline form or solvate of any of the foregoing, or a pharmaceutical composition as defined in claim 12, for the preparation of a medicament for the treatment of a disease associated with Janus kinase;

the disease associated with Janus kinase may be an autoimmune disease or cancer.